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Stellingen 
1. Ouderen vormen voor wat betreft hun risicoprofiel en hun risico op coronaire 
hartziekten een zeer heterogene groep. 
Dit proefschrift. 
2. Het aantal witte bloedcellen en seramalbumine, routinematig gemeten klinisch-
chemische bloedparameters, kunnen, naast de klassieke risicofactoren, bijdragen aan een 
betere voorspelling van het voorkomen van klinisch manifeste coronaire hartziekten bij 
ouderen. 
Dit proefschrift. 
3. De voedingsmiddelenindustrie vervult een sleutelrol bij populatie-gerichte strategieën 
met betrekking tot beïnvloeding van risicofactoren. Ook ouderen zouden hiervan kunnen 
profiteren vanwege het gunstige effect op de bloeddruk, serumlipiden en 
serumhomocysteme, en het risico op coronaire hartziekten en sterfte in deze leeftijdsgroep. 
Dit proefschrift. 
4. Bij ouderen zijn risicofactoren voor coronaire hartziekten over het algemeen 
belangrijkere voorspellers van sterfte aan de aandoening dan voor de klinische manifestatie 
ervan. 
Dit proefschrift. 
5. With respect to the distinctions between aging and disease, from an epidemiologic and 
particularly an etiologic perspective, the processes of aging and the processes 
encompassing the pathogenesis of diseases should be regarded as a single category that 
contributes to ill health. For an etiologic study the distinction between these processes is 
largely semantic and administrative. 
Kaplan GA, Haan MN, Cohen RD. Risk factors and the study of prevention in the elderly: 
methodological issues. In: Wallace RB, Woolson RF, editors. The epidemiologic study of 
the eldelry. Ney York: Oxford University Press, 1992:20-36. 
6. There is greater variation in physical and mental health in old age than at younger 
ages; nevertheless, age in itself should not be a barrier to promoting health and preventing 
or postponing disease, disability and death. 
WHO Study Group on Epidemiology and Prevention of Cardiovascular Diseases in the 
Elderly. Epidemiology and prevention of cardiovascular diseases in elderly people: report 
of a WHO study group (WHO Technical Report Series, No. 853). Geneva: World Health 
Organization, 1995. 
7. Een grotere en meer langdurige deelname van ouderen aan het maatschappelijk verkeer 
draagt bij aan een algehele verbetering van het welzijn van zowel ouderen als andere 
leeftijdsgroepen. 
8. The sin comes in believing a causal hypothesis is true because your study came up 
with a positive result, or believing the opposite because your study was negative. 
Greenland S. 1995. In: Taubes G. Epidemiology faces its limits. Science 1995;269:164-
169. 
9. The essence of knowledge is generalization. 
Rothman KJ. Modern Epidemiology. Boston: Little, Brown and Company, 1986. 
10. Een investering door de werkgever in een cursus time-management, betrekking 
hebbend op zowel het werk als het privé-leven van de werknemer, draagt bij aan een 
optimaal werkrendement. 
11. De vrijstelling van houderschapsbelasting van auto's ouder dan 25 jaar kan leiden tot 
een afname van de verkeersveiligheid. 
12. I made up my mind, so don't confuse me with the facts. 
13. Maintenant je sais, je sais qu'on ne sait jammais, ... c'est tout ce que je sais, mais ca 
j ' le sais. 
Jean Gabin, Maintenant je sais. 
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Abstract 
PROSPECTIVE STUDIES ON CORONARY HEART DISEASE IN THE ELDERLY 
The role of classical and new risk factors 
PhD Thesis. Agricultural University Wageningen, the Netherlands and the National Institute of 
Public Health and the Environment, Bilthoven, the Netherlands. 
Matty P. Weijenberg 
In this thesis associations between biological risk factors and the occurrence of coronary heart 
disease in elderly persons are described. The focus is on classical (i.e. total and high density 
lipoprotein cholesterol and blood pressure) and some new (i.e. homocysteine, white blood cell 
count and serum albumin) biological risk factors. The studies are based on two Dutch cohorts. 
One is a cohort of 292 men and women, aged 64 to 87 years in 1971, from a general practice in 
Rotterdam, with a mortality follow-up of 17 years. The other is the Dutch cohort of the Seven 
Countries Study which consists of 939 men aged 64 to 84 years in 1985 from the town of 
Zutphen. The morbidity and mortality follow-up embraced five years. 
In general, the classical risk factors were important predictors of coronary heart disease 
occurrence in elderly people. Systolic blood pressure was a strong independent long-term predictor 
of coronary heart disease mortality in elderly women, but the long-term association was less clear 
in elderly men. Total cholesterol was also significantly associated with long-term mortality from 
coronary heart disease in elderly women, but in men the association tended to be inverted U-
shaped, i.e. men with cholesterol levels in the median tertile of the cholesterol distribution had a 
higher risk than those with levels in the first and third tertile. Regarding the Zutphen study, the 
short-term associations with incidence of coronary heart disease were usually weaker than with 
mortality from the disease. Elevated systolic and diastolic blood pressure, and especially isolated 
systolic hypertension, were important short-term predictors of sudden cardiac death in elderly men. 
For mortality from coronary heart disease, which was not additionally recorded as sudden, U-
shaped associations with systolic and diastolic blood pressure levels were observed, i.e. men with 
the lowest blood pressure levels and those with the highest blood pressure levels and using anti-
hypertensive medication had the highest risk. Serum total cholesterol was related to short-term 
coronary heart disease mortality in elderly men. For incidence of the disease, an association was 
only observed in a subgroup of the population with serum albumin levels below the median. High 
density lipoprotein cholesterol was not predictive of mortality from coronary heart disease, but 
there appeared to be an association with the incidence of the disease. 
Concerning the new risk factors, serum homocysteine appeared to be associated with mortality 
from coronary heart disease in elderly men in the first one-and-a-half years of follow-up only. A 
strong association with mortality from cerebrovascular disease was observed in normotensive men. 
In addition, an association with an increased risk of cognitive impairment was suggested. Both 
white blood cell count and serum albumin were important predictors of coronary heart disease 
independent of the classical risk factors for coronary heart disease. The association with serum 
albumin could only partly be explained by baseline health status indicators. 
The experience obtained from the studies described in this thesis has made clear that elderly 
people are a heterogenous group with respect to risk factor levels as well as coronary heart disease 
risk. It would therefore be desirable to have a measure of susceptibility for coronary heart disease 
to identify elderly people who are at increased risk of the disease. Our studies suggest that white 
blood cell count and serum albumin, routine clinical blood chemistry values, may be useful in this 
respect in addition to the classical risk factors. Future studies should aim at assessing the 
effectiveness of a multifactorial approach of risk factor management on coronary heart disease and 
all-cause mortality as well as on quality of life in older men and women. 
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Chapter 1 
Introduction 
Coronary heart disease in the elderly 
Since the 1950's, an overwhelming body of knowledge on risk factors for coronary heart 
disease in middle-aged men has been accumulated.1"3 Modifications in the major risk 
factors, e.g. blood cholesterol, blood pressure and cigarette smoking, have proven to 
contribute to a reduction in the risk of the disease.4"7 It is only relatively recently that 
epidemiologic research on coronary heart disease has begun to focus on elderly people. 
Several reasons underlie this interest. 
First, demographic shifts in industrialized countries will lead to striking increases in 
the number of older people. In the Netherlands, the total number of people is expected to 
increase by approximately 11 percent from 15.0 to 16.7 million between 1990 and 2010, 
but this trend will not be equally distributed over different age categories.8 The largest 
increase will occur in people over 45 years of age, with the number of people aged 65 
years and older forecasted to increase by more than 25 percent from approximately 1.9 
to 2.4 million between 1990 and 2010.8 , 9 Life expectancy at birth will rise by a mean of 
1.5 years in the same period, only half of which will be in good health.8 If these 
projections are correct they will be accompanied by growing health care costs.8 
Second, cardiovascular diseases, of which coronary heart disease is the most common, 
constitute the major cause of death in the majority of the industrialized countries including 
the Netherlands.10 Moreover, 80 percent of all deaths from cardiovascular causes occur in 
people over 65 years of age.11 Age-specific mortality rates for cardiovascular diseases as 
well as coronary heart disease more than double between the age groups 65 to 74 years 
and 75 to 84 years.11 Overall, the age-standardized mortality rate from coronary heart 
disease has been decreasing steadily for the past two decades in most industrialized 
countries. In the Netherlands a decline of 29 percent among men and 38 percent among 
women has been observed between 1972 and 1990, corresponding to a decline of 4 per 
100,000 persons a year in men as well as women.8 Part of the decline is a result of 
improved clinical care of the disease and/or reduced severity of the disease leading to a 
postponement of death, which in turn accounts for a less marked decline in coronary heart 
disease mortality rates at older ages.8 The overall decline may also be due to a reduced 
incidence of the disease.11 Accurate population-based information on the prevalence and 
incidence of the disease is lacking for the elderly. Nonetheless, the effect of demographic 
changes is expected to be larger than that of the reduced relative prevalence of the disease. 
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This is expected to result in an increase in the absolute number of patients with 
myocardial infarction by approximately 34 percent, from 255,500 in 1990 to 343,000 in 
2010, in the Netherlands.8 The elderly are expected to contribute most to this increase and 
this is estimated to be associated with a considerable rise in the social, health care, and 
economic burden of the disease in the coming decades.8 
Finally, although advanced coronary atherosclerosis (i.e. more than 50 percent 
occlusion of one of the coronary arteries) may be present in approximately half of the 
elderly population, it is not considered to be an aging phenomenon per se.n Evidence 
from angiography studies indicates that progression of atherosclerosis can be stopped and 
regression can be induced through the management of established risk factors.1 3 , 1 4 Hence, 
reduction in coronary heart disease risk in elderly persons can be expected through risk 
factor management. It is therefore imperative to obtain insight into possible risk factors 
for coronary heart disease in the elderly. 
Risk factors for coronary heart disease in the elderly 
Most prospective studies on risk factors for coronary heart disease have been conducted 
in middle-aged people. Although several studies have addressed the role of conventional 
risk factors, i.e. blood cholesterol, blood pressure and cigarette smoking, in elderly 
populations, consensus has not yet been established on the existence or shape of 
associations in this age group. 1 5 , 1 6 Several factors, specific to epidemiologic research in 
older persons, may explain the lack of consensus.17 
Comorbidity and comortality are common in older populations and may obscure the 
associations between risk factors and the end-point of interest. Health status of an 
individual at the time of the risk factor measurement can influence the level of the risk 
factor and thereby alter its relation with coronary heart disease. In addition, underlying or 
overt disease may interact with the progression or development of coronary heart disease 
thereby modifying the association between risk factor and outcome. A similar mechanism 
may underlie the diluting effect of possible competing causes of mortality. Careful 
consideration of the health status of an individual is therefore imperative in studying 
coronary heart disease risk in elderly populations. In addition, since death is eventually 
inevitable and comortality may be considerable in prospective studies in the elderly, it is 
necessary to address the impact of risk factors on all-cause mortality. 
Selective survival of older persons with unfavorable risk factor profiles may also 
explain discordant results between studies of older and middle-aged people. Indeed, 
12 
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persons with unfavorable risk factor levels who survived a coronary heart disease event 
at middle-age and have reached old age may constitute a specific group of people less 
susceptible to the effect of the specific risk factors. 
An additional matter of concern in epidemiologic studies in the elderly is the possibility 
that risk factors may change with advancing age. The measured level of a risk factor at 
old age may not be representative of lifetime exposure and misclassification of subjects 
is possible. However, one must keep in mind the mechanisms that underlie the 
associations between risk factors and coronary heart disease. If the risk factor is expected 
to have an acute effect on the disease outcome an assessment of the factor shortly before 
disease occurrence is most appropriate, whereas if the risk factor is thought to act 
cumulatively on the progression of coronary heart disease a longer term assessment of the 
risk factor would be preferable. Unfortunately, the role of risk factors in the pathogenesis 
of coronary heart disease is complex and not yet resolved, and short- and long term effects 
may frequently intermingle. 
Another issue is the interpretation of the measure of association in studies among 
elderly persons. Relative risks for coronary heart disease associated with a specific risk 
factor may decline with advancing age, but absolute excess risks tend to increase with age. 
From a public health point of view the absolute rates are most important and this should 
be considered when comparing the impact of a risk factor on disease occurrence between 
older and younger populations. 
Finally there may be other factors, alone or in addition to the conventional risk factors, 
which become increasingly important in predicting coronary heart disease in elderly 
people. One such a factor may be homocysteine which has recently been associated with 
coronary heart disease in middle-aged people. 1 8 1 9 Homocysteine is readily modifiable 
through adequate intakes of or supplementation with folate, vitamin B12 and vitamin B6. 2 0 
Since elderly people generally have low levels of these vitamins,21 it is important to know 
whether homocysteine is also associated with coronary heart disease in this age group. 
Known markers of underlying disease, inflammation, infection, or a poor nutritional 
status may also be more effective in predicting coronary heart disease in elderly people 
than the measurement of the conventional risk factors alone. Some routinely measured 
blood chemistry values, such as white blood cell count and albumin, may be promising 
in this respect. Elevated white blood cell count is a marker for underlying inflammation. 
The epidemiologic evidence for an association between increased white blood cell count 
and coronary heart disease in middle-aged people is convincing.22 In addition, plausible 
mechanisms for the associations have been described23 suggesting that the count is more 
than just a marker of possible underlying disease processes. The serum albumin 
concentration is another marker of general underlying disease and poor nutritional status, 
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especially in the elderly.24 Biological mechanisms have also been described for the 
association between low albumin concentrations and coronary heart disease.25"27 Since data 
from elderly populations are lacking, the question arises whether these routine clinical 
measurements are predictive of the disease in this age group and whether the associations 
can wholly or partially be accounted for by underlying disease. 
Outline of thesis 
The prevailing uncertainties regarding the predictive value of risk factors for coronary 
heart disease in the elderly were the rationale for conducting the studies described in this 
thesis. Biological risk factors are the main focus of interest. They can be defined as 
indicators of an acquired physiologic state presumably associated with an increased risk 
of the disease. They are frequently intermediates between lifestyle factors and disease 
occurrence. The studies are based on two Dutch cohorts. One is a cohort of 292 men and 
women, aged 64 to 87 years in 1971, from a general practice in Rotterdam,28 with a 
mortality follow-up of 17 years. The other is the Dutch cohort of the Seven Countries 
Study3 which consists of 939 men aged 64 to 84 years in 1985 from the town of Zutphen. 
The morbidity and mortality follow-up embraced five years. Some of the analyses also 
included other outcome measures than coronary heart disease in view of the known or 
suspected role of these factors in the etiology of other conditions. 
In the first part of the thesis, the classical risk factors for coronary heart disease are 
addressed. Chapter 2 deals with blood pressure and isolated systolic hypertension as risk 
factors for coronary heart disease, sudden cardiac death and stroke in elderly men. In 
chapter 3, the associations between both systolic blood pressure and total cholesterol and 
17-year mortality from coronary heart disease were investigated in elderly men and 
women. The associations of total and high density lipoprotein cholesterol with the five-
year risk of coronary heart disease in elderly men is described in chapter 4. Chapter 5 
addresses the age related changes in total and high density lipoprotein cholesterol in 
elderly men during the 1977/1978 - 1993 period. 
The second part of the thesis deals with new biological factors which have more 
recently been associated with coronary heart disease in middle-aged persons and may also 
be of importance in the elderly. Chapter 6 addresses the role of serum homocysteine, 
chapter 7 that of white blood cell count and chapter 8 deals with serum albumin and the 
five-year risk of coronary heart disease in elderly men. Finally, in chapter 9, some 
methodological issues involved in conducting epidemiologic research in the elderly, the 
14 
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pathophysiology and etiology of coronary heart disease in this age group and some public 
health implications are discussed. 
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Chapter 2 
Blood pressure and isolated systolic hypertension and the 
five-year risk of coronary heart disease and mortality in 
elderly men 
Abstract 
The associations of diastolic (DBP) and systolic (SBP) blood pressure with the risk of 
coronary heart disease, sudden cardiac and all-cause mortality were investigated in elderly 
men followed for five years. 885 randomly selected men, aged 64 to 84 years and from 
the Dutch town of Zutphen participated in the study. Relative risks were adjusted for age, 
body mass index, total and high density lipoprotein cholesterol, cigarette smoking, alcohol 
consumption, use of blood pressure lowering medications, and physician who took the 
blood pressure. Neither DBP nor SBP were significantly associated with the incidence of 
a first coronary heart disease event, and only DBP showed a U-shaped association with 
mortality from coronary heart disease (p-quadratic trend = 0.049). However, positive 
associations with sudden cardiac death were observed (p-linear trend = 0.013 for DBP and 
0.002 for SBP). The adjusted relative risk for sudden cardiac death in men with definite 
isolated systolic hypertension was 9.20 (95% confidence interval: 1.76 - 47.97). DBP and 
SBP showed a U-shaped relation with coronary heart disease mortality which was not 
recorded as sudden (p-quadratic trend = 0.007 and 0.018 respectively). DBP and SBP were 
positively associated with all-cause mortality when possible co-morbidity at the time of 
the blood pressure measurement was accounted for. Overall, the highest risk for all end-
points was observed in men on anti-hypertensive medication, who formed a distinct group 
with a clustering of cardiovascular risk factors. In conclusion, elevated DBP and SBP, and 
especially isolated systolic hypertension, are important predictors of sudden cardiac death 
in elderly men. The highest risk of non-sudden coronary heart disease mortality was found 
at the lower end of the blood pressure distributions and among men on anti-hypertensive 
medication. 
Submitted as: 
Weijenberg MP, Feskens EJM, Kromhout D. Blood pressure and isolated systolic 
hypertension and the risk of coronary heart disease and mortality in elderly men (The 
Zutphen Elderly Study). 
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Introduction 
Diastolic and systolic blood pressure are well established risk factors for coronary heart 
disease in middle-aged persons.1 However, among elderly people it is still not clear how 
diastolic and systolic blood pressure levels are associated with coronary heart disease.2 
Apart from possible selection mechanisms in elderly cohorts,3 factors related to the 
physiology of blood pressure may offer an explanation. 
Diastolic blood pressure decreases with advancing age after 60 years of age, whereas 
systolic blood pressure increases continually with age.4 , 5 The lower diastolic blood pressure 
in the elderly has been associated with increased arterial stiffness,6"8 partly as a result of 
increased atherosclerosis,6,9 and with reduced diastolic coronary flow.8 , 1 0 This may explain 
the inverted, U- or J-shaped associations observed between diastolic blood pressure and 
coronary heart disease in some studies.10"15 In line with these findings and the reduced 
arterial compliance with advancing age,6 isolated systolic hypertension has been identified 
as a stronger coronary heart disease risk factor among the elderly than an elevated systolic 
blood pressure per s6. 9 , 1 6" 1 9 
However, U -shaped associations have also been observed between systolic blood 
pressure and cardiovascular diseases and all-cause mortality.1 1'1 3 , 1 4 Since blood pressure 
levels have a tendency to be low in the presence of certain diseases, comorbidity has been 
suggested to be responsible for part of the increased morbidity and mortality rates at the 
lower ends of the blood pressure distributions.5,11 ,20"23 
In the present study, we attempted to further clarify these associations in elderly people. 
Therefore, we investigated the associations of diastolic and systolic blood pressure and 
isolated systolic hypertension with the risk of coronary heart disease as well as sudden 
cardiac death in elderly men followed for five years. 
Methods 
Population 
The Zutphen Study is a longitudinal investigation of chronic disease risk factors initiated 
in 1960 among middle-aged men as the Dutch contribution to the Seven Countries Study.24 
In 1985, 555 men from the 1960 cohort were still alive and were invited for new 
examinations. In addition, a random sample (two out of three) of all men of the same age 
living in Zutphen and not part of the 1960 cohort were invited to take part in the study. 
From then on, the study was continued as the Zutphen Elderly Study. The study was 
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approved by the Medical Ethics Committee of the University of Leiden, The Netherlands, 
in 1985. Of the 1266 men approached 939 (74%) agreed to participate. Hundred-and-nine 
men (9%) could not be examined because of serious illness or death, 62 men (5%) had 
moved and 156 men (12%) refused to participate or could not be reached. All participants 
signed an informed consent form. Complete information on risk factors was available for 
885 men aged 64 to 84 years. 
Examinations 
Physical examinations and dietary surveys took place between March and June 1985. 
Physical examinations were carried out by five trained physicians according to a 
standardized protocol. Diastolic (fifth Korotkoff phase) and systolic blood pressures were 
measured in duplicate with a random zero sphygmomanometer (Hawksley) at the right arm 
while subjects were in supine position. A standard cuff-size was used (12 x 23 cm) which 
was eventually judged adequate for all men. The measurements were done at the end of 
the physical examination. The mean of the two blood pressure values was used in the 
analyses. With the use of a standardized questionnaire, the physicians obtained information 
on whether men had ever been diagnosed with hypertension. In addition, information was 
collected on whether these men were currently using anti-hypertensive medication and on 
the type of medication used, which they had been asked to bring with them. 
Categories of diastolic and systolic blood pressures and of isolated systolic 
hypertension were formed and the lowest category was always regarded as the reference 
category. Diastolic blood pressure was divided into five categories. The first four 
categories consisted of men not using anti-hypertensive medication with 75, 85 and 95 
mmHg as cut-off values. The highest category consisted of men using anti-hypertensive 
medication regardless of their blood pressure level. For systolic blood pressure we 
distinguished between four categories of which the first three consisted of men not using 
anti-hypertensive medication with 140 and 160 mmHg as cut-off values, and the highest 
category consisted of men using anti-hypertensive medication. Isolated systolic 
hypertension was defined excluding men on anti-hypertensive medication. A systolic blood 
pressure of 160 mmHg or higher and a diastolic blood pressure lower than 90 mmHg 
constituted the definite category. A systolic blood pressure level between 140 and 160 
mmHg with a diastolic blood pressure lower than 90 mmHg was indicative of borderline 
isolated systolic hypertension. Men with a systolic blood pressure lower than 140 mmHg 
and a diastolic blood pressure lower than 90 mmHg constituted the reference category ("no 
isolated systolic hypertension"). 
Height was measured to the nearest 0.1 cm and body weight was measured to the 
nearest 0.5 kg while the men were in underwear. Body mass index (weight (kg)/ height 
21 
Chapter 2 
(m)2) was calculated. Non-fasting serum total and high density lipoprotein (HDL) 
cholesterol were determined enzymatically with the CHOD-PAP mono-testkit from 
Boehringer Mannheim.2 5 , 2 6 HDL was isolated after precipitation of apolipoprotein B 
containing particles by dextran sulphate-Mg2"1".27 The analyses were carried out in the 
standardized lipid laboratory of the Department of Human Nutrition, Agricultural 
University, Wageningen, The Netherlands. Information on medication use, prescribed diets 
and smoking habits (missing for one person) was assessed with a standardized 
questionnaire. Men using medications known to lower the blood pressure but who had 
never been diagnosed with hypertension were identified. In the present study smoking was 
defined as never, former or current cigarette smoking. Information on alcohol consumption 
was assessed by trained dietitians with a cross-check dietary history,28 adapted to the 
Dutch situation.29 This information was available for 825 men. 
Follow-up 
Information on the prevalence of coronary heart disease was obtained during the physical 
examination in 1985 and a similar examination between March and June 1990. For men 
who did not participate in the 1990 examination, information on major chronic diseases 
was obtained from a questionnaire for non participants. Information on angina pectoris and 
myocardial infarction was obtained through the Dutch translation of a questionnaire 
developed at the London School of Hygiene and Tropical Medicine.30 The diagnosis of 
angina pectoris was made when the following symptoms were present:30 chest pain or 
discomfort located at the sternum or left chest and left arm due to effort of walking or 
hurrying, compelling the patient to slow down or take nitroglycerin, and relieved within 
10 rninutes after stopping the effort. For definite myocardial infarction the final diagnosis 
was based on whether two of the following three criteria were met: a specific medical 
history, i.e. severe chest pain lasting for more than 20 minutes and not disappearing in 
rest, characteristic electrocardiogram changes and specific enzyme elevations. All 
diagnoses were verified with hospital discharge data and written information from the 
subjects' general practitioners. All information was eventually coded by a single physician, 
and the year of first diagnosis was recorded. 
Information on the vital status of the participants was obtained till July 1990. One 
person had moved abroad and was lost to follow-up. The date on which he moved was 
used as his (censored) end-point date. Information on the causes of death was obtained 
from the Dutch Central Bureau of Statistics, after verification with hospital discharge data 
and information from the deceased's general practitioners. The causes of death were coded 
according to the 9th Revision of the International Classification of Diseases (ICD).31 
Because of the frequency of possible comorbidity and comortality in elderly people the 
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underlying cause of death is often difficult to establish. Therefore both the primary and 
secondary cause of death were recorded in defining the end-points. Death due to coronary 
heart disease was defined by ICD codes 410 through 414 (n = 53), death due to 
cerebrovascular disease by codes 430 through 438 (n = 29), death due to cardiovascular 
diseases by codes 390 through 459 (n = 110) and death due to cancer by codes 140 
through 208 (n = 69). Sudden cardiac death was recently coded by one trained expert. 
Because of limitations in the available information sudden cardiac death was regarded to 
have occurred in the following two situations (n = 44). One was when death was 
documented to have occurred within two hours after the onset of typical symptoms, and 
no other causes of death were known. The other was in subjects with a history of heart 
disease: when "mors subita" was notified by the physician or death occurred unwitnessed 
(within 12 hours after men had been observed to be well). Men who died of coronary 
heart disease were also classified according to whether the cause of death was additionally 
recorded as sudden (n = 30) or non-sudden (n = 23). 
The incidence of coronary heart disease was defined by the first occurrence ever of 
either myocardial infarction, angina pectoris or mortality from coronary heart disease (n 
= 56). 
Statistical methods 
Statistical analyses were carried out using the SAS program (SAS Institute Inc., Cary, 
North Carolina, USA, 1989-1993, version 6.10). All tests were two sided and p-values 
smaller than five percent were considered statistically significant. Differences in risk factor 
levels between blood pressure categories were assessed using analysis of variance. Cox's 
proportional-hazard (survival) analysis was carried out to investigate the associations 
between blood pressure variables and the end-points of interest during five years of 
follow-up.32 Dummy variables for the categories of blood pressure and covariates were 
used in the analyses. Tests for linear and quadratic trends were performed.32 Associations 
were adjusted for age, body mass index, total and HDL cholesterol, cigarette smoking, 
alcohol consumption, use of medications known to lower blood pressure levels without a 
specific indication for hypertension, and physician who took the blood pressure. Additional 
adjustment for the use of a sodium-restricted diet (n = 34) did not alter any of the 
associations, therefore the associations described in the results section were not 
additionally adjusted for this factor. Interaction terms were evaluated at p-values smaller 
than 10 percent. 
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Results 
At baseline, mean diastolic and systolic blood pressure levels of the cohort were 85.4 
rrirnHg and 151.1 mmHg respectively. Twelve percent (n = 106) of the men were on anti-
hypertensive medication and both their diastolic and systolic blood pressures were 
significantly higher compared to men who were not on anti-hypertensive medication (p 
< 0.001). Only 4.6 percent of the men on anti-hypertensive medication had diastolic and 
systolic blood pressure levels below 90 and 160 mmHg respectively. The 106 men on anti-
hypertensive medication were therefore selected to form a separate systolic and diastolic 
blood pressure category. The most common anti-hypertensive medications used by the 
participants were diuretics (59%) and beta-blocking agents (40%), and 22 percent were 
using both. One hundred and thirty six men were using medications known to lower blood 
pressure levels without a specific indication for hypertension of which vasodilators (51%), 
diuretics (43%) and beta-blocking agents (25%) were the most frequent. These men were 
significantly older (73.6 years versus 71.1 years, p < 0.001) and had significantly lower 
diastolic and systolic blood pressure levels (80.3 mmHg versus 85.2 mmHg and 143.8 
mmHg versus 149.7 mmHg respectively, p < 0.001 in both cases) compared to men not 
using this type of medication. 
Men with a diastolic blood pressure lower than 75 mmHg were significantly older than 
men with levels of 85 mmHg or higher, as where men with definite isolated systolic 
hypertension compared to men without this type of hypertension (table 1). Body mass 
index increased with increasing category of diastolic and systolic blood pressure. The 
mean total cholesterol level of men with a diastolic blood pressure between 75 and 94 
mmHg was significantly higher than that of men in the lowest diastolic blood pressure 
category. HDL cholesterol was lowest among men on anti-hypertensive medication 
compared to the reference blood pressure categories. There were no other significant 
differences between blood pressure categories. 
Diastolic blood pressure was not associated with the incidence of coronary heart disease 
(p-linear trend = 0.38 and p-quadratic trend = 0.69), but there was a U-shaped association 
with mortality from this disease (table 2). The adjusted relative risk for sudden cardiac 
death increased gradually with increasing category of diastolic blood pressure. The highest 
risk was observed among men using anti-hypertensive medication. Since the associations 
of diastolic blood pressure with coronary heart disease and with sudden cardiac death were 
discordant additional analyses were performed. There was a positive association between 
diastolic blood pressure and mortality from coronary heart disease when sudden cardiac 
death had also been recorded (figure 1 A). For non-sudden coronary heart disease mortality 
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Table 1. Mean levels of baseline characteristics by blood pressure category among men from The Zutphen Elderly Study 
Blood pressure category N Age Diastolic blood Systolic blood Body mass Total HDL 
(years) pressure pressure index cholesterol cholesterol 
(mmHg) (mmHg) (kg/m2) (mmol/L) (mmol/L) 
Diastolic blood pressure 
< 75 mmHg 145 73.3 (5.9)* 69.2 (4.5) 133.4 (15.8) 23.9 (3.4) 5.77 (1.04) 1.18 (0.36) 
75 - 84 mmHg 265 71.5 (5.2) 79.6 (2.9) 142.2 (15.5) 25.3 (2.8) 6.21 (1.12) 1.11 (0.29) 
85 - 94 mmHg 222 70.8 (5.0) 89.1 (2.8) 153.4 (17.3) 25.6 (2.9) 6.22 (1.15) 1.12 (0.26) 
>. 95 mmHg 147 70.8 (5.2) 100.8 (5.5) 168.4 (17.6) 26.3 (3.0) 6.08 (1.11) 1.14 (0.28) 
Anti-hypertensive use 106 71.3 (5.5) 93.5 (11.2) 168.5 (22.4) 26.5 (3.8) 6.01 (0.98) 1.05 (0.25) 
Systolic blood pressure 
< 140 rnniHg 275 71.1 (5.4) 77.6 (8.1) 128.0 (8.1) 24.9 (3.2) 6.06 (1.09) 1.15 (0.32) 
140 - 159 mmHg 282 71.4 (5.4) 84.1 (9.5) 149.1 (5.7) 25.4 (3.0) 6.15 (1.10) 1.11 (0.29) 
> 160 mmHg 222 72.2 (5.2) 93.0 (10.1) 173.9 (12.2) 25.6 (3.0) 6.12 (1.18) 1.14 (0.28) 
Anti-hypertensive use 106 71.3 (5.5) 93.5 (11.2) 168.5 (22.4) 26.5 (3.8) 6.01 (0.98) 1.05 (0.25) 
Isolated systolic hypertension^ 
No$ 252 71.1 (5.4) 76.2 (6.9) 127.5 (8.1) 24.7 (3.2) 6.04 (1.11) 1.15 (0.32) 
Borderline§ 200 72.2 (5.4) 79.6 (6.8) 148.7 (5.7) 25.1 (2.8) 6.20 (1.15) 1.12 (0.31) 
Defmitel 83 73.1 (5.1) 82.8 (5.8) 171.0 (10.8) 25.5 (3.1) 6.12 (1.23) 1.13 (0.25) 
*: mean (standard deviation) 
f: excluding men on anti-hypertensive medication 
systolic blood pressure < 140 mmHg and diastolic blood pressure < 90 mmHg 
§: systolic blood pressure between 140 and 159 mmHg and diastolic blood pressure < 90 mmHg 
[: systolic blood pressure £ 160 mmHg and diastolic blood pressure < 90 mmHg 
Table 2. Crude rates and adjusted relative risks for mortality from coronary heart disease, sudden cardiac and all-causes according 
to categories of diastolic blood pressure in elderly men followed for five years (The Zutphen Elderly Study: 1985 -1990) 
Diastolic blood pressure (mmHg) category /rvalue p-value 
linear quadratic 
Cause of < 75 75 - 84 85 - 94 > 95 Anti-hypertensive use trend trend 
death (n = 145) (n = 265) (n = 222) (n = 147) (n = 106) 
Coronary 
heart disease 
Sudden 
cardiac 
All-causes 
Rate* 20.8 9.9 12.2 11.7 14.7 
RRt 1.00 0.52 
(0.22 - 1 24) 
0.59 
(0.24 - 1 47) 
0.83 
(0.30 - 2.31) 
1.40 
(0.49 - 4.01) 
0.36 0.040 
Rate* 8.0 8.2 10.3 14.6 16.8 
RRt 1.00 1.42 
(0.37 - 5 51) 
2.03 
(0.53 - 7 73) 
3.04 
(0.75 - 12.37) 
4.32 
(1.01 - 18.40) 
0.013 0.98 
Rate* 73.6 52.6 35.6 49.7 63.1 
RRf 1.00 0.98 
(0.64 - 1 48) 
0.72 
(0.44 - 1 16) 
1.10 
(0.65 - 1.83) 
1.47 
(0.87 - 2.49) 
0.25 0.039 
*: /l ,000 person years 
f: relative risk (95% confidence interval) adjusted for age, body mass index, serum total and HDL cholesterol, cigarette smoking, alcohol consumption, use 
of medications known to lower blood pressure levels without an indication for hypertension and physician who took blood pressure 
Blood pressure and short-term CHD risk 
a U-shaped association was observed (figure 1A). Concerning all-cause mortality, there 
was a significant U-shaped association with diastolic blood pressure. Additional analyses 
did not reveal clear associations between diastolic blood pressure and cancer mortality (p-
linear trend = 0.85, p-quadratic trend = 0.27) nor mortality from causes other than 
cardiovascular diseases or cancer (p-linear trend = 0.32, p-quadratic trend = 0.25). 
o . i ^ 1 . 1 1 
< 75 75 - 84 85 - 94 * 95 Anti-hypertensive use 
Diastolic blood pressure (mmHg) 
0.1 A , , . 
< 140 140-159 5160 Anti-hypertensive use 
Systolic blood pressure (mmHg) 
- « - CHD sudden CHD -* - non-sudden CHD 
Figure 1. Adjusted relative risks for mortality from coronary heart disease and from coronary heart 
disease which was not additionally recorded as sudden according to diastolic (A) and systolic (B) 
blood pressure categories in elderly men followed for five years (The Zutphen Elderly Study: 1985 -
1990) 
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Systolic blood pressure was not significantly associated with the incidence of coronary 
heart disease (p-linear trend = 0.35, p-quadratic trend = 0.78) nor with mortality due to 
the disease (table 3). However, a strikingly strong association was observed between 
systolic blood pressure and sudden cardiac death with the highest adjusted relative risk 
observed among men using anti-hypertensive medication. Additional analyses revealed a 
positive association between systolic blood pressure and mortality from coronary heart 
disease when sudden cardiac death had also been recorded (figure IB). For non-sudden 
coronary heart disease mortality however, the association was U-shaped (figure IB). 
Systolic blood pressure tended to be positively associated with all-cause mortality and the 
relative risk reached statistical significance for men on anti-hypertensive medication. 
Systolic blood pressure was not associated with death due to cancer (p-linear trend = 0.61, 
p-quadratic trend = 0.57) nor death due to causes other than cardiovascular diseases and 
cancer (p-linear trend = 0.48, p-quadratic trend = 0.46). 
Regarding isolated systolic hypertension, the association with sudden cardiac death was 
even stronger than that described for systolic blood pressure (table 4). Associations with 
coronary heart disease and all-cause mortality were lacking. 
Age appeared to be an effect modifier in the associations of diastolic and systolic blood 
pressure with sudden cardiac and all-cause mortality. Additional analyses were therefore 
performed for younger and older men using the median age of 71 years as a cut-off value 
(table 5). Regarding sudden cardiac death, the younger men using anti-hypertensive 
medication had a five-fold higher rate than the older men using this medication. Apart 
from the men using anti-hypertensive medication, the differences in rates (i.e. the absolute 
risks) between blood pressure categories were generally larger for the older men, whereas 
the rate ratios (i.e. the relative risks) were generally smaller. Regarding all-cause mortality, 
the U-shaped association with diastolic blood pressure was more pronounced in the 
younger than in the older men when relative risks were compared. However, the absolute 
risks between categories of diastolic blood pressure were similar for both age groups. For 
systolic blood pressure the association with all-cause mortality was more pronounced in 
younger compared to older men and this was observed comparing relative as well as 
absolute risks. 
The use of medication known to lower blood pressure levels without an indication for 
hypertension was also an effect modifier in the associations of diastolic blood pressure 
with sudden cardiac death (p = 0.024) and all-cause mortality (p = 0.064) and of systolic 
blood pressure with all-cause mortality (p = 0.051). Additional analyses revealed that the 
associations were stronger among non-users of this type of medication. Regarding all-
cause mortality, the adjusted association with diastolic blood pressure was linear instead 
of U-shaped (p-linear trend = 0.038). 
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Table 3. Crude rates and adjusted relative risks for mortality from coronary heart disease, sudden cardiac and all-causes according 
to categories of systolic blood pressure in elderly men followed for five years (The Zutphen Elderly Study: 1985 - 1990) 
Systolic blood pressure (mmHg) category p-value 
linear trend 
p-value 
quadratic 
trend Cause of 
death 
< 140 
(n = 275) 
140 - 159 
(n = 282) 
> 160 
(n = 222) 
Anti-hypertensive use 
(n = 106) 
Coronary 
heart disease Rate* 10.9 15.5 11.8 14.7 
RRt 1.00 1.21 
(0.58 - 2.52) 
0.92 
(0.39 - 2.18) 
2 21 
(0.83'-5.94) 
0.36 0.28 
Sudden 
cardiac Rate* 2.3 13.9 14.7 16.8 
RRt 1.00 4.80 
(1.36 - 16.95) 
5.56 
(1.54- 20.08) 
8.70 
(2.11 - 35.90) 
0.002 0.17 
All-causes 
Rate* 45.4 52.6 54.9 63.1 
RRt 1.00 1.11 
(0.76- 1.61) 
1.10 
(0.74 - 1.63) 
1.70 
(1.04 - 2.76) 
0.096 0.28 
*: /1,000 person years 
t: relative risk (95% confidence interval) adjusted for age, body mass index, serum total and HDL cholesterol, cigarette smoking, alcohol consumption, use 
of medications known to lower blood pressure levels without an indication for hypertension and physician who took blood pressure 
Table 4. Crude rates and adjusted relative risks for mortality from coronary heart disease, sudden cardiac and all-causes according 
to isolated systolic hypertension category in elderly men followed for five years (The Zutphen Elderly Study: 1985 - 1990) 
Isolated systolic hypertension category* p-value 
Cause of death No 
(n = 252) 
Borderline 
(n = 200) 
Definite 
(n = 83) 
linear trend 
Coronary heart 
disease Ratef 10.3 15.3 19.4 
RR+ 1.00 1.18 
(0.50 - 2.78) 
1.55 
(0.51 - 4.66) 
0.45 
Sudden cardiac 
Ratet 1.7 13.2 22.2 
RRt 1.00 4.23 
(0.86 - 20.76) 
9.20 
(1.76 - 47.97) 
0.005 
All-causes 
Ratet 47.2 54.8 74.8 
RRt 1.00 1.03 
(0.68 - 1.56) 
1.24 
(0.74 - 2.08) 
0.46 
*: for definition see footnotes from table 1 
f: /l.OOO person years 
t*. relative risk (95% confidence interval) adjusted for age, body mass index, serum total and HDL cholesterol, cigarette smoking, alcohol consumption, use 
of medications known to lower blood pressure levels without an indication for hypertension and physician who took blood pressure 
Blood pressure and short-term CHD risk 
Table 5. Crude rates of sudden cardiac death and all-cause death according to categories of diastolic 
and systolic blood pressure by age in elderly men followed for five years (The Zutphen Elderly Study: 
1985 - 1990) 
Sudden cardiac death All-cause death 
Age < 71 
years 
(n = 330) 
Age ä 71 
years 
(n = 455) 
Age < 71 
years 
(n = 330) 
Age ä 71 
years 
(n = 455) 
Number of cases 17 27 57 155 
Diastolic blood pressure 
p-value for 
interaction* 
0.006 0.072 
< 75 mmHg 3.9t 10.8 43.2 94.5 
75 - 84 mmHg 1.7 14.6 23.4 81.0 
85 - 94 mmHg 6.9 14.4 12.0 63.9 
> 95 mmHg 10.1 20.9 23.8 73.1 
Anti-hypertensive use 25.5 5.0 43.7 89.8 
Systolic blood pressure 
p-value for 
interaction* 
0.010 0.072 
< 140 mmHg 0.0 5.0 17.8 76.2 
140 - 159 mmHg 8.8 19.7 30.6 77.3 
> 160 mmHg 8.5 20.0 25.4 80.1 
Anti-hypertensive use 25.5 5.0 43.7 89.8 
*: p-value for interaction of age with blood pressure in age-adjusted model 
t: Rate (/ 1,000 person years) 
Discussion 
The main findings of this study show that diastolic and systolic blood pressures, especially 
isolated systolic hypertension, are independently associated with the risk of sudden cardiac 
death in elderly men. Associations with coronary heart disease were less clear. However, 
for coronary heart disease mortality which was not recorded as sudden cardiac death, the 
highest risk was observed in men at the lower end of the blood pressure distribution and 
in men on anti-hypertensive medication. Regarding all-cause mortality, the associations 
with diastolic and systolic blood pressures were positive among men who were not using 
medications which may lower blood pressure levels without an indication for hypertension. 
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Sudden cardiac death and coronary heart disease 
Both diastolic and systolic blood pressures were strong predictors of sudden cardiac death 
in elderly men in this study. To our knowledge, this end-point has not previously been 
investigated in relation to blood pressure specifically in elderly persons, but the evidence 
for a positive association is convincing in middle-aged populations.33 The ascertainment 
of sudden cardiac death may have been more prone to misclassification than the other end-
points in this study since the exact time between the first occurrence of symptoms and 
death was not always available. However, differential misclassification is unlikely and thus 
cannot be an explanation for our findings. A possible biologic mechanism underlying the 
observed association may be an increased sympathetic drive unopposed by 
parasympathetic stimulation. This change in autonomic control has been described to occur 
with advancing age. Norepinephrine increases34 and baroreflex sensitivity declines7 with 
advancing age leading to increased sympathetic activity. In addition, sympathetic 
stimulation increases blood pressure levels. Among the same group of elderly men from 
Zutphen, a prolonged heart rate adjusted QT interval on the electrocardiogram was shown 
to be independently associated with the risk of sudden cardiac death.35 It could be 
hypothesized that this abnormality in the electrocardiogram results from ventricular 
electrical instability of the heart which in turn may be a consequence of increased 
sympathetic activity. Evidence is accumulating for an important role of increased 
sympathetic activity, and thus of increased blood pressure levels, in predicting sudden 
cardiac death36 especially in elderly people. 
No clear associations were observed between blood pressure levels and the incidence 
of coronary heart disease in the present study. Although we included the incidence of 
angina pectoris in the definition of coronary heart disease, which is rather uncommon, 
additional analyses including only myocardial infarction and mortality from coronary heart 
disease (ICD: 410 - 414) as an end-point also did not reveal an association with systolic 
blood pressure either. Clear linear relations between blood pressure and coronary heart 
disease have also been lacking in other studies of elderly persons.2 However, diastolic 
blood pressure showed a U-shaped relation with mortality from the disease and strong U-
shaped associations of both diastolic and systolic blood pressure levels with non-sudden 
coronary heart disease mortality were observed in this study. These findings may in part 
be explained by an increase in arterial stiffness6"8 and a reduction in diastolic coronary 
flow8,10 with advancing age. These changes have been associated with both a reduced 
diastolic blood pressure6"8 and an increase in atherosclerosis6,9 and thus coronary heart 
disease.6 Concerning systolic blood pressure, we observed the lowest risk of non-sudden 
coronary heart disease mortality among men with a pressure of 160 mmHg or higher and 
not on anti-hypertensive medication. An elevated pressure may be necessary in the 
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presence of stiffer arteries to guarantee adequate blood flow through the arteries4 and may 
therefore be protective of non-sudden coronary heart disease mortality. 
Both possible underlying mechanisms, increased sympathetic activity and increased 
arterial stiffness accompanied by a reduced diastolic coronary flow, are probably present 
in different degrees in older people. The underlying factor or factors deterrnining which 
mechanism predominates in elderly men is not clear. Although an effort was made to 
distinguish between these possible mechanisms through the unique definition of the end-
points, i.e. sudden and non-sudden coronary heart disease death, it cannot be deducted 
from this study whether these mechanisms drive the observed associations. 
All-cause mortality 
Regarding all-cause mortality, there was an indication for a U-shaped association with 
diastolic blood pressure and a linear positive association with systolic blood pressure, but 
the relative risks in the different categories did not reach statistical significance. However, 
the absolute excess risk of death in some of the blood pressure categories is considerable 
compared to the baseline category, although the relative risk remains small because of a 
high baseline rate. This phenomenon is often encountered in prospective studies in elderly 
populations.37 Bulpitt and Fletcher recently reviewed the epidemiologic evidence for the 
relationship between blood pressure and mortality in elderly people and observed that the 
relationship was still not clear among the very old.2 Very high baseline rates may offer 
an explanation, as we also observed in the age-stratified analyses. Another possible 
explanation for the weak association between blood pressure and all-cause mortality, and 
especially the U-shaped association with diastolic blood pressure, could be increased 
morbidity with advancing age. The presence of illness may lower the blood pressure5 , 1 1 , 2 1"2 3 
and increases the risk of death.23 However no clear associations were observed between 
blood pressure levels and mortality due to causes other than cardiovascular diseases. 
Additional adjustment for self-rated health and the presence of chronic diseases at 
baseline, such as cardiovascular diseases and cancer, also did not alter any of the 
associations investigated (results not shown). However, the U-shaped association between 
diastolic blood pressure and all-cause mortality became a positive linear association when 
men using blood pressure lowering medication without an indication for hypertension were 
excluded from the analyses. This type of medication is usually prescribed to treat 
cardiovascular diseases, and is thus indicative of the presence of these diseases in people 
while, at the same time, the blood pressure is lowered. Taylor and coworkers therefore 
postulated that treatment for cardiovascular diseases obscures the association of blood 
pressure with all-cause mortality.21 In a recent Norwegian study among people 65 years 
or older,22 the exclusion of men using blood pressure lowering medication substantially 
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reduced the J-shaped association between diastolic blood pressure and all-cause mortality. 
There may be a third phenomenon involved in our study. Possibly, associations between 
blood pressure variables and all-cause mortality are weak because of a dilution effect of 
positive associations observed with specific causes of death, such as sudden cardiac causes 
and cerebrovascular disease (results not shown). Indeed 141 men died of causes other than 
sudden cardiac causes or cerebrovascular disease. 
Isolated systolic hypertension, and systolic versus diastolic blood pressure 
We observed that isolated systolic hypertension was a very strong predictor of sudden 
cardiac death. This type of hypertension has long been recognized as an important risk 
factor for cardiovascular diseases in elderly people.18 The prevalence of isolated systolic 
hypertension increases with age,1 8 and is the result of decreased arterial compliance with 
advancing age.6 Apart from isolated systolic hypertension, we also observed systolic blood 
pressure per sé to be a stronger predictor of sudden cardiac death than diastolic blood 
pressure. Although the importance of systolic over diastolic blood pressure in predicting 
cardiovascular diseases increases with age, this predominance of systolic blood pressure 
has also been observed in middle aged people.38 Differences in the reproducibility of 
diastolic versus systolic blood pressure measurements may partly explain the differences 
in their predictive value. 
Age as an effect-modifier 
The associations of blood pressure levels with sudden cardiac and all-cause death were 
stronger in the younger than the older men of this cohort. However, the absolute rates and 
rate differences tended to be larger in the older men as compared to the younger ones. 
Therefore, the absolute impact of elevated blood pressure levels in an older population 
may be substantial especially when compared to middle-aged populations.37 In contrast, 
for men on anti-hypertensive medication the rates of sudden cardiac death were five-fold 
higher in the younger men as compared to the older men. These findings may be 
explained by selective survival of older men on anti-hypertensive medication. 
Anti-hypertensive medication use 
Men on anti-hypertensive medication were at the highest risk of coronary heart disease, 
sudden cardiac death and all-cause death. The untreated blood pressure level of these men 
is unknown and may be much higher than the level measured during the examination, 
which was already higher than the blood pressure of the rest of the cohort. In addition, 
men on anti-hypertensive medication generally had the highest prevalence of other risk 
factors for cardiovascular diseases. Therefore, these findings do not suggest that the use 
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of anti-hypertensive medication is causally associated with an increased risk of these end-
points. Rather, men on anti-hypertensive medication in this study form a distinct group 
with a clustering of risk factors for cardiovascular diseases, thus a group at increased risk 
for cardiovascular diseases. Regarding anti-hypertensive medication use in elderly people, 
clinical trials have provided evidence for significant reductions in blood pressure levels 
and in cardiovascular diseases and all-cause mortality in people up to 80 years of age 
using diuretics and or beta-blockers.2,39 Whether pharmacological treatment is beneficial 
after 80 years of age has yet to be evaluated.2 
The findings from this study suggest that, among elderly men followed for five years, 
elevated diastolic and systolic blood pressure, and especially isolated systolic hypertension 
are important predictors of sudden cardiac death. Elderly men on antihypertensive 
medication may form a distinct group with a clustering of risk factors for coronary heart 
disease and at the highest risk of coronary heart disease, sudden cardiac and all-cause 
death. Apart from this group, there is a suggestion for an inverse association between 
blood pressure levels and coronary heart disease mortality in elderly men. Both diastolic 
and systolic blood pressure levels are suggested to be positively associated with all-cause 
mortality when possible comorbidity at the time of blood pressure measurements has been 
accounted for. 
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Serum total cholesterol, systolic blood pressure and the 
long-term risk of coronary heart disease mortality in 
elderly men and women 
Abstract 
Serum total cholesterol and systolic blood pressure were investigated as risk factors for 
mortality from ischemic heart disease among 272 elderly men and women during 17 years 
of follow-up. For men, total cholesterol was not significantly associated with mortality 
from ischemic heart disease. Among women, a significant positive association was found 
(p-trend = 0.03 when adjusted for age, body mass index, systolic blood pressure, alcohol 
consumption, smoking, and the prevalence of myocardial infarction, angina pectoris and 
diabetes mellitus). Among women a significant positive association was also observed for 
systolic blood pressure after adjustment for all potential confounders (p-trend = 0.05). 
Among men, the adjusted association with systolic blood pressure was not statistically 
significant. The results suggest that total cholesterol and systolic blood pressure are 
stronger independent risk factors for mortality from ischemic heart disease among elderly 
women than among elderly men. These differences between gender may be due to 
selective mortality among middle-aged men and physiological changes in women during 
menopause. 
Published as: 
Weijenberg MP, Feskens EJM, Bowles CH, Kromhout D. Serum total cholesterol and 
systolic blood pressure as risk factors for mortality from ischemic heart disease among 
elderly men and women. J Clin Epidemiol 1994;2:197-205. 
Copyright holder Elsevier Science, Inc. 
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Introduction 
The total elderly population (65 years and older) in The Netherlands is expected to 
increase by 100% in the next 50 years. The total number of very old individuals (80 years 
and older) will increase by 150% in the same period. Despite some improvements in 
survival over the past ten years, ischemic heart disease continues to be the leading cause 
of death among the elderly.1 Therefore prevention of ischemic heart disease in the elderly 
deserves special attention. However, most studies on risk factors for ischemic heart disease 
have focussed specifically on middle-aged populations. 
In middle-aged men and women, high serum total cholesterol levels, high blood 
pressure and smoking have been identified as major risk factors for morbidity and 
mortality due to ischemic heart disease.2'3 It remains questionable, however, whether these 
risk factors retain their predictive power among the elderly.1'4"12 Many studies have shown 
that the associations of serum total cholesterol, blood pressure and smoking with ischemic 
heart disease decrease with age. 5^ 8^ 1 1- 1 2 Several reasons for this progressive decline have 
been suggested. In the first place, a true picture of mortality from ischemic heart disease 
among the elderly is difficult to obtain because of comorbidity and comortality.13 In 
addition, the predictive force of risk factors may decrease because those most sensitive or 
more exposed to the risk factor die first, and the remaining population on the average 
consists of more resistant or less exposed individuals.1 Furthermore, in many studies the 
follow-up time, and thus possibly the duration of exposure, may have been too short to 
detect an association between risk factors and mortality from ischemic heart disease in the 
elderly.6,11 
In the present 17-year follow-up study, the predictive power of serum total cholesterol and 
systolic blood pressure for mortality from ischemic heart disease among elderly men and 
women was investigated. 
Methods 
In 1971 a longitudinal health survey was started by one of the authors (CHB) among 
eligible men and women from his general practice in Rotterdam, The Netherlands. All of 
his non-institutionalized patients, born before 1907 and able to participate, were invited 
to take part in the study. Of these 394 subjects 340 (86%) agreed to participate. Due to 
limited laboratory facilities a total of 292 patients was examined medically in 1971. 
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During the physical examination, information on the medical history was obtained from 
the Dutch translation of the questionnaire developed by the London School of Hygiene 
and Tropical Medicine.14 Weight and height were measured with patients wearing 
underwear and socks only. A fasting blood sample was obtained by venipuncture and 
analyzed for serum total cholesterol by thin layer chromatography.15 This method was 
compatible with the Abell-Kendall method. The results were verified by the WHO 
Regional Lipid Reference Center of the Institute for Clinical and Experimental Medicine 
in Prague, Czechoslovakia, and were found to be within recommended limits.16 Blood 
pressure was measured in the right arm with subjects in the supine position, using a 
mercury sphygmomanometer. The measurements were carried out in triplicate and the 
lowest values of the systolic and diastolic (fourth Korofkoff phase) blood pressures were 
recorded. Hypertension was defined, largely in accordance with the WHO, 1 7 as a systolic 
blood pressure greater than or equal to 160 mmHg or a diastolic blood pressure greater 
than or equal to 95 mmHg or the use of anti-hypertensive medication. Because of possible 
misclassification of the diastolic blood pressure due to measurement at the fourth 
Korotkoff sound instead of the fifth, the present study specifically focussed on systolic 
blood pressure. Information on smoking habits was obtained from a standardized 
questionnaire. Smoking was defined as smoking cigarettes, pipe or cigars at baseline. 
Since nearly all men (70.8%) and almost none of the women (18.5%) in this study 
smoked, the associations between smoking and mortality from ischemic heart disease were 
not investigated. Information on alcohol consumption was obtained using the cross-check 
dietary history method,18 carried out by one trained dietitian. Drug use was determined by 
studying the patients' records. 
Information on the vital status of all 292 participants was obtained in 1988, covering 
the period January 1=, 1971 through December 31, 1987. Information on the causes of 
death was obtained from the Dutch Central Bureau of Statistics. The causes of death were 
coded according to the 9th Revision of the International Classification of Diseases (ICD). 
Because elderly people often suffer from multiple diseases, making it difficult to determine 
the underlying cause of death, ischemic heart disease was defined as ICD-codes 410-414 
recorded for either the primary or secondary cause of death. Twenty subjects were 
excluded from the analysis: blood samples were not drawn from seventeen individuals, one 
person was lost to follow-up and the cause of death of two people was unknown. 
Statistical analysis was carried out using the SAS program (SAS Institute Inc., Cary, 
North Carolina, USA, 1989, version 6.07). Analyses were carried out separately for men 
and women and all tests were two-tailed. Differences in risk factor levels between the 
levels of categorical variables were tested using Student's t-tests. In case of skewness of 
the risk factor distributions, the Mann-Whitney U-test was used. For differences in levels 
of categorical variables (smoking, alcohol intake, prevalence of myocardial infarction or 
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angina pectoris, clinical diabetes mellitus and hypertension) the %2-test statistic was 
calculated. Mortality rates for ischemic heart disease were computed per sex-specific 
tertiles for serum total cholesterol and systolic blood pressure. The proportionality 
assumption of Cox's proportional-hazard (survival) analysis was tested by including a 
time-dependent explanatory variable in the models and testing the significance of its 
regression coefficient.19 Since the regression coefficients were not significant, the 
proportionality assumption was regarded to be satisfied and survival analysis was carried 
out to investigate the association between serum total cholesterol, systolic blood pressure 
and mortality from ischemic heart disease adjusted for selected confounders. Dummy 
variables for serum total cholesterol and systolic blood pressure were used in the analysis 
to compare tertiles separately. P-values for trend were derived by testing the significance 
of the regression coefficients for the categorized cholesterol and blood pressure variables 
(coded 0,1,2). The difference between men and women in the association of risk factors 
with mortality from ischemic heart disease was tested by including an interaction variable 
of gender with the specific risk factor in the model and testing the significance of its 
regression coefficient. Interactions of selected confounders with each specific risk factor 
were tested in a similar manner, and no significant interactions were observed. 
Results 
In 1971, the cohort consisted of 137 men and 135 women between the ages of 64 and 87 
years. During the 17-year follow-up period 188 subjects died, 34 men and 24 women died 
of ischemic heart disease. For eight of these 58 subjects ischemic heart disease was a 
secondary cause of death. The overall mortality rate for ischemic heart disease was 19.6 
per 1,000 person years (py) and was significantly higher for men (25.4 per 1,000 py) than 
for women (14.8 per 1,000 py) (p < 0.05). The baseline mean serum total cholesterol level 
was significantly lower in men than in women: 6.44 ± 1.32 mmol/L versus 6.98 ± 1.29 
mmol/L (p < 0.001). Systolic blood pressure was also significantly lower in men than in 
women: 150.5 ± 22.4 mmHg versus 167.9 ± 24.5 mmol/L (p < 0.001). At baseline 44.5% 
of the men versus 71.1% of the women were classified as hypertensive (p < 0.001). 
For both men and women, serum total cholesterol was inversely associated with age. 
Serum total cholesterol levels were significantly lower in participants 70 years or older 
than in those younger than 70 years (p < 0.01 for men and p < 0.05 for women). Systolic 
blood pressure was significantly higher in men aged 70 years or older compared to those 
younger than 70 years (p < 0.001) and in men with diabetes compared to those without 
diabetes (p < 0.05). 
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Baseline values of selected risk factors according to prevalence of ischemic heart disease 
at baseline are presented in table 1. Among both men and women there were no 
significant differences in the selected risk factors between subjects with and without 
ischemic heart disease at baseline. 
Table 1. Baseline values of selected risk factors for 272 elderly men and women according to the 
prevalence of ischemic heart disease (IHD) at baseline 
Risk factor 
Men Women 
IHD* at baseline 
No (n=106) Yes (n=31) 
IHD* at baseline 
No (n=108) Yes (n=27) 
Age (years) 
BMI (kg/m2) 
Serum total cholesterol 
(mmol/L) 
Systolic blood pressure 
(mmHg) 
Diastolic blood pressure 
(mmHg) 
Smoking 
Alcohol (> Og/day) 
Diabetes mellitusf 
Hypertension^ 
71.6 ± 5.6 
24.81 ± 2.95 25.07 ± 2.65 
Mean ± Standard Deviation 
69.9 ± 4.2 70.1 ± 4.6 
6.38 ± 1.34 
150.0 ± 23.1 
86.5 ±11.8 
74.5 
71.7 
7.6 
40.6 
6.63 ± 1.27 
152.1 ± 20.1 
70.9 ± 3.7 
27.53 ± 3.97 26.54 ± 2.30 
7.06 ± 1.34 6.67 ±1.03 
167.9 ± 24.3 167.8 ± 25.7 
¡.7 ± 10.6 93.2 ± 11.7 90.6 ±11.3 
Percentage 
58.1 20.4 11.1 
74.2 38.9 25.9 
0.0 10.2 18.5 
58.1 70.4 74.1 
Prevalence of myocardial infarction and/or angina pectoris in 1971 
Clinical diagnosis 
Systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 95 mmHg and/or on anti-hypertensive 
medication 
In table 2 baseline values of selected risk factors according to mortality from ischemic 
heart disease are shown. Systolic blood pressure and the prevalence of myocardial 
infarction or angina pectoris were significantly higher among men who died of ischemic 
heart disease than those who did not. There were no significant differences in serum total 
cholesterol levels, smoking habits and prevalence of hypertension between the two groups 
of men. Among women serum total cholesterol levels, systolic blood pressure and 
prevalence of hypertension were significantly higher for those who died of ischemic heart 
disease than those who did not. 
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Table 2. Baseline values of selected risk factors for 272 elderly men and women according to 
mortality from ischemic heart disease (IHD) during 17 years of follow-up (1971 -1987) 
Men Women 
Risk factor Died of IHD Died of IHD 
No (n=103) Yes (n=34) No (n=lll) Yes (n=24) 
Mean ± Standard Deviation 
Age (years) 70.9 ± 5.4 72.2 ± 5.0 70.0 ± 4.4 71.5 ± 4.5 
BMI (kg/m2) 24.69 ± 2.72 25.40 ± 3.29 27.31 ± 3.79 27.43 ± 3.41 
Serum total 
cholesterol 
(mmol/L) 
6.44 ± 1.39 6.44 ± 1.10 6.89 ± 1.32 7.42 ± 1.07* 
Systolic blood 
pressure (mmHg) 147.7 ±21.6 159.0 ± 23.0* 164.7 ± 22.8 182.3 ± 27.3f 
Diastolic blood 
pressure (mmHg) 86.6 ± 12.4 88.4 ± 8.4 91.9 ± 11.5 96.3 ± 11.6 
Percentage 
Smoking 70.9 70.6 18.9 16.7 
Alcohol 
(> Og/day) 70.9 76.5 33.3 50.0 
Myocardial 
infarction and/or 
angina pectoris 
12.6 52.9$ 18.9 25.0 
Diabetes 
mellitus§ 6.8 2.9 9.9 20.8 
Hypertension! 40.8 55.9 66.7 91.7* 
*: pi 0.05 
t: pi0.0\ 
| : 0.001 
§: Clinical diagnosis 
1: Systolic blood pressure 2 160 mmHg and/or diastolic blood pressure £ 95 mmHg and/or on anti-hypertensive 
medication 
The mortality rate for ischemic heart disease was highest among men in the medium 
cholesterol tertile, but the difference with respect to the mortality rates for the other tertiles 
was not statistically significant (table 3). For women, the mortality rate for ischemic heart 
disease increased with each cholesterol tertile. Regarding systolic blood pressure, mortality 
rates for ischemic heart disease increased with each tertile for both men and women. The 
mortality rate for men in the highest tertile of systolic blood pressure was significantly 
higher than the rate for the lowest tertile (p < 0.05). Mortality rates for women in the 
medium and highest tertiles were significantly higher than the rate for the lowest tertile 
of systolic blood pressure (p < 0.05 in both cases). 
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Table 3. Mortality rates (per 1,000 person years) for ischemic heart disease among men and women 
after 17 years of follow-up (1971 - 1987), listed according to the tertiles of serum total cholesterol 
and systolic blood pressure 
Risk factor category Men (n=137) Women (n=13S) 
Serum total cholesterol* 
Low 20.7 (8)t 7.1 (4) 
Medium 36.5 (16) 17.9 (9) 
High 19.5(10) 19.8(11) 
Systolic blood pressure^. 
Low 13.9 (6) 5.4 (3) 
Medium 21.1(11) 18.4 (11)§ 
High 44.5 (17)§ 21.6 (10)§ 
*: For men the cut-off points for the tertiles of serum total cholesterol were 5.84 mmol/L and 6.90 mmol/L. For women 
the cut-off points were 6.34 mmol/L and 7.32 mmol/L 
t: In parentheses, the number of deaths due to ischemic heart disease 
p . For men the cut-off points for the tertiles of systolic blood pressure were 135 mmHg and 155 mmHg. For women 
the cut-off points were 155 mmHg and 175 mmHg 
§: pi 0.05, significant difference with respect to the lowest tertile of systolic blood pressure 
For men, serum total cholesterol was not significantly associated with mortality from 
ischemic heart disease when adjusted for age and also not when additionally adjusted for 
body mass index, systolic blood pressure, alcohol consumption, smoking, and the 
prevalence of myocardial infarction, angina pectoris and diabetes mellitus (p-trend = 0.68) 
(table 4). Among women, serum total cholesterol was significantly associated with 
mortality from ischemic heart disease when adjusted for age and for the other selected risk 
factors O-trend = 0.03). For women in the highest cholesterol fertile ( > 7.32 mmol/L) the 
age-adjusted relative risk for mortality from ischemic heart disease was 3.8 with a 95% 
confidence interval (CI) excluding unity (95% CI: 1.2-12.2). When adjusted for the other 
selected risk factors, the relative risk for women in the highest cholesterol tertile remained 
significantly greater than one (relative risk = 3.9, 95% CI: 1.1-13.7). The adjusted 
association between serum cholesterol and mortality from ischemic heart disease was 
significantly different between men and women (p = 0.04). 
The age-adjusted relative risk for mortality from ischemic heart disease for men 
increased with each tertile of systolic blood pressure (table 4). When the model was 
adjusted for all potential confounders, including anti-hypertensive and/or diuretic 
medication, there was no significant association between systolic blood pressure and 
mortality from ischemic heart disease among men (p-trend = 0.34). Among women, 
systolic blood pressure was positively associated with mortality from ischemic heart 
disease when adjusted for age (p-trend = 0.08) and for all selected confounders (p-trend 
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Table 4. Relative risks and 95% confidence intervals (in parentheses) for mortality from ischemic 
heart disease for the medium and the highest versus the lowest tertiles of serum total cholesterol and 
systolic blood pressure for 272 elderly men and women during 17 years of follow-up (1971 - 1987) 
Risk factor 
category 
Men (n=137) 
Adjusted Adjusted for 
for age selected risk 
factorst 
Women (n=135) 
Adjusted 
for age 
Adjusted for 
selected risk 
factorst 
Total (n=272)* 
Adjusted Adjusted for 
for gender gender and 
and age selected risk 
factorst 
Serum total cholesterol^ 
Low 1.0 1.0 1.0 1.0 
Medium 1.9 
(0.8-4.4) 
2.0 
(0.8-5.0) 
2.9 
(0.9-9.3) 
2 2 
(0.7-7.7) 
High 1.0 
(0.4-2.6) 
1.3 
(0.5-3.3) 
3.8 
(1.2-12.2) 
3.9 
(1.1-13.7) 
p-trend 0.92 0.68 0.03 0.03 
Systolic blood pressure^ 
Low 1.0 1.0 1.0 1.0 1.0 1.0 
Medium 1.4 
(0.5-3.9) 
1.5 
(0.6-4.3) 
3.1 
(0.8-11.3) 
3.6 
(1.0-13.6) 
2.0 
(1.0-4.2) 
1.5 
(0.7-3.1) 
High 2.5 
(0.9-6.5) 
1.7 
(0.6-4.9) 
3.5 
(0.9-13.3) 
4.1 
(1.0-16.4) 
2.3 
(1.1-4.9) 
1.6 
(0.7-3.5) 
p-trend 0.05 0.34 0.08 0.05 0.04 0.25 
Results only shown when the association was not significantly different between men and women 
The relative risks are adjusted for age, body mass index, alcohol consumption, prevalence of myocardial infarction 
and/or angina pectoris and diabetes mellitus, smoking, systolic blood pressure or serum total cholesterol and anti-
hypertensive and/or diuretic medication 
See footnote 1 in table 3 for sex-specific cut-off points for the tertiles of serum total cholesterol 
See footnote 2 in table 3 for sex-specific cut-off points for the tertiles of systolic blood pressure. For the total 
population the cut-off points were 145 mmHg and 165 mmHg 
= 0.05). For women in the medium and highest tertiles of systolic blood pressure, the 
relative risk adjusted for all selected risk factors was significantly different from one, i.e. 
3.6 (95% CI: 1.0-13.6) and 4.1 (95% CI: 1.0-16.4) respectively. The adjusted association 
between systolic blood pressure and mortality from ischemic heart disease did not differ 
significantly between men and women (p = 0.26). For the total population the association 
between systolic blood pressure and mortality from ischemic heart disease was significant 
when adjusted for gender and age (p-trend = 0.04) but not after additional adjustment for 
the other risk factors (p-trend = 0.25). 
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Discussion 
The results of the present study suggest that serum total cholesterol and systolic blood 
pressure are independent risk factors for mortality from ischemic heart disease among 
elderly women and to lesser extent among elderly men. 
Concerning serum total cholesterol, it must be noted that the cut-off points for the tertiles 
were higher for women than for men. However, when the cholesterol cut-off point ( < 6.5 
mmol/L) suggested by the Dutch cholesterol consensus was used,20 the results were 
essentially the same. Recently at a National Heart, Lung, and Blood Institute workshop, 
the cholesterol-ischemic heart disease association was re-examined in 25 initially middle-
aged populations, from 22 different studies, who had aged.21 Contrary to the present 
findings, the strongest association was found among elderly men (pooled relative risk = 
1.3). The data on elderly women (16 of the 25 study populations) supported a positive 
relationship between serum total cholesterol and ischemic heart disease, but there was 
clearly less consistency in the association (pooled relative risk = 1.1). However, in these 
studies the National Cholesterol Education Program definitions of a desirable cholesterol 
level ( < 5.17 mmol/L) and a high-risk cholesterol level ( > 6.20 mmol/L) were used; in 
the present study, according to these definitions, only 3.7% of the elderly women had a 
desirable cholesterol level and 71.9% had a high-risk level. This higher serum total 
cholesterol level could partly explain the higher relative risks found for the elderly women 
in our study. Of the men in the present study, 16.8% had a desirable cholesterol level and 
53.3% had a high-risk level, according to the National Cholesterol Education Program 
definitions. Possibly these men may have also had relatively higher serum total cholesterol 
levels at middle-age, suggesting that selective mortality at that age may have played a 
more important role for these men than for those included in the meta-analysis. This could 
partly explain the discrepancy in the results for men. 
Middle-aged men with high serum total cholesterol levels are indeed at increased risk 
for mortality from ischemic heart disease.2'3 In the present study, lower mortality among 
men in the highest cholesterol tertile versus men in the median tertile may partly be due 
to selective mortality at middle age. Recently, this effect was observed in the Dutch male 
cohort of the Seven Countries Study, the Zutphen Study.22 This phenomenon of 'survival 
of the fittest' may be less applicable to female populations. In general, middle-aged 
women are known to have lower serum total cholesterol levels than middle-aged men and 
the mortality rates for ischemic heart disease are lower for middle-aged women with 
elevated serum total cholesterol levels than middle-aged men with elevated cholesterol 
levels.4'23 Witteman and co-workers observed that the rate of atherosclerosis increases after 
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ovarian involution24 which may in part be due to the fact that serum total cholesterol 
levels have been shown to increase in women around menopause.2 3 , 2 6 In fact, among the 
elderly, more women than men have cholesterol levels that exceed the cutoff point of 6.5 
mmol/L; for levels above the cutoff point treatment is recommended.20 Together with the 
possible absence of selective mortality in the female population of this study, these 
changes around menopause may offer an explanation for the association found between 
serum total cholesterol and mortality from ischemic heart disease among the women in 
this study. 
Whether reduction of serum lipid levels in the elderly would have a beneficial effect, 
as suggested by the observations of this study, should preferably be further investigated 
in clinical trials. As yet only one trial of a serum cholesterol-lowering diet has been 
conducted among elderly men 2 7 and none among elderly women. The results of this trial, 
which ended in 1968, suggested that a cholesterol-lowering diet can reduce the morbidity 
and mortality rates of ischemic heart disease. The effect appeared stronger among younger 
men, aged 50 to 65.5 years, than for men over 65.5 years of age. 
Elevated blood pressure is known to be an important risk factor for mortality from 
ischemic heart disease among middle-aged men and women.2,3 In the present study, like 
serum total cholesterol, systolic blood pressure appears to be an independent risk factor 
for mortality from ischemic heart disease among elderly women but not elderly men. The 
cut-off points for the tertiles of systolic blood pressure were also higher for women than 
men. However, when hypertension (yes or no) or a variable indicating whether an 
individual's systolic blood pressure exceeded the 160 mmHg cut-off value was included 
in the fully adjusted model, the results were essentially the same. Selective mortality may 
also have occurred among men with high systolic blood pressure at middle age, leading 
to fewer but on the whole "stronger" elderly men with an elevated systolic blood pressure. 
This could explain the lack of association between systolic blood pressure and mortality 
from ischemic heart disease among the elderly men of this cohort. Nevertheless, the age-
adjusted model revealed a significant trend in the association among men and the 
unadjusted mortality rate for men in the highest tertile of systolic blood pressure was 
significantly higher than that for those in the lowest tertile. Possibly the suggested lack 
of association between systolic blood pressure and mortality from ischemic heart disease 
among men in this study is due to chance. The difference in the association between men 
and women was not significant and among women systolic blood pressure was 
significantly associated with mortality from ischemic heart disease. In many studies this 
association has also been found to persist with age2 8"3 0 and no differences between men 
and women have been reported. 
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Several recent trials on the effect of lowering blood pressure in elderly people have shown 
that clinically relevant reductions in overall mortality and that from ischemic heart disease 
can be achieved.30"32 In these trials no differences in reduction of morbidity and mortality 
between gender have been observed. However, among very old subjects (85 years and 
older) J and U-shaped associations have been reported8'9'31 and it remains questionable 
whether treatment is beneficial in the very old. 9 , 3 3 
Some studies have suggested that a long-term accumulated exposure to certain risk factors 
is needed for the development of ischemic heart disease.34'35 The association between 
cholesterol or blood pressure and mortality from ischemic heart disease seems to be 
strongest in studies among elderly with long follow-up periods, 3 4 , 3 6 ' 3 7 as in the present 
study, and weak or absent in studies with short follow-up periods, i.e. 2 years.6 , 1 1 In the 
Whitehall study (18 years of follow-up) of men aged 40 to 69 years at baseline, for 
instance, the longer the follow-up time the more predictive the cholesterol concentration 
was for ischemic heart disease.34 
As people age, competing causes of mortality increase38 and this could theoretically 
have affected the outcome of the present study. To overcome part of this problem 
ischemic heart disease was defined as the primary or secondary cause of death. Additional 
survival analysis of all-cause mortality instead of mortality from ischemic heart disease 
as end-point revealed similar associations with serum total cholesterol or systolic blood 
pressure for both men and women, but these associations were not statistically significant. 
This may be due to the fact that only 58 of the 188 subjects who died actually had 
ischemic heart disease as the primary or secondary cause of death, which is a normal 
proportion for the Netherlands, and dilution of the effect may have occurred. 
In summary, the results of the present study suggest that serum total cholesterol and 
systolic blood pressure are stronger independent risk factors for mortality from ischemic 
heart disease among elderly women than elderly men. These differences between men and 
women may be due to selective mortality among middle-aged men and physiological 
changes in women during menopause. These associations should preferably be reexamined 
in larger longitudinal studies of the elderly. 
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Total and high density lipoprotein cholesterol and the 
five-year risk of coronary heart disease in elderly men 
Abstract 
The associations of serum total and high density lipoprotein (HDL) cholesterol with 
coronary heart disease were investigated in men aged 64 to 84 years from the Dutch town 
of Zutphen during five years of follow-up. In 1985, 885 randomly selected men, 710 of 
whom did not have a history of clinical coronary heart disease, participated in the study. 
Associations were adjusted for age, body mass index, systolic blood pressure, cigarette 
smoking and alcohol consumption. Total cholesterol was not significantly associated with 
the incidence of coronary heart disease, but for mortality the relative risk (RR) 
corresponding to a 1.00 mmol/liter increase was 1.40 (95 percent CI 1.07-1.83). HDL 
cholesterol was not associated with mortality from coronary heart disease. The RR for the 
incidence of the disease, corresponding to a 0.26 mmol/liter increase, was 0.80 (95 percent 
CI 0.60-1.08). Regarding the ratio of HDL to total cholesterol, the RR for coronary heart 
disease incidence corresponding to a 0.05 increase amounted to 0.70 (95 percent CI 0.51-
0.95). These results show that in elderly men followed for five years, both total and HDL 
cholesterol are important in predicting coronary heart disease. Total cholesterol seems to 
be a stronger risk factor for mortality from the disease, whereas HDL cholesterol is more 
strongly associated with the incidence of a first coronary heart disease event. 
Published as: 
Weijenberg MP, Feskens EJM, KromhoutD. Total and high density lipoprotein cholesterol 
as risk factors for coronary heart disease in elderly men during 5 years of follow-up. The 
Zutphen Elderly Study. Am J Epidemiol 1996;143:151-158. 
Copyright holder American Journal of Epidemiology. 
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Introduction 
The associations of serum total and high density lipoprotein (HDL) cholesterol levels with 
the risk of coronary heart disease among middle-aged men are currently well established.1,2 
It is not clear whether these associations pertain to elderly people.3"10 Several issues should 
be considered when follow-up studies are conducted among elderly people, which could 
explain part of this controversy. 
When quality of life is considered, it seems more meaningful to investigate the 
incidence of a first coronary heart disease event rather than death due to this disease. 
However, most studies among elderly people have focused on mortality from coronary 
heart disease, and potential risk factors have often been measured in populations that 
included individuals with the disease at baseline.4"8 Possible confounding and effect 
modification of observed associations due to the prevalence of coronary heart disease at 
baseline may be larger among older persons than among those who are younger because 
of the higher prevalence of coronary heart disease in the elderly.11 In addition, due to 
possible increasing comorbidity and comortality with age, true associations between risk 
factors and incidence or mortality may be difficult to establish.12 These problems can 
possibly be circumvented by conducting prospective studies among apparently disease-free 
older people during a relatively short follow-up period. 
Besides these methodological issues, controversy concerning the predictive value of 
total cholesterol for coronary heart disease among the elderly may exist because HDL 
cholesterol has rarely been investigated in this age group. It has been suggested that with 
increasing age low HDL cholesterol levels may be a more important predictor of coronary 
heart disease than elevated total cholesterol levels.13 
We therefore investigated serum total and HDL cholesterol as risk factors for the 
incidence of and mortality from coronary heart disease among elderly men during five 
years of follow-up. 
Materials and methods 
Population 
The Zutphen Study is a longitudinal investigation of chronic disease risk factors initiated 
in 1960 among middle-aged men as the Dutch contribution to the Seven Countries Study.14 
In 1985, 555 men from the 1960 cohort were still alive and were invited for new 
examinations. In addition, a random sample (two of three) of all men of the same age 
living in Zutphen who were not part of the 1960 cohort were invited to take part in the 
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study. From then on, the study was continued as the Zutphen Elderly Study. Of the 1,266 
men approached 939 (74 percent) agreed to participate. A total of 109 men (9 percent) 
could not be examined because of serious illness or death, 62 men (5 percent) had moved 
and 156 men (12 percent) refused to participate or could not be reached. Complete 
information on risk factors was available for 885 men aged 64 to 84 years. The two 
groups of men, those who participated since 1960 and those who did since 1985, did not 
differ significantly from each other with regard to coronary heart disease risk factors such 
as age, body mass index, total and HDL cholesterol and blood pressure levels. 
Examinations 
Physical examinations and dietary surveys took place between March and June 1985. 
Physical examinations were carried out by five trained physicians according to a 
standardized protocol. Height was measured to the nearest 0.1 cm and body weight was 
measured to the nearest 0.5 kg while the men were in underwear. Body mass index 
(weight (kg)/ height (m)2) was calculated. Systolic and diastolic (fifth Korotkoff phase) 
blood pressures were measured in duplicate with a random zero sphygmomanometer at the 
right arm while subjects were in the supine position. These measurements were taken at 
the end of the physical examination. The mean of the two blood pressure values was used 
in the analyses. Hypertension was defined as a systolic blood pressure greater than or 
equal to 160 mmHg or a diastolic blood pressure greater than or equal to 95 mmHg or the 
use of anti-hypertensive medication regardless of the blood pressure levels.15 Information 
on medication use, prescribed diets and smoking habits was assessed with a standardized 
questionnaire. In our study, smoking was defined as never, former, or current cigarette 
smoking. Amount of cigarette years (amount (cigarettes/day) x duration (years)) was also 
computed to investigate its correlation with other baseline variables. Information on 
alcohol consumption was assessed by trained dietitians with a cross-check dietary history,16 
adapted to the Dutch situation.17 Dietary information was available for 825 men. 
Nonfasting venous blood samples were taken for the analysis of serum total and HDL 
cholesterol. The analyses were carried out in the standardized lipid laboratory of the 
Department of Human Nutrition, Agricultural University, Wageningen, the Netherlands. 
High density lipoprotein was isolated after precipitation of apo B containing particles by 
dextran sulfate-Mg2+.18 Total and HDL cholesterol were determined enzymatically with the 
CHOD-PAP mono-testkit from Boehringer Mannheim.1 9 , 2 0 Standardization was realized by 
using calibration sera from the Foundation of Chemical Analysis Quality Control (The 
Netherlands) for total cholesterol, and calibration sera were prepared according to the 
method of van der Haar et al.2 1 for HDL cholesterol. Control sera were obtained from the 
Centers for Disease Control, Atlanta, Georgia, USA. 
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Information on the presence of diabetes mellitus was obtained through a standardized 
medical questionnaire during the physical examination. Both patients with insulin-
dependent and non-msulin-dependent diabetes mellitus were considered in this study. 
Follow-up 
Information on the prevalence of coronary heart disease was obtained during the physical 
examination in 1985 and a similar examination between March and June 1990 with the 
use of the Dutch translation of a questionnaire developed at the London School of 
Hygiene and Tropical Medicine.22 For men who did not participate in the 1990 
examination, information on major chronic diseases was obtained from a questionnaire for 
nonparticipants. Coronary heart disease was considered to be present when either 
myocardial infarction or angina pectoris was diagnosed. For myocardial infarction the final 
diagnosis was based on whether two of the following three criteria were met: a specific 
medical history, i.e. severe chest pain lasting for more than 20 minutes and not 
disappearing in rest, characteristic electrocardiogram changes and specific enzyme 
elevations. The diagnosis of angina pectoris was based on information obtained from the 
Rose questionnaire.22 The diagnoses were additionally verified with hospital discharge data 
and written information from the subjects' general practitioners. All information was 
eventually coded by a single physician, and the year of first diagnosis was recorded. 
Information on the vital status of the participants was obtained till July 1990. One 
person had moved abroad and was lost to follow-up. The date on which he moved was 
used as his (censored) end-point date. Information on the causes of death was obtained 
from the Dutch Central Bureau of Statistics, after verification with hospital discharge data 
and information from the deceased's general practitioners. The causes of death were coded 
according to the 9th Revision of the International Classification of Diseases.23 Because of 
the frequency of possible comorbidity and comortality in elderly people the underlying 
cause of death is often difficult to determine. Death due to coronary heart disease was 
therefore defined by International Classification of Diseases codes 410-414 recorded for 
either the primary or secondary cause of death. 
The end-points investigated were the incidence of a first fatal or non-fatal coronary 
heart disease event (i.e. incidence of coronary heart disease), mortality from coronary heart 
disease, from causes other than coronary heart disease and from all-causes. 
Statistical methods 
Statistical analyses were carried out using the SAS program (SAS Institute Inc., Cary, 
North Carolina, USA, 1989, version 6.07). All tests were two sided and p-values smaller 
than five percent were considered statistically significant. Spearman correlation 
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coefficients (r) were calculated between total and HDL cholesterol levels and levels of 
other risk factors for coronary heart disease. Differences in risk factor levels between 
levels of categorical variables were evaluated using Student's t-tests and Mann-Whitney 
U-tests in case the risk factor distributions were skewed. For differences in levels of 
categorical variables the Chi-square test statistic was used. Incidence and mortality rates 
were computed for tertiles of total and HDL cholesterol. 
Cox's proportional-hazard (survival) analysis was carried out to investigate the 
associations between lipid variables and the end-points of interest during five years of 
follow-up.24 Relative risks (RR) for the incidence or mortality end-points are presented 
according to 1.00 mmol/liter (38.7 mg/dl) increase in total cholesterol and 0.26 mmol/liter 
(10.0 mg/dl) increase in HDL cholesterol. Associations were adjusted for age, body mass 
index, systolic blood pressure, cigarette smoking and alcohol consumption. No adjustment 
was made for the use of cholesterol lowering medication and/or diet because only 25 men 
were receiving cholesterol lowering treatment (3 percent of the 825 men for whom the 
information was available) and additional adjustment for this potential confounder did not 
alter the associations. Total physical activity, as calculated by Caspersen et al.,2 5 was also 
not adjusted for because the inclusion of this variable in the multivariate models did not 
alter the associations and this information was available for a limited number of men (n 
= 827). 
Interaction terms were evaluated at the 10 percent level. A significant interaction was 
observed between total cholesterol and body mass index. Therefore, this result is also 
presented separately for lean and overweight men. The chosen cut-off value was mean 
body mass index (25 kg/m2, a cut-off point also often used to indicate overweight26). 
Results 
In 1985, 885 men aged 64 to 84 years (mean age 71.5 years) were examined. The mean 
baseline serum total cholesterol level was 6.10 (standard deviation (SD) 1.11) mmol/liter 
and the mean baseline HDL cholesterol level was 1.12 (SD 0.29) mmol/liter. Thirty five 
percent of the men were hypercholesterolemic (total cholesterol > 6.5 mmol/hter),27 23 
percent of the men had HDL cholesterol levels lower than 0.9 mmol/hter. 
Serum total and HDL cholesterol levels were significantly correlated with each other 
(r = 0.13). Total cholesterol was inversely associated with age (r = -0.21) and positively 
associated with body mass index (r = 0.18), alcohol intake (r = 0.08), and amount of 
cigarette smoking years (r = 0.11). HDL cholesterol was inversely associated with body 
mass index (r = -0.27) and positively associated with alcohol intake (r = 0.31), but did not 
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vary significantly with age. All these correlation coefficients are statistically significant 
at the five percent level. 
At the initial examination, the prevalence of coronary heart disease was 19.8 percent. Men 
with coronary heart disease at baseline were significantly older, had lower levels of HDL 
cholesterol, and a lower mean HDL/total cholesterol level than men without the disease 
(table 1). Baseline serum total cholesterol levels were higher among men with coronary 
heart disease at baseline than among men without the disease, although this difference was 
not statistically significant (p = 0.15). Among men with coronary heart disease in 1985 
there were fewer alcohol drinkers, more former smokers, and fewer current smokers than 
among men without the disease (table 1). 
Table 1. Baseline values of selected risk factors according to prevalence of coronary heart disease 
in 1985, in 885 men aged 64 to 84 years from The Zutphen Elderly Study 
Risk factors 
Prevalence of coronary heart disease* 
No (n=710) Yes (n=175) 
Age (years) 
Body mass index (kg/m2) 
Serum total cholesterol (mmol/liter) 
HDL cholesterol (mmol/liter) 
HDL/total cholesterol 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Hypertension 
Prevalence of diabetes mellitus 
Alcohol use (> 0 g/day) 
Former cigarette smoker in 1985 
Current cigarette smoker in 1985 
Mean (standard deviation) 
71.3 (5.4) 
25.5 (3.2) 
6.06 (1.10) 
1.14 (0.30) 
0.19 (0.06) 
151.2 (21.1) 
85.6 (11.4) 
43.2 
6.2 
75.0 
48.9 
32.0 
Percentage 
72.2 (5.3)t 
25.5 (3.0) 
6.24 (1.11) 
1.06 (0.28)$ 
0.17 (0.05)§ 
150.6 (22.9) 
84.7 (11.7) 
37.7 
8.0 
64.0$ 
61.If 
22.9t 
prevalence of myocardial infarction and/or angina pectoris 
t: p<0.05 
$: p<0.m 
p <0.001 
Among the 710 men free of coronary heart disease at baseline, a first fatal or non-fatal 
coronary heart disease event occurred in 56 men during five years of follow-up. The 
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incidence rate was 17.2 per 1,000 person years. During the follow-up period 212 men 
from the total population died (52.1 per 1,000 person years), 53 from coronary heart 
disease (13.0 per 1,000 person years). Four of these men had coronary heart disease coded 
as a secondary cause of death. 
The incidence rate of coronary heart disease did not vary with tertiles of total 
cholesterol and decreased gradually with increasing tertiles of HDL cholesterol (table 2). 
The mortality rate from coronary heart disease more than doubled between the first and 
second tertiles of total cholesterol. For HDL cholesterol the mortality rates did not differ 
between tertiles of HDL cholesterol. 
Table 2. Incidence and mortality rates for coronary heart disease among elderly men aged 64 to 84 
years according to tertiles of total and HDL cholesterol (The Zutphen Elderly Study, 1985) 
Incidence of Mortality from 
Tertiles coronary heart disease* coronary heart diseasef 
Range$ N Rate§ Range$ N Rate§ 
Total cholesterol 
Low 2.78-5.55 237 17.2 2.78-5.61 296 7.6 
Medium 5.57-6.52 236 16.4 5.62-6.53 293 16.8 
High 6.53-13.20 237 18.1 6.54-13.20 296 14.5 
HDL cholesterol 
Low 0.56-0.97 234 22.5 0.56-0.95 292 11.2 
Medium 0.98-1.22 239 17.3 0.96-1.21 303 16.5 
High 1.23-3.34 237 12.0 1.22-3.34 290 11.3 
*: based on 710 men free of coronary heart disease at baseline 
t: based on 885 men 
p . range in mmoWiter for total and HDL cholesterol 
§: rate per 1,000 person years 
Survival analysis revealed that HDL cholesterol appeared to be associated with a reduced 
incidence of coronary heart disease (table 3). The unadjusted association was borderline 
significant (p for trend = 0.08), and the adjusted relative risk was of the same magnitude 
but was not significantly different from unity. The relative risk was lower among men 
without diabetes mellitus at baseline (adjusted RR = 0.74, 95 percent confidence interval 
(CI) 0.53-1.02, p-interaction = 0.14). HDL/total cholesterol was independently associated 
with a decreased incidence of coronary heart disease (adjusted RR for a 0.05 increase = 
0.70, 95 percent CI 0.51-0.95). HDL cholesterol was not significantly associated with 
mortality from coronary heart disease. 
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Table 3. Relative risks for the incidence of and mortality from coronary heart disease in men aged 
64 to 84 years associated with total and HDL cholesterol (The Zutphen Elderly Study, 1985) 
Incidence of Mortality from 
coronary heart disease* coronary heart diseasef 
RR 95% CI RR 95% CI 
Total cholesterol (for 1.00 mmol/liter increase) 
Crude 1.03 0.81-1.32 1.25 0.98-1.59 
Adjusted for age 1.11 0.86-1.43 1.41 1.10-1.81 
Adjusted for risk factors! 1.17 0.90-1.52 1.40 1.07-1.83 
HDL cholesterol (for 0.26 mmol/liter increase) 
Crude 0.78 0.59-1.03 1.00 0.78-1.28 
Adjusted for age 0.80 0.61-1.05 1.02 0.77-1.31 
Adjusted for risk factors! 0.80 0.60-1.08 1.01 0.76-1.34 
*: based on 710 men free of coronary heart disease at baseline with 56 new events during follow-up 
t: based on 885 men with 53 mortality cases during follow-up 
$: adjusted for age, body mass index, systolic blood pressure, cigarette smoking and alcohol consumption 
Serum total cholesterol was not significantly associated with the incidence of coronary 
heart disease (table 3). No association was observed among men free of diabetes mellitus 
at baseline (p for trend = 0.79, p-interaction = 0.01). Total cholesterol was positively and 
independently associated with mortality from coronary heart disease in the total 
population. The risk factor adjusted relative risk was 1.40 and was reduced to 1.29 (95 
percent CI 0.99-1.69) after additional adjustment for the prevalence of coronary heart 
disease and diabetes mellitus at baseline. In the association with mortality from coronary 
heart disease there was a significant interaction between total cholesterol and body mass 
index (p = 0.005). Total cholesterol was independently associated with increased mortality 
from coronary heart disease in overweight men (body mass index > 25 kg/m2) (adjusted 
RR = 1.70, 95 percent CI 1.22-2.38), but not in lean men (adjusted RR = 1.06, 95 percent 
CI 0.67-1.66). 
Serum total and HDL cholesterol were not significantly associated with all-cause mortality 
(adjusted RR = 1.05, 95 percent CI 0.92-1.21 for total cholesterol, and RR = 0.99, 95 
percent CI 0.86-1.14 for HDL cholesterol). There were no significant associations between 
the different lipid variables and mortality from causes other than coronary heart disease. 
For total cholesterol the adjusted relative risk was 0.96 (95 percent CI 0.81-1.13). 
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Discussion 
The main results of this study show that, in elderly men followed for five years, total 
cholesterol is an independent risk factor for mortality from coronary heart disease, whereas 
HDL cholesterol seems to be a stronger risk factor for the incidence of coronary heart 
disease. 
We did not find a convincing relation between total cholesterol and the incidence of 
coronary heart disease. In a previous investigation among men from the Zutphen Study 
followed from 1960 until 1985, an inverted U-shaped relation between quartiles of serum 
total cholesterol and the incidence of myocardial infarction was observed. This was a 
result of a selective loss of men with serum total cholesterol levels in the highest quartile 
due to early incidence of, or death from, myocardial infarction.28 In five studies that were 
part of a recent National Heart, Lung, and Blood Institute workshop entitled "Cholesterol 
and Heart Disease in Older People and Women", the association between cholesterol and 
the incidence of coronary heart disease was also investigated.29"33 Three of the studies3 0'3 2 
found serum total cholesterol to be an independent risk factor for the incidence of 
coronary heart disease among healthy men aged 65 years or older. In the Framingham 
Study the association was borderline significant in men aged 65 years or older (p-value 
for trend = 0.07).29 In the Italian cohorts of elderly men from the Seven Countries Study, 
total cholesterol was not an independent risk factor for the incidence of coronary heart 
disease.33 A possible explanation for these discrepancies may be the duration of follow-up. 
A positive and significant, or borderline significant, association was indeed observed 
among elderly men who were followed for at least 14 years.29"32 The association was 
lacking in the Italian studies,33 in a recent study by Krumholz and colleagues,9 and in our 
study, in which the durations of follow-up were only five years or less. Thus, a longer 
follow-up period may be necessary to reveal an association, whether inverted U-shaped 
of not, between total cholesterol and the incidence of coronary heart disease in elderly 
men. 
HDL cholesterol was measured in only two of the studies presented during the National 
Heart, Lung, and Blood Institute workshop in which the incidence of coronary heart 
disease was investigated.29,30 Although HDL cholesterol was inversely associated with the 
incidence of coronary heart disease in both studies, the associations did not reach 
statistical significance. This is in accordance with our findings. The ratio of HDL to total 
cholesterol was independently associated with a decreased incidence of coronary heart 
disease. HDL cholesterol is probably the underlying factor driving this association since 
there is no evidence from this study for an independent association between total 
cholesterol and the incidence of coronary heart disease. The inverse association with HDL 
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cholesterol was especially pronounced among men initially free of diabetes mellitus. In 
the Bronx Aging Study,34 a consistently low HDL cholesterol level (< 0.8 mmol/liter at 
two separate assessments) was significantly independently associated with the incidence 
of cardiovascular disease among men aged 75 to 85 years. In the general male population 
serum total cholesterol increases with age until 60 years and decreases after 70 years, 
whereas HDL cholesterol does not change with age.3 5 It has been suggested that HDL 
cholesterol is more important in predicting coronary heart disease with increasing age than 
total cholesterol is. 1 3 In the Framingham Study for example, HDL cholesterol was found 
to be inversely associated with the incidence of coronary heart disease regardless of the 
total cholesterol level in men and women aged 49 to 82 years.36 Our study confirms the 
importance of HDL cholesterol in predicting the incidence of coronary heart disease in 
elderly men followed for only five years. 
For mortality from coronary heart disease, the results of this study are in accordance with 
those from the review of the National Heart, Lung, and Blood Institute workshop in which 
the associations between total cholesterol and mortality from coronary heart disease were 
reinvestigated in 25 initially middle-aged populations that had aged.5 Caution is warranted 
in interpreting the results from this review because the relative risks were not adjusted for 
potential confounders. In our study age and the prevalence of coronary heart disease at 
baseline were the main confounding factors in the associations between lipid variables and 
mortality end-points. Adjustment for the prevalence of coronary heart disease and diabetes 
mellitus at baseline attenuated the association of total cholesterol with mortality from 
coronary heart disease. The presence of coronary heart disease at baseline may be 
considered as a confounder because the disease is associated with these mortality end-
points and because of acute effects of myocardial infarction on cholesterol levels or the 
use of cholesterol lowering medication after the diagnosis of coronary heart disease. 
However, the actual event among men with the disease at baseline may have occurred a 
long time before baseline cholesterol measurement and treatment for high cholesterol 
levels was very limited in our cohort. The prevalence of the disease at baseline is, 
therefore, probably not a confounder but, rather, is an intermediate step in the causal 
pathway. Thus, additional adjustment for the prevalence of coronary heart disease may 
have resulted in an over-adjustment of the relative risks. Additional survival analysis 
among men initially free of coronary heart disease revealed a relative risk (adjusted RR 
= 1.3) similar to that of the entire population, indicating that the baseline prevalence of 
disease could not explain our findings. 
It should be noted that we observed an interaction of total cholesterol with body mass 
index. Harris and colleagues31 found that considerable weight loss in elderly people 
modified the association between total cholesterol and the incidence of coronary heart 
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disease, and a significant association was observed only when people who had lost weight 
were excluded from the analysis. The association between total cholesterol and mortality 
from coronary heart disease in our cohort was absent among lean men. The mean total 
cholesterol level of these men was lower than that of overweight men (5.87 (SD 1.09) 
versus 6.28 (SD 1.09) mmol/liter). A low body mass index and a low total cholesterol 
level could be a sign of poor health and possible subclinical disease.3 7 , 3 8 Therefore this 
older group of lean men could form a heterogenous group including both healthy people 
who are at a decreased risk of morbidity and mortality and people with clinical or 
subclinical disease who are thereby at an increased risk of morbidity and mortality.38 This 
may explain the lack of association between total cholesterol and coronary heart disease 
mortality among lean men in our study. 
No clear association between HDL cholesterol and mortality from coronary heart 
disease was seen in contrast to the result for the incidence of the disease. In the Rancho 
Bernardo Study, which was presented at the National Heart, Lung, and Blood Institute 
workshop, low HDL cholesterol levels were also not associated with mortality from 
coronary heart disease among elderly men followed for three years.3 9 Our results suggest 
that in elderly men and during a relatively short period of time, HDL cholesterol is 
important in predicting less severe coronary heart disease (i.e. not leading to death) 
whereas total cholesterol predicts fatal coronary heart disease. Additional analyses showed 
that this is especially the case for acute myocardial infarction (adjusted RR = 1.8). This 
is supported by the fact that angina pectoris constituted a larger portion of the incidence 
(39 out of 56) than of mortality from coronary heart disease (3 out of 53). It is also 
supported by the baseline data: HDL cholesterol was significantly lower in men with 
coronary heart disease and for total cholesterol the difference between men with or 
without coronary heart disease did not reach statistical significance. The latter finding 
could be due to earlier death of men with elevated total cholesterol levels28 and survival 
of men with low HDL cholesterol levels. Moreover, a low HDL cholesterol level in itself 
is not known to be atherogenic.40 Possibly, the protective effect of HDL cholesterol is 
strongest in less advanced atherogenesis, thus in men without pre-existing coronary heart 
disease. 
Neither total nor HDL cholesterol appeared to be predictive for all-cause mortality. This 
would suggest an inverse association between total cholesterol and mortality from non-
coronary heart disease.41 However, such an association was not observed, and neither was 
an inverse association between total cholesterol and all-cause cancer as suggested by 
others.42 The effect of total cholesterol on mortality from coronary heart disease has 
probably been diluted regarding all-cause mortality as end-point. Indeed, coronary heart 
disease constituted 25 percent of deaths in this study. 
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The use of a ratio including both total and HDL cholesterol may not be correct since it 
remains unknown which component of the ratio is important for the effect under study. 
However, such a ratio has been strongly suggested for routine use in screening to identify 
patients with hyperhpidemia43 and has been identified as most efficiently predicting 
coronary heart disease at all ages.44 The Framingham Study was the only one presented 
at the National, Heart, Lung, and Blood Institute workshop in which such a ratio was 
investigated and it was the only lipid predictor independently related to the incidence of 
coronary heart disease in elderly men.2 9 This is in accordance with our results. 
In summary, evidence from this study indicates that total cholesterol remains an 
independent predictor of mortality from coronary heart disease in elderly men and that 
HDL cholesterol appears to be protective of a first coronary heart disease event. Moreover, 
the associations were observed during a relatively short follow-up time, stressing the short 
term predictive importance of total and HDL cholesterol for coronary heart disease in 
older men. 
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Chapter 5 
Age related changes in total and high density lipoprotein 
cholesterol in elderly men 
Abstract 
To investigate changes in total and high density lipoprotein cholesterol concentrations with 
age and time in elderly men a cohort of men born between 1900 and 1920 from the Dutch 
town of Zutphen was examined in 1977/78 (n=571), 1985 (n=885), 1990 (n=555) and 
1993 (n=345). Linear regression analysis and random effects models were used to assess 
cross-sectional and longitudinal age and time related changes in cholesterol concentrations. 
In both cross-sectional and longitudinal analyses total cholesterol decreased by 0.04 
mmol/L a year with age. The longitudinal change was observed in the entire population 
as well as in men who participated in all four examinations (n=135), and in a subgroup 
of men who were free of common chronic diseases, not on cholesterol lowering 
medication and/or prescribed diet and rated themselves as being 'healthy' (n=64). High 
density lipoprotein cholesterol did not change significantly with age on a cross-sectional 
nor on a longitudinal basis. Among elderly men, total cholesterol diminishes with age both 
on a cross-sectional and longitudinal basis and high density lipoprotein cholesterol does 
not vary with age in any way. 
In press as: 
Weijenberg MP, Feskens EJM, Kromhout D. Age-related changes in total and high-
density-lipoprotein cholesterol in elderly Dutch men. Am J Puhl Health 1996. 
Copyright holder American Public Health Association. 
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Introduction 
The importance of total and high density lipoprotein cholesterol concentrations for 
coronary heart disease in the elderly is still a subject of debate.1"9 Part of the controversy 
may be due to changing cholesterol concentrations with advancing age.1 0 Concentrations 
measured in old age may not be representative of a lifetime exposure and may therefore 
attenuate associations. Total cholesterol declines with advancing age in elderly men both 
on a cross-sectional and longitudinal basis.10"13 It is still unclear whether this observed 
decline is a consequence of selective survival,16 clinical or subclinical disease,12"14 other 
unknown factors associated with age and cholesterol concentrations,1 7 1 8 or the aging 
process itself. High density lipoprotein cholesterol concentrations do not seem to vary with 
age on a cross-sectional basis in elderly men.19"21 Longitudinal changes in high density 
lipoprotein cholesterol have not specifically been reported for elderly subjects. 
We studied changes in total and high density lipoprotein cholesterol concentrations with 
age in older Dutch men both in a cross-sectional and longitudinal setting, and investigated 
whether these were independent of secular trends, selective mortality, loss to follow-up 
or changes in health status. 
Methods 
Study cohort 
The Zutphen Study is a longitudinal investigation of chronic disease risk factors initiated 
in 1960 among middle-aged men, born between 1900 and 1919, as the Dutch contribution 
to the Seven Countries Study.22 In 1985, 555 men from the 1960 cohort were still alive. 
In addition to this group, a new random sample (two out of three) of all men born 
between 1900 and 1920, living in Zutphen and not part of the 1960 cohort were selected 
to take part in the study. Both total and high density lipoprotein cholesterol concentrations 
have been measured four times between 1977/78 and 1993 (table 1). 
Lipid measurements 
Clinical examinations took place between March and June of each examination year. 
During the 1977/78 examination information from the participants was collected during 
the same months in one of either years. In all examination years non-fasting venous blood 
samples were taken for the analysis of total and high density lipoprotein cholesterol. 
Analyses were carried out in the standardized lipid laboratory of the Department of 
Human Nutrition, Agricultural University, Wageningen, The Netherlands. High density 
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Table 1. Population size and participation rate according to examination year (The Zutphen Study: 
1977/78 - 1993) 
1977/78 1985 1990 1993 
Invited (N) 671 1 266 721 544 
Participated (N) 611 939 560 390 
Participation rate (%) 91 74 78 72 
Men with total and high density lipoprotein 
cholesterol measurements (N) 571* 885 555 345 
*: high density lipoprotein cholesterol concentrations available for 570 men 
lipoprotein cholesterol was isolated after precipitation of apo-lipoprotein B containing 
particles by heparin-Mn2+ in 1977/7823 and by dextran sulphate-Mg2* in the other years.24 
In 1977/78, cholesterol was determined using Huang's method,25 which was calibrated on 
Abell-Kendall standardized sera. In 1985, 1990 and 1993, cholesterol was determined 
enzymatically with the CHOD-PAP mono-testkit from Boehringer Mannheim. 2 6 2 7 For total 
cholesterol standardization was realized by using calibration sera from the Lipid 
Standardization Laboratory from the Center for Disease Control (Atlanta, Georgia, USA) 
in 1977/78 and from the Foundation of Chemical Analysis Quality Control (The 
Netherlands) since 1985. For high density lipoprotein cholesterol, calibration sera prepared 
according to van der Haar and coworkers28 were used since 1985. In all four examination 
rounds the deviations of total cholesterol concentrations from the control sera were below 
the international norm of three percent. For high density lipoprotein cholesterol the 
deviations from control sera were always lower than 10 percent. The combined within-
and between-run coefficient of variation for control sera was lower than three percent for 
both total and high density cholesterol at the time of analyses in all four examination 
periods. In 1977/78, 1985 and 1990 cholesterol concentrations were measured in serum 
and in 1993 in EDTA plasma. Plasma values were multiplied by 1.03029 to make them 
comparable to the serum values in the other examination years, since plasma values may 
be diluted due to the addition of EDTA.29 Because of the systematic lower concentrations 
of total cholesterol in 1993 as compared to the concentrations in the other examination 
years, even after adjustment of the values, plasma of a random sample of 50 men was 
reanalyzed in July 1994 using the same method as in the 1985, 1990 and 1993 
examinations. 
Measurement of other variables 
In 1985 and 1990 extensive information on cholesterol lowering medication use and 
prescribed diets for a high cholesterol concentration was obtained through a standardized 
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questionnaire. In 1993 information was only collected on prescribed diets. In 1977/78, no 
such information was collected. Note that only very few men were on cholesterol lowering 
therapy during the examinations (25 in 1985, 10 in 1990 and 8 in 1993). 
In 1977/78, 1985 and 1990 information on the presence or a history of angina pectoris 
or myocardial infarction was obtained through the Dutch translation of the Rose 
questionnaire30. History of diabetes mellitus and any form of cancer was reported using 
a standardized questionnaire. All the information was verified with hospital discharge data 
and information from the subjects' general practitioners. In 1993 additional information 
on the presence or history of these diseases was obtained using a self-administered 
questionnaire. 
Information on self-rated health was collected in 1985, 1990 and 1993 with the 
question: 'How do you feel?'. The four answer categories were: 'healthy', 'rather healthy', 
'moderately healthy' and 'not healthy'. This information was not collected in 1977/78. 
Low self-rated health has been associated with an increased risk of mortality independent 
of traditional risk factors and a history of chronic diseases.31 It is thought to be an 
indicator of underlying (subclinical) disease which may in turn be accompanied with 
lowered total cholesterol concentrations. 
Statistical methods 
In order to account for selective survival or selective participation and the possibility that 
the total cholesterol concentration is lowered in diseased people,12 we analyzed three 
subgroups of participants. The first group comprises the total population of men who 
participated in at least one of the examination periods (N=1118). Another group consists 
of those men who participated in each examination (N=135). Finally we selected a 
'healthy' group defined as those men from the former group without a history of 
myocardial infarction, angina pectoris, diabetes mellitus or cancer, never having used 
cholesterol lowering medication or prescribed diet, and rating themselves as 'healthy' or 
'rather healthy' (N=64). 
Statistical analyses were carried out using the SAS program (SAS Institute Inc., Cary, 
North Carolina, USA, 1989, version 6.09). All tests were two sided. A paired-t-test was 
conducted to evaluate the difference between newly analyzed total cholesterol values and 
the original values from the random sample of 50 men. Cross-sectional analyses were 
performed using linear regression analysis of total or high density lipoprotein cholesterol 
on age in each of the examination years. The assumption of linearity was checked visually 
using the plots of the studentized residuals by age. To perform the longitudinal analyses 
the repeated measures of cholesterol were related to age and time effects using a model 
which allowed for two sources of error - 1) within subjects between occasions and 2) 
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between subjects. Age and time related changes in total and high density lipoprotein 
cholesterol were estimated from the model. This was done using the SAS Proc Mixed 
Procedure, which deals with unbalanced data, by assuming missing observations are 
missing at random.32 
Results 
Total cholesterol concentrations increased between 1977/78 and 1985 and thereafter 
decreased with the largest drop observed in the last three years (table 2). This was 
Table 2. Mean values of baseline characteristics by examination period in all men, and in sub-groups 
of the total study population (The Zutphen Study: 1977/78 - 1993) 
Examination Maximum All men* Men who 'Healthy' men who 
year number of participated in each participated in each 
men examination examination 
(N=135) (N=64)t 
Age (years) 
1977/78 571 66.3 (5.2)$ 63.7 (4.1) 63.5 (4.2) 
1985 885 71.5 (5.3) 70.7 (4.1) 70.5 (4.2) 
1990 555 75.1 (4.7) 75.7 (4.1) 75.5 (4.2) 
1993 345 77.8 (4.4) 78.7 (4.1) 78.5 (4.2) 
Total cholesterol (mmol/L) 
1977/78 571 5.90 (1.06) 5.94 (0.97) 5.96 (1.00) 
1985 885 6.10 (1.11) 6.10 (0.99) 6.13 (1.06) 
1990 555 6.07 (1.13) 6.08 (1.01) 6.07 (1.05) 
1993 345 5.56 (1.06) 5.43 (1.06) 5.47 (1.00) 
High density lipoprotein cholesterol (mmol/L) 
1977/78 570 1.23 (0.31) 1.20 (0.28) 1.26 (0.29) 
1985 885 1.12 (0.29) 1.10 (0.27) 1.12 (0.27) 
1990 555 1.16 (0.31) 1.10 (0.30) 1.13 (0.31) 
1993 345 1.20 (0.35) 1.13 (0.35) 1.18 (0.36) 
:: mean values are based on maximum number of men 
f: men not having or ever having had angina pectoris, myocardial infarction, diabetes mellitus and cancer, not using 
or ever having used cholesterol lowering medication or diet, and who rated themselves to be 'healthy' or 'rather 
healthy' 
p. mean (standard deviation) 
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observed for all men, as well as for men who participated in each examination and for the 
'healthy' men who participated in each examination. The drop in total cholesterol between 
1990 and 1993 was not due to measurement error. New analyses for plasma total 
cholesterol from a random sample of 50 men in 1994 revealed no significant differences 
in mean concentrations as compared to the total cholesterol analyzed in 1993 (5.54 
mmol/L (standard deviation 0.90) as measured in 1994 versus 5.51 mmol/L (standard 
deviation 0.88) as measured in 1993, p = 0.15). High density lipoprotein cholesterol 
exhibited a decrease between 1977/78 and 1985 and a slight increase over the later 
examination years (table 2). These results were similar among the three groups of men. 
When the birth cohorts were examined separately, the changes of total and high density 
lipoprotein cholesterol between examination years were generally similar with the 
exception of an earlier drop in total cholesterol for the oldest birth cohort as compared to 
the two younger cohorts (figure 1). Whether this is an age related or a secular change with 
time cannot be deducted from the figure. 
Total cholesterol (mmol/L) High density lipoprotein cholesterol (mmol/L) 
6.5-1 I 
5- 1 1 0 5 J 
1977/1978 1985 1990 1993 1977/1978 1985 1990 1993 
Examination period Examination period 
• 1915-1920 (n=59) • 1910-1914 (n=50) * 1900-1909 (n=26) 
Figure 1. Cholesterol concentrations by examination year and by birth cohort (n=135) 
On a cross-sectional basis, total cholesterol diminished significantly with age in every 
examination year (table 3 and figure 2). The decrease tended to be stronger in the more 
recent examinations, it ranged from a 0.04 mmol/L decrease a year in 1977/78 to a 
decrease of 0.06 mmol/L a year in 1993. High density lipoprotein cholesterol did not 
change consistently with age in any of the examination rounds. 
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Table 3. Regression coefficients from linear regression of total or high density lipoprotein cholesterol 
on age and expected concentrations in a man of mean age in each examination year among men aged 
58 to 91 years (The Zutphen Study: 1977/78 - 1993) 
Regression coefficient for age* 
1977/78 
1985 
1990 
1993 
1977/78 
1985 
1990 
1993 
Mean age Expected concentration in a 
man of mean age (mmol/L) 
Total cholesterol (mmol/L) 
66.3 5.89 
71.5 6.07 
75.1 6.11 
77.8 5.55 
High density lipoprotein cholesterol (mmol/L) 
0.004 (-0.001; 0.009) 66.3 1.24 
-0.002 (-0.006; 0.001) 71.5 1.14 
0.004 (-0.002; 0.009) 75.1 1.18 
-0.002 (-0.010; 0.007) 7X8 L16_ 
-0.038 (-0.054; -0.022) 
-0.043 (-0.056; -0.029) 
-0.043 (-0.063; -0.024) 
-0.058 (-0.083; -0.033) 
regression coefficient (95 percent confidence limits) 
Total cholesterol (mmol/L) High density lipoprotein cholesterol (mmol/L) 
70 75 80 
Age (years) 
70 75 80 
Age (years) 
• 1977/1978 (n=571) • 1985 (n=885) * 1990 (n=555) • 1993 (n=345) 
Figure 2. Cholesterol concentrations by mean age of five-year birth cohorts (the oldest two combined) 
and by examination 
On a longitudinal basis, total cholesterol decreased by 0.04 mmol/L a year with increasing 
age of the men (table 4). There was no evidence for a stronger age-related change in the 
older birth cohorts as compared to the younger ones (not shown). Total cholesterol 
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increased between 1977/78 and 1985 and between 1985 and 1990. Between 1990 and 
1993 total cholesterol decreased by 0.14 mmol/L a year solely due to a period effect. High 
density Epoprotein cholesterol did not change with age. Between 1977/78 and 1985 high 
density lipoprotein cholesterol decreased by 0.02 mmol/L a year. These results were 
essentially the same for the 'healthy' men who participated in every examination period. 
Table 4. Estimated mean changes in total and high density lipoprotein cholesterol per year with age 
and between examination rounds for all men aged 58 to 91 years and 'healthy' men who participated 
in each examination (The Zutphen Study: 1977/78 - 1993) 
Change with age 
Change between 1977/78-1985 
Change between 1985-1990 
Change between 1990-1993 
Change with age 
Change between 1977/78-1985 
Change between 1985-1990 
Change between 1990-1993 
All men who participated in 
at least one examination* 
'Healthy' men who participated 
in each examinationt 
Total cholesterol (mmol/L) 
-0.043 (-0.054; -0.032)$ -0.040 (-0.094; 0.014) 
0.066 ( 0.052; 0.081) 0.065 ( 0.005; 0.124) 
0.029 ( 0.012; 0.045) 0.028 (-0.037; 0.092) 
-0.135 (-0.164; -0.106) -0.159 (-0.239;-0.079) 
High density lipoprotein cholesterol (mmol/L) 
-0.000 (-0.003; 0.003) 0.010 (-0.007; 0.026) 
-0.016 (-0.020; -0.080) -0.029 (-0.047;-0.011) 
0.007 ( 0.003; 0.012) -0.007 (-0.027; 0.190) 
0.011 ( 0.003; 0.019) 0.007 (-0.018; 0.032) 
*: for number of participants see table 2 
t: N = 64, for definition see table 2 
$: mean change (95 percent confidence limits) 
Discussion 
Among men aged 58 to 91 years in our study, total cholesterol decreased with age by 0.04 
mmol/L a year, and this was observed in both cross-sectional and longitudinal analyses 
even after the effect of selective mortality, loss to follow-up or impaired health had been 
taken into account. A considerable secular drop in total cholesterol was observed between 
1990 and 1993. High density lipoprotein cholesterol did not vary with age, but showed a 
secular drop between the first and second examination periods. 
Secular changes in total and high density lipoprotein cholesterol 
The change in the method of cholesterol determination between 1977/78 and 1985 has 
probably not led to systematic differences in cholesterol concentrations between the years. 
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Huang's method,25 which was used in 1977/78, was calibrated on Abell-Kendall 
standardized sera, and the enzymatic determinations with the CHOD-PAP mono-testkit 
used in 1985 through 1994 were proven to agree rigidly with the method of Abell et a/. 2 6 , 3 3 
However, the change in precipitation method of apo B containing particles between 
191111% and 1985 may have led to systematic differences in the high density lipoprotein 
cholesterol concentrations between the examination years. Warnick et al found that the 
heparin-Mn2+ method of precipitation generally overestimates the cholesterol 
concentrations of high density lipoprotein as compared to the dextran sulphate-Mg2* 
method.24 Their regression equation can be used to estimate the expected high density 
lipoprotein cholesterol concentration in 1977/78 if dextran sulphate-Mg2+ had been used 
(0.023 mmol/L + 0.955 x heparin-Mn2+ value (mmol/L)). The mean expected high density 
lipoprotein cholesterol value was 1.17 mmol/L (standard deviation 0.27) for the men who 
participated in every examination. This value is 2.5 percent lower than the original value 
and is still significantly higher than the value measured in 1985 (p < 0.001). Thus the 
change in precipitation method cannot fully explain the secular drop in high density 
lipoprotein cholesterol observed between 1977/78 and 1985. 
The drop in total cholesterol between 1990 and 1993 is unexpected. Since the newly 
analyzed plasma total cholesterol concentrations of the random sample of men in 1994 
were not different from the concentration determined in 1993, this cannot be due to 
measurement error. However, the laboratory analyses were generally higher than the true 
cholesterol content of the control sera in 1990 (mean 0.9 percent) and were generally 
lower than the true cholesterol content of the control sera in 1993 (mean 1.7 percent). 
These deviations from the control sera suggest that total cholesterol may have dropped by 
2.6 percent between 1990 and 1993 due to measurement error alone. The cholesterol 
determinations in the high density lipoproteins were susceptible to the same measurement 
errors as the total cholesterol determinations. Since there were no changes in high density 
lipoprotein cholesterol concentrations between 1990 and 1993, this implies that 
measurement error alone cannot explain the drop in total cholesterol concentrations in the 
same period. Dietary changes among men of the cohort during 1990 and 1993 may also 
partly explain the decline in the total cholesterol concentration of the men. In 1991, 1992 
and 1993 'Fat Watch' campaigns were carried out on a national level in The 
Netherlands.34 Although it remains difficult to establish the effect of such mass media 
community intervention programs, it has been estimated that it may have caused a drop 
of 3.5 percent in total cholesterol from 5.7 mmol/L to 5.5 mmol/L in the Dutch population 
between 1987 and 1992.35 If we assume that possible changes in diet in the present cohort 
also resulted in a 3.5 percent decline in total cholesterol, together with the possible 
difference in measurement of total cholesterol (3.5 + 2.6 = 6.1 percent) this may explain 
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most of the 6.7 percent (0.135 mmol/L per year) secular drop in the total cholesterol 
concentration observed in just three years in the present study. 
Age related changes in total and high density lipoprotein cholesterol 
Our cross-sectional analyses reveal that among men over 58 years of age total cholesterol 
a^rninishes with increasing age. The percentage decline in total cholesterol estimated from 
regression analysis amounted to 20 percent for men aged 72 to 92 years. Newschaffer et 
al observed a 21 percent drop among both men and women between 75 and 95 years of 
age.1 5 An increased age-related drop with advancing age has been observed in other 
studies among elderly m e n . 1 5 1 9 - 2 1 3 6 In the present study, the effect also tended to be 
stronger in the later examination periods and possibly with increasing age of the 
population. These cross-sectional observations of declining total cholesterol concentrations 
with age may however have been confounded by selective survival of older men with 
lower cholesterol concentrations.16 
Our longitudinal analyses also showed that total cholesterol decreases with age. The 
magnitude of the decline was comparable to the cross-sectional one (0.04 mmol/L per 
year), and the percentage decline was 15 percent. These results were similar for those men 
who participated in every examination which shows that selective survival or participation 
did not affect our results. Newschaffer et al reported a longitudinal decline of nine percent 
among men and women between 75 and 95 years of age.1 5 
Total cholesterol concentrations are known to be reduced in people with clinical or 
subclinical disease and there is evidence that this is a consequence of a host's 
inflammatory response.12 Since there is generally increasing morbidity with advancing age 
in older people13 3 7 it is plausible that clinical or subclinical disease has led to the decrease 
in total cholesterol with age in this study. However, the decline in total cholesterol with 
age was still of the same magnitude in the subgroup of men who appeared to be and felt 
healthy, were not on cholesterol lowering medication or prescribed diet, and participated 
in every examination year. Similar observations have been made in the Honolulu Heart 
Program cohort of men aged 70 to 90 years.1 0 Possibly other factors are involved. 
Metabolic and hormonal changes with advancing age may play a role by reducing the 
absorption of dietary determinants of cholesterol, thus leading to reduced cholesterol 
concentrations in the blood.18 
Confirming earlier findings from cross-sectional studies, 1 9" 2 1 3 6 3 8 high density lipoprotein 
cholesterol did not vary with age in the cross-sectional analyses. Wilson and coworkers39 
have recently reported that high density lipoprotein cholesterol declined by 0.07 mmol/L 
between 1979 and 1983 among men initially aged 65 to 79 years from the Framingham 
Study. However, they did not take account of possible time related changes in cholesterol 
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concentrations. Moreover, the aim of their study was to investigate the determinants of 
change in cholesterol concentrations and not to specifically describe longitudinal changes 
with advancing age. Our report is the first on longitudinal changes in high density 
lipoprotein cholesterol concentrations with age in elderly men in which time and age 
related changes have been disentangled. It shows no longitudinal changes in high density 
lipoprotein cholesterol with increasing age. 
Our study shows that total cholesterol diminishes with age in elderly men both on a cross-
sectional and longitudinal basis whereas high density lipoprotein cholesterol does not vary 
with age in any way. A secular drop in total cholesterol was observed between 1990 and 
1993, and this group will be followed to see whether this secular reduction sustains. 
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Serum homocysteine and the five year risk of 
cardiovascular diseases, cancer and cognitive impairment 
in elderly men 
Abstract 
The associations of non-fasting serum homocysteine (Hey) levels with coronary heart 
disease (CHD), cerebrovascular disease (CVA), cancer and cognitive impairment was 
investigated in elderly men followed for five years. 878 men aged 64 to 84 years at 
baseline from the Dutch town of Zutphen participated in the study. The main outcome 
measures included the prevalence of, mortality from, and incidence of "first ever" CHD, 
CVA, and cancer; and the prevalence of cognitive impairment at the follow-up 
examination as assessed by the Mini Mental State Examination. Thirty-one percent of the 
men had Hey levels of 17 umol/1 or higher. After adjustment for major other risk factors, 
high Hey levels (upper tertile) at baseline were associated with an increased prevalence 
of CHD (odds ratio (OR) (95% confidence interval) 1.95 (1.24-3.05)) and of CVA (OR 
4.16 (1.99-8.97)), but not of cancer (OR 1.69 (0.83-3.45)). High Hey levels were 
associated with increased risks of dying from CHD in the first 1.5 years of observation 
(crude relative risk (RR) 5.62 (1.23-25.64)), of dying from CVA (2.13 (0.89-5.07)), and 
of dying from cancer (2.94 (1.32-4.72)). After adjustment, these RR's were reduced for 
CHD (3.65 (0.76-17.42)) and for cancer (1.87 (0.97-3.59)), and increased for CVA in men 
without hypertension (17.23 (1.91-154.29)). High Hey levels were not associated with an 
increased risk of first ever CHD, CVA, or cancer. Finally, high Hey levels were associated 
with an increased risk of cognitive impairment at follow-up (OR 1.73 (1.03-2.92)), which 
was reduced after adjustment for age and occupation (OR 1.38 (0.79-2.40)). In conclusion, 
in a general population of elderly men, a high non-fasting Hey level is common and is 
strongly associated with the prevalence of CHD and CVA and with fatal CVA in men 
without hypertension. It may also be a risk factor or marker for cancer and for cognitive 
dysfunction. 
Submitted as: 
Stehouwer CDA, Weijenberg MP, van den Berg M, Kalmijn S, Jakobs C, Feskens EJM, 
Kromhout D. Serum homocysteine and risk of cardiovascular disease, cancer, and 
cognitive impairment: a five year follow-up of elderly men. 
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Introduction 
In the elderly, cardiovascular disease, cancer and cognitive impairment are major threats 
to the ability to lead an independent life. It is therefore important to identify reversible risk 
factors for these conditions. In this respect, a high homocysteine level may be a unique 
risk factor because it has been linked to cardiovascular disease,1 cancer2 and neurological 
dysfunction,3,4 and because it can usually be treated by simple means.5 
Cross-sectional1 and prospective6"9 studies in young and middle-aged subjects have 
shown that high levels of homocysteine are associated with an increased risk of 
atherosclerotic cardiovascular disease. How homocysteine affects atherogenesis is not 
known with certainty, but it is thought to induce endothelial injury and dysfunction1 0 , 1 1 , 1 2 
and to stimulate vascular smooth muscle cell proliferation13 -both important events in the 
pathogenesis of atherosclerosis. 
A high homocysteine level may be linked to cancer because it is a marker of rapid eel 
growth2 and of nutritional habits which themselves are associated with an increased risk 
of cancer.14 
A very high level of homocysteine, most often the result of certain rare inborn errors 
of metabolism, is associated with neurological dysfunction. This is thought to be caused 
by homocysteine-induced vascular damage and by homocysteine-associated neurotoxicity, 
the basis of which is poorly understood.3 It is conceivable that a moderately elevated 
homocysteine level, through similar mechanisms, is also associated with neurological 
dysfunction, but this has not been investigated. Homocysteine is formed from the 
demethylation of the essential amino acid methionine, an ubiquitous methyl donor in many 
biochemical pathways. Homocysteine can be remethylated, which requires vitamin B12 
and folic acid, or degraded to cystathionine and cysteine, a process that requires vitamin 
B6. Deficiencies of these vitamins are common in the elderly and, in cross-sectional 
studies, are associated with high homocysteine levels 1 5 , 1 6 and with cognitive impairment.4 
There are no population-based data on homocysteine and clinical cardiovascular 
disease, cancer or cognitive impairment in the elderly. We therefore wished to investigate 
these issues in the Zutphen Elderly Study, a population-based prospective investigation in 
elderly men. 
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Methods 
Population 
The Zutphen Elderly Study is a longitudinal investigation of risk factors for chronic 
diseases in elderly men.17 It represents a continuation of the Zutphen Study, the Dutch 
contribution to the Seven Countries Study. In 1985, 555 men of the original cohort, born 
between 1900 and 1920, were still alive and were invited for new investigations, together 
with an additional random sample of 711 men of the same age group living in Zutphen 
and not part of the original cohort. Seventy-four percent (939/1266) of those invited 
entered the study -from then on called the Zutphen Elderly Study. Complete information 
was available for 878 men aged 64 to 84 years. In 1990, 551 of the surviving men 
participated in the examinations; there were 119 non-responders. 
Examinations 
The baseline examination took place between March and June, 1985. Physical 
examinations were carried out by five trained physicians according to a standardised 
protocol. Height was measured to the nearest 0.1 cm, and weight to the nearest 0.5 kg 
while the men were in their underwear. The body mass index was calculated as weight 
(kg) / height (m)2. Systolic and diastolic (Korotkoff phase V) blood pressure were 
measured in duplicate using a random zero sphymomanometer, with the men supine. 
Hypertension was defined as a systolic blood pressure of 160 mmHg or more, a diastolic 
blood pressure of 95 mmHg or more, and / or use of antihypertensive drugs. Smoking 
habits were assessed with a standardised questionnaire; subjects were categorised as never, 
former or current cigarette smokers. Information on the presence of diabetes was obtained 
through a standardised medical questionnaire. Information on coronary heart disease was 
obtained with the Dutch translation of the Rose Questionnaire. Coronary heart disease was 
considered present when either myocardial infarction or angina pectoris were diagnosed. 
The diagnosis of myocardial infarction required two or more of the following three 
criteria: severe chest pain lasting for more than 20 minutes that did not disappear in rest, 
characteristic changes on electrocardiography, and specific enzyme elevations. Information 
on cerebrovascular disease (stroke and transient ischaemic attack) and cancer was collected 
with a standardised questionnaire. All diagnoses were verified with hospital discharge data 
and written information from the subjects' general practitioners. All information was 
eventually coded by a single physician. 
Venous blood samples were obtained in the non-fasting state. Samples were centrifuged 
after about 60 minutes, which has been shown to be sufficient to prevent increases in 
serum homocysteine resulting from ex vivo generation of homocysteine by erythrocytes.18" 
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2 2 Serum was stored at -20°C and assayed in 1995. There is good evidence that total (free 
plus protein bound) homocysteine levels are stable in serum or plasma stored for 10 years 
or more.15*23"25 Serum total homocysteine was measured as previously described in detail.5 , 2 6 
The intra- and interassay coefficients of variation are 2.1% and 5.1%, respectively. 
Because the available amount of serum per subject was limited, we performed duplicate 
assays in only 65/878 samples (the mean difference in these samples was 6%). Serum 
homocysteine levels are consequently given as whole numbers. Serum total and high 
density lipoprotein cholesterol were determined enzymatically with the CHOD-PAP 
method (Boehringer Mannhein, Mannheim, Germany). High density lipoprotein was 
isolated by precipitation of apo B-containing particles with dextran sulphate-Mg2+. The 
lipid analyses were carried out in the standardised lipid laboratory of the Department of 
Human Nutrition, Agricultural University, Wageningen, the Netherlands. 
The intake of alcohol (g per day) and of vitamin B6 (mg per day) was assessed by 
trained dieticians from a cross check dietary history adapted for the Dutch.27 Information 
on the intake or serum levels of folic acid and vitamin B12 was not available. We 
therefore used anaemia (haematocrit <, 0.40) and macrocytosis (erythrocyte mean 
corpuscular volume > 100 fl) as proxies for clinical folic acid and vitamin B12 
deficiencies. 
Follow-up 
Information on the vital status on July 1st, 1990 was obtained. Information on the causes 
of death was obtained from the Dutch Central Bureau of Statistics. The causes of death 
were coded according to the 9th revision of the International Classification of Diseases 
(ICD). Because the underlying cause of death in the elderly is often difficult to determine, 
both the primary and the secondary cause of death were considered in the analyses. Death 
from coronary heart disease, cerebrovascular disease, and cancer was defined by ICD 
codes 410-414, 430-438, and 140-239, respectively. 
Survivors were invited for a reinvestigation between March and June, 1990. In case of 
non-response, information on major chronic diseases was obtained from a questionnaire 
for non-participants. Among the responders, data on cardiovascular disease and cancer 
were obtained in similar fashion as in 1985 examination. Global cognitive function was 
tested with the Mini-Mental State Examination,28 which has been shown to be a reliable 
and valid indicator of cognitive impairment in epidemiological studies.29 It was 
administered by two trained nurses in a hospital setting. When less than four individual 
items were missing they were rated as errors30 (n=22), with the exception of those that 
could not be done because of physical disability, and in that case a weighted total score 
was given (n=10). When four or more individual items were missing, the entire score was 
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considered missing (n=5). Complete information on cognitive function and its main 
determinants was available for 502 of the 551 surviving men. Two men died between the 
1990 examination and July 1st, 1990. They were included in both the mortality and the 
cognitive function analyses. We used a score of 23 or lower as indicative of impaired 
cognitive function.29 Lifelong occupation, obtained from a self-administered questionnaire, 
rather than education level was used as an indicator of intellectual capacity, since these 
elderly Dutch subjects had had a reduced access to education. Subjects were divided into 
four categories (class I-IV): professionals, managers and teachers; small business owners; 
administrative personnel; and manual workers. 
Main outcome measures 
The main end-points investigated were the prevalence and the mortality from coronary 
heart disease (52/878), cerebrovascular disease (29/878), or cancer (68/878); mortality 
from causes other than any cardiovascular disease or cancer (37/878); the incidence of a 
first ever coronary (56/707) or cerebrovascular event (49/806) and cancer (81/810), ie, 
after exclusion of those who had the relevant disease at baseline; and the prevalence of 
cognitive impairment at the five year follow-up examination (84/502). 
Statistical methods 
SAS statistical programmes were used for the analyses (SAS Institute Inc., Cary, North 
Carolina, USA, 1989-1993, version 6.10). All tests were two-sided. P values less than 0.05 
were considered statistically significant. The subjects were categorised in tertiles of 
homocysteine levels. Differences in their baseline characteristics were then evaluated using 
analysis of variance for normally distributed variables, the Kruskal-Wallis test for variables 
with a skewed distribution, and an overall chi-square test for categorical variables. Logistic 
regression analysis was used to investigate the association between tertiles of 
homocysteine levels and the prevalence of cardiovascular disease and cancer at baseline, 
and of cognitive impairment at follow-up. Cox's proportional-hazard (survival) analysis 
was used to investigate the associations between tertiles of homocysteine levels and 
incidence of cardiovascular disease and cancer. The highest tertile was compared to the 
two lower tertiles if necessary to avoid empty cells and thus the inability to estimate the 
relative risk. Interaction terms were investigated at the 0.10 level. One person had moved 
abroad and was lost to follow-up. The date on which he moved was used as his (censored) 
endpoint date. Unless stated otherwise, adjusted analyses are those in which the effects of 
major risk factors are taken into account, ie, age, body mass index, systolic blood pressure, 
total and high density lipoprotein cholesterol, diabetes mellitus and cigarette smoking 
habits for cardiovascular end-points; age, body mass index, total cholesterol and cigarette 
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smoking habits for cancer; and age and occupation for cognitive impairment. The analysis 
of mortality from causes other than cardiovascular disease and cancer was adjusted for 
age, body mass index, total cholesterol, cigarette smoking habits, and the presence of 
chronic obstructive pulmonary disease. 
Results 
The mean (SD) homocysteine level at baseline was 15.8 (8.2) umol/1. High homocysteine 
levels were common; 268/878 subjects (31%) had serum levels > 17 umol/1. Vitamin B6 
intake was 0.02 mg per g protein or lower in 736/818 subjects (90%) and 0.016 mg per 
g protein or lower in 429 subjects (52%). Anaemia and/or macrocytosis were present in 
367 subjects (42%). Table 1 shows that higher homocysteine levels were associated with 
age, lower levels of high density lipoprotein cholesterol, current smoking, lower vitamin 
B6 intake, a higher prevalence of anaemia and/or macrocytosis, and a history of coronary 
heart disease, cerebrovascular disease and cancer. 
Table 2 shows that higher homocysteine levels were associated with an increased 
prevalence of coronary heart disease and cerebrovascular disease which remained after 
adjustment. The association with cerebrovascular disease was stronger in normotensive 
than in hypertensive subjects. High homocysteine levels were also associated with a higher 
prevalence of cancer; this was not significant after adjustment. 
The mortality rate was 12.9 per 1,000 person-years for coronary heart disease and 7.2 per 
1,000 person-years for cerebrovascular disease. The survival curve (figure 1A) shows that 
coronary heart disease mortality was higher in subjects with homocysteine levels in the 
third tertile, especially in the first 1.5 years of observation. This was not significant after 
adjustment (table 3). Mortality from cerebrovascular disease was higher in subjects with 
homocysteine levels in the third tertile (figure IB). Further analyses showed that this was 
significant only in subjects without hypertension (adjusted relative risk 17.23; table 3). 
Additional adjustment for the presence of cerebrovascular disease at baseline did not 
appreciably change this risk estimate (relative risk (95% confidence interval) 21.64 (2.21-
211.71)). All 29 cases of fatal cerebrovascular disease occurred in patients who had had 
a previous cerebrovascular event either before the 1985 examination (16 cases) or between 
the 1985 examination and the time of the fatal event (13 cases). 
The mortality rates per 1,000 person-years were 16.9 for cancer and 9.2 for causes 
other than cardiovascular disease and cancer. High homocysteine levels were associated 
with an increased risk of dying from cancer (figure 1C). After adjustment, this was of 
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borderline significance (p for trend =0.056; table 3). Further adjustment for the presence 
of cancer at baseline resulted in a similar risk estimate (relative risks for the second and 
third tertiles compared to the first tertile 1.28 (0.66-2.48) and 1.79 (0.92-3.48); p for trend 
=0.076). High homocysteine levels were also associated with an increased risk of dying 
from causes other than cardiovascular disease and cancer, which was not significant after 
adjustment (adjusted relative risks for the second and third tertiles 0.90 (0.35-2.29) and 
1.94 (0.83-2.29); p for trend =0.17). 
Table 1. Baseline (1985) characteristics of 878 men according to tertiles of serum homocysteine in 
the Zutphen Elderly Study 
Characteristic Homocysteine tertile p value 
First Second Third 
Homocysteine range (|imol/l) 6-12 13-16 17-97 
Mean (standard deviation) 
Age (years) 70.0 (4.6) 71.5 (2.7) 73.0 (5.7) < 0.0001 
Body mass index (kg/m2) 25.8 (3.3) 25.3 (2.7) 25.2 (3.6) 0.08 
Systolic blood pressure 
(mmHg) 149.1 (21.4) 151.6 (21.7) 152.7 (21.2) 0.1 
Total cholesterol (mmol/L) 6.13 (1.00) 6.13 (1.10) 6.02 (1.21) 0.3 
HDL cholesterol (mmol/L) 1.15 (0.31) 1.11 (0.27) 1.09 (0.30) 0.06 
Vitamin B6 intake (mg/day)* 1.34 (0.33) 1.30 (0.30) 
Percentage 
1.18 (0.30) < 0.0001 
Current cigarette smokersf 27 30 34 0.02 
History of diabetes mellitus 
9 6 5 0.1 
History of coronary heart 
disease 15 18 26 0.01 
History of cerebrovascular 
disease 3 7 15 0.001 
History of cancer 5 9 20 0.04 
Haematocrit < 0.40 and/or 
macrocytosis 36 43 47 0.02 
*: information available for 818 men 
t: information available for 877 men 
The incidence rates per 1,000 person-years of "first ever" coronary heart disease, 
cerebrovascular disease and cancer were 17.3, 13.3, and 21.7, respectively. Homocysteine 
levels were not related to these incidence rates. The adjusted relative risks for the second 
and third tertiles were 1.13 (0.59-2.14) and 1.15 (0.57-2.32) for coronary heart disease (p 
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for trend =0.76), 0.80 (0.40-1.57) and 0.80 (0.39-1.65) for cerebrovascular disease (p for 
trend =0.45), and 0.59 (0.34-1.02) and 0.92 (0.53-1.56) for cancer (p for trend =0.74). The 
risk estimates for coronary heart disease and cerebrovascular disease did not differ 
significantly between normotensive and hypertensive subjects. 
Table 2. Odds ratios and 95% confidence intervals for the prevalence of coronary heart disease, 
cerebrovascular disease, and cancer according to tertiles of serum homocysteine in 878 men in the 
Zutphen Elderly Study 
Disease Homocysteine tertiles p value for 
First Second Third trend 
Coronary heart 
disease 
crude 1* 1.28 
0.83 - 1.97 
2.10 
1.37 - 3.22 
0.0005 
adjustedt 1* 1.16 
0.75 - 1.82 
1.95 
1.24 - 3.05 
0.003 
Cerebrovascular 
disease 
crude 1* 1.93 
0.89 - 4.16 
5.00 
2.45 - 10.21 
< 0.0001 
adjustedt 1* 1.70 
0.78 - 3.73 
4.16 
1.99 - 8.97 
< 0.0001 
normotensive 
adjustedt 
1* 1* 4.51 
2.16 - 9.41 
hypertensive 
adjustedt 
1* 1* 2.04 
0.99 - 4.21 
Cancer crude 1* 2.00 
1.02 - 3.94 
2.36 
1.19 - 4.68 
0.02 
adjustedt 1* 1.67 
0.84 - 3.34 
1.69 
0.83 - 3.45 
0.18 
*: Reference group 
t: See Statistical Methods 
Table 4 shows that high homocysteine levels in 1985 were associated with an increased 
risk of cognitive impairment in 1990. Adjustment for age and occupation weakened the 
association. Further analysis indicated that the risk estimate was not altered appreciably 
by additional adjustments for body mass index, systolic blood pressure, total and high 
density lipoprotein cholesterol, cigarette smoking habits, diabetes mellitus, alcohol 
consumption, presence of cerebrovascular disease at baseline, and vitamin B6 intake. The 
risk estimates tended to be higher, however, in subjects who had no anaemia and/or 
macrocytosis (table 4). 
90 
Serum homocysteine and CHD risk 
B Mortality from cerebrovascular disease 
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Figure 1. Mortality (expressed as 1 minus the survival fraction) from coronary heart disease (A), 
cerebrovascular disease (B), and cancer (C) according to tertiles of serum homocysteine in the 
Zutphen Elderly Study. The first, second and third tertiles are indicated by the grey, black and heavy 
black lines, respectively 
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Table 3. Relative risks and 95% confidence intervals for mortality from coronary heart disease, 
cerebrovascular disease, and cancer acording to tertiles of serum homocysteine in 878 men in the 
Zutphen Elderly Study 
Disease Homocysteine tertile p value for 
First Second Third trend 
Coronary heart 
disease 
crude 1* 1.49 
0.74 - 2.97 
1.68 
0.82 - 3.43 
0.16 
first 1.5 years 1* 1.78 
0.33 - 9.71 
5.62 
1.23 - 25.6 
0.01 
adjustedf 1* 1.30 
0.64 - 2.63 
1.39 
0.66 - 2.93 
0.51 
first 1.5 years 1* 1.41 
0.25 - 7.89 
3.65 
0.76 - 17.4 
0.06 
Cerebrovascular 
disease 
crude 1* 0.80 
0.29 - 2.21 
2 13 
0.89- 5.07 
0.07 
adjustedf 1* 0.60 
0.21 - 1.71 
1.24 
0.50 - 3.08 
0.47 
normotensive 
crude 
1* 1* 21.35 
2.67 - 170.7 
adjustedf 1* 1* 17.23 
1.91 - 154.3 
hypertensive 
crude 
1* 1* 0.99 
0.38 - 2.57 
adjustedf 1* 1* 0.81 
0.30 - 2.16 
Cancer crude j * 1.63 
0.85 - 3.14 
2.94 
1.32 - 4.72 
0.004 
adjustedf 1* 1.40 
0.72 - 2.70 
1.87 
0.97 - 3.59 
0.06 
*: Reference group 
t: See Statistical Methods 
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Table 4. Odds ratios and 95% confidence intervals for the prevalence of cognitive impairment in 1990 
according to tertiles of serum homocysteine in 1985 in the Zutphen Elderly Study 
Odds ratios* adjusted for All subjects (n = 502) Subjects with haematocrit > 0.40 
and erythrocyte mean corpuscular 
volume < 100 fl (n = 301) 
Crude 1.73 2.13 
1.03 - 2.92 1.09-4.18 
Occupation 1.59 2.00 
0.94 - 2.71 1.00 - 4.01 
Age and occupation 1.38 1.98 
0.79 - 2.40 0.96 - 4.08 
Age, occupation, and other risk 1.34 2.22 
factorsf 0.76 - 2.35 1.05 - 4.68 
Age, occupation, other risk 1.25 1.97 
factorsf, and vitamin B6 intake 0.70 - 2.25 0.91 - 4.24 
*: All odds ratios compare the third tertile to the lower two tertiles of serum homocysteine 
f: body mass index, systolic blood pressure, total and high density lipoprotein cholesterol, cigarette smoking habits, 
diabetes mellitus, alcohol consumption and presence of cerebrovascular disease at baseline 
Discussion 
This is the first prospective, population-based study to examine the role of high 
homocysteine levels as a risk factor for cardiovascular disease, cancer, and cognitive 
impairment in the elderly. We found that a high non-fasting serum homocysteine level was 
common among elderly men, and was strongly associated with the prevalence of coronary 
heart disease and cerebrovascular disease. It was also a strong risk factor for fatal 
cerebrovascular disease in men without hypertension. In addition, we found that a high 
homocysteine level tended to be related to cancer prevalence and mortality, and to the 
prevalence of cognitive impairment at follow-up. Blood samples were taken in the non-
fasting state and serum was not separated immediately. These sampling conditions tend 
to increase the serum homocysteine level, but relatively more so at low levels.7 ,20"22 It is 
therefore unlikely that the associations between high homocysteine levels and outcome 
measures were biased by the blood sampling conditions. 
Homocysteine levels and cardiovascular disease 
Several cross-sectional1 and two prospective6,7 studies in middle-aged subjects have shown 
an increased risk of myocardial infarction with high homocysteine levels. A Finnish 
population-based study25 was negative, but the prevalence of high homocysteine levels in 
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that study was too low to allow definitive conclusions. We found a high homocysteine 
level to be associated with a history of coronary heart disease at baseline, and, marginally, 
with mortality from coronary heart disease in the first 1.5 years of observation, but not 
with the incidence of first ever coronary heart disease. These results suggest that, in men, 
the coronary risk associated with high homocysteine levels decreases with age. In both 
previous prospective studies homocysteine was also a stronger risk factor among younger 
than among older subjects.6,7 
In cross-sectional studies, a high homocysteine level is strongly associated with 
cerebrovascular disease in young and middle-aged subjects.1 Three prospective studies, all 
in middle-aged subjects, have yielded somewhat inconsistent results. Verhoef et al 
observed an increased risk of stroke that was confined to normotensive men.8 A 
relationship between homocysteine levels and stroke risk was absent in the Finnish study25 
but strongly positive among British men.9 The latter study a synergistic interaction 
between homocysteine and blood pressure was suggested but the interaction was not 
statistically significant.9 In both the cross-sectional and the mortality analyses, we found 
that the association of a high homocysteine level with cerebrovascular disease was much 
stronger among normotensive than among hypertensive men. All deaths from 
cerebrovascular disease occurred in subjects who had had a previous cerebrovascular 
event; a high homocysteine level was not associated with an increased risk of a first ever 
cerebrovascular event. A high homocysteine level thus was strongly associated with 
repetitive and ultimately fatal cerebrovascular disease. Overall, these and previously 
published data8 , 9 suggest that, in men without hypertension, the risk of cerebrovascular 
disease associated with high homocysteine levels does not decrease with age; on the other 
hand, there is no indication that a high homocysteine level increases the risk of 
cerebrovascular disease in elderly men in whom the risk of cerebrovascular disease is 
already high because of the presence of hypertension. 
Homocysteine levels and cancer 
The relationship between a high homocysteine level and cancer was apparent mainly for 
cancer mortality, where it was of borderline statistical significance (table 3). This finding 
may nevertheless be important, because a high homocysteine level may be linked to an 
increased risk of cancer through at least three pathways. First, it may be a marker of 
spillage of homocysteine into the extracellular space by rapidly dividing tumour cells, as 
observed in acute leukaemia.2 The increase in cancer mortality associated with a high 
homocysteine level was not confined to the first years of observation (figure 1), however, 
which argues against this being the only pathway. Second, a high homocysteine level may 
be a marker of a marginal vitamin intake which itself may increase the risk of cancer.14 
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More speculatively, homocysteine or a closely related intracellular metabolite might be 
directly carcinogenic, or a high homocysteine level might be a marker of altered 
intracellular methylation which may affect the control of cellular growth. These 
suggestions merit further investigation, because our study clearly raises the possibility that, 
among elderly men, a high homocysteine level -whether a risk marker or a causal risk 
factor- may be a clinically useful indicator of an increased risk of dying from cancer. 
There was a weak tendency for high homocysteine levels to be associated with 
mortality from causes other than cardiovascular disease and cancer. Further studies are 
needed to determine whether this is an artefact or not. 
Homocysteine levels and cognitive impairment 
High homocysteine levels were associated with a 73% increase in the risk of cognitive 
impairment, although this decreased to a non-significant 38% after adjustment for age and 
level of occupation (as an estimate of intellectual capacity). It should be noted that 
adjusting for age may result in overcorrection if the effect of age on cognitive function 
is mediated in part through high homocysteine levels. The associations were stronger in 
subjects without anaemia and/or macrocytosis, which were used as proxies for clinical 
vitamin B12 and/or folic acid deficiencies, and were not materially affected by the level 
of vitamin B6 intake (table 4). 
Several mechanisms, not mutually exclusive, may be responsible for the relationship 
between homocysteine and cognitive function. First, hyperhomocysteinaemia increases the 
risk of atherosclerotic cerebrovascular disease, which, even in the absence of clinical 
stroke, is associated with cognitive impairment.31,32 Second, there is some evidence that 
homocysteine (or a closely related intracellular derivative) is itself directly neurotoxic.3 
Third, hyperhomocysteinaemia may be a marker of a cellular deficiency of vitamin B12, 
folic acid and/or vitamin B6, all of which may be linked to cognitive impairment through 
other pathways than high homocysteine levels only. For example, hyperhomocysteinaemia 
induced by vitamin B12 deficiency indicates a decreased intracellular activity of 
methionine synthase and thus a decreased formation of the methyl group donor s-
adenosylmethionine. Decreased methylation of myelin basic protein plays an important 
role in the demyelination and the neurological dysfunction observed in vitamin B12 
deficiency and in inborn errors that impair the remethylation of homocysteine to 
methionine.33 Remethylation is thought to be relatively spared in folic acid deficiency;33 
it is not known to what extent the association between folic acid deficiency and 
neurological dysfunction4 can be explained by subtle abnormahties in methyl group tranfer 
or other mechanisms. We did not measure serum vitamin B12 and folic acid levels and 
cannot exclude that clinical deficiencies of these vitamins were responsible for cognitive 
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impairment in some subjects. The association between high homocysteine levels and 
cognitive impairment were actually stronger in subjects without anaemia and/or 
macrocytosis, either of which is present in 80% or more of patients with clinical vitamin 
B12 or folic acid deficiency.19,34 This suggests that clinical deficiencies of these vitamins 
cannot explain the observed relationships. Vitamin B6, in turn, is involved in the 
biosynthesis of several neurotransmitters, which might provide a link between vitamin B6 
deficiency and cognitive impairment that is separate from its role in homocysteine 
metabolism. A marginal vitamin B6 intake was common in the study population35 and is 
closely related to low serum levels.16 The relationship between homocysteine levels and 
cognitive impairment, however, was not clearly affected by adjustment for vitamin B6 
intake. 
Implications 
In our study the mean homocysteine level was 15.8 umol/1; one third of the subjects had 
levels of 17 umol/1 or above. Suggested cutoff values for hyperhomocysteinaemia have 
ranged from 11.4 to 15.8 umol/1. 6 , 8 , 1 5 , 1 6 , 3 6 Thus, in our study, high homocysteine levels were 
common by any standard. Because high homocysteine levels can be reduced by simple 
treatment with folic acid and vitamin B6 even in the absence of deficiencies of these 
vitamins,5 studies are now needed of the effect of treatment of high homocysteine levels 
on cardiovascular disease, cancer, and cognitive function in the elderly. 
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White blood cell count and the five-year risk of coronary 
heart disease and all-cause mortality in elderly men 
Abstract 
Since the importance of established risk factors for coronary heart disease is unclear in 
older people, the associations of white blood cell count with the risk of coronary heart 
disease and all-cause mortality were investigated in an elderly cohort followed for five 
years. In 1985, complete information on risk factors of interest was available for 884 
randomly selected men, aged 64 to 84 years, from the Dutch town of Zutphen 
(participation rate 74 percent). Relative risks for a 109/L increase in white blood cell count 
were obtained for the five year incidence of and mortality from coronary heart disease and 
all-cause mortality. Relative risks were adjusted for age, body mass index, systolic blood 
pressure, total and high density lipoprotein cholesterol and cigarette smoking habit. Mean 
white blood cell count was 6.7 (standard deviation 1.8) 109/L at baseline. Increased white 
blood cell count was independently associated mortality from coronary heart disease. The 
relative risk amounted to 1.32 (95 percent confidence interval (% CI): 1.15 - 1.51). For 
the incidence of the disease the relative risk was 1.14 (0.98 - 1.32). These associations 
were observed regardless of cigarette smoking habit. Regarding all-cause mortality, the 
relative risk amounted to 1.25 (95% CI: 1.17 - 1.35). This association was especially 
observed among the never and former smokers. In conclusion, white blood cell count 
predicts coronary heart disease and all-cause mortality in elderly men, during five years 
of follow-up, independent of conventional risk factors for coronary heart disease. 
In press as: 
Weijenberg MP, Feskens EJM, Kromhout D. White blood cell count and the risk of 
coronary heart disease and all-cause mortality in elderly men. Arterio Thromb Vase Biol 
1996. 
Copyright holder American Heart Association. 
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Introduction 
Epidemiologic evidence is accumulating implicating moderately increased white blood cell 
count as a risk factor for coronary heart disease.1"8 Although the observed effect has often, 
for the largest part, been ascribed to smoking,2 ,3 ,7 biologic mechanisms for the association 
have also been described.9,10 Most evidence is based on middle-aged people1"8 but little is 
known on the importance of white blood cell count in predicting coronary heart disease 
in the elderly.9 
In general, there is currently much debate regarding the importance of conventional risk 
factors for coronary heart disease in the elderly.1 1 , 1 2 Likewise, it can be questioned whether 
white blood cell count continues to predict coronary heart disease with advancing age. On 
the other hand, since there may be selective survival of elderly people with elevated levels 
of conventional risk factors,13 other factors, such as white blood cell count, may become 
more important. Since atherosclerosis is generally well advanced in the elderly, factors 
associated with thrombosis may be more significant in predicting coronary heart disease 
in this age group.14 In the presence of atherosclerosis, activated monocytes and neutrophils 
may release products which promote plaque disruption and subsequent thrombus formation 
and may eventually lead to a coronary event. 1 0 , 1 5 
We investigated whether elevated white blood cell count is associated with coronary 
heart disease and all-cause mortality in an elderly cohort followed-up for five years. 
Methods 
Population 
The Zutphen Study is a longitudinal investigation of chronic disease risk factors initiated 
in 1960 among middle-aged men as the Dutch contribution to the Seven Countries Study.16 
In 1985, 555 men from the 1960 cohort were still alive and were invited for new 
examinations. In addition, a random sample (two out of three) of all men of the same age 
living in Zutphen and not part of the 1960 cohort were invited to take part in the study. 
From then on, the study was continued as the Zutphen Elderly Study. Of the 1266 men 
approached 939 (74 percent) agreed to participate. Hundred-and-nine men (9 percent) 
could not be examined because of serious illness or death, 62 men (5 percent) had moved 
and 156 men (12 percent) refused to participate or could not be reached. Complete 
information on risk factors was available for 884 men aged 64 to 84 years. 
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Examinations 
Physical examinations took place between March and June 1985 and were carried out by 
five trained physicians according to a standardized protocol. Height was measured to the 
nearest 0.1 cm and body weight was measured to the nearest 0.5 kg while the men were 
in underwear. Body mass index (weight (kg)/ height (m)2) was calculated. At the end of 
the examination, systolic and diastolic (fifth Korotkoff phase) blood pressures were 
measured in duplicate with a random zero sphygmomanometer at the right arm while 
subjects were in the supine position. The mean of the two blood pressure values was used 
in the analyses. 
Non-fasting venous blood samples were taken. A Coulter Counter S880 was used to 
determine white blood cell count and hematocrit. The variation coefficient for the within-
and between-run measurement error was less than two percent for both white blood cell 
count and hematocrit. Serum total and high density lipoprotein cholesterol were 
determined enzymatically with the CHOD-PAP mono-testkit from Boehringer 
Mannheim. 1 7 1 8 High density lipoprotein was isolated after precipitation of apo B 
containing particles by dextran sulphate-Mg2*.19 The lipid analyses were carried out in the 
standardized lipid laboratory of the Department of Human Nutrition, Agricultural 
University, Wageningen, The Netherlands. Serum albumin levels were analyzed in an 
auto-analyzer (SMAC, Technicon, Tarytown, USA) and these analyses were performed 
in blood samples of 879 men. 
Information on smoking habits was assessed with a standardized questionnaire and is 
missing for one person. Information on the presence of diabetes mellitus, cancer and 
chronic obstructive pulmonary disease at baseline was obtained through a standardized 
medical questionnaire during the physical examination and was verified with hospital 
discharge data and written information from the subjects' general practitioners. 
Follow-up 
Information on the prevalence and incidence of coronary heart disease was obtained during 
the physical examination in 1985 and a similar examination in 1990. For men who did not 
participate in the 1990 examination, information on major chronic diseases was obtained 
from a questionnaire for non-participants. Coronary heart disease was considered to be 
present when either myocardial infarction or angina pectoris were diagnosed. For 
myocardial infarction the final diagnosis was based on whether two of the following three 
criteria were met: a specific medical history, i.e. severe chest pain lasting for more than 
20 minutes and not disappearing in rest, characteristic electrocardiogram changes and 
specific enzyme elevations. The diagnosis of angina pectoris was based on information 
obtained from the Dutch translation of the Rose questionnaire.20 All diagnoses were 
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additionally verified with information from electrocardiograms, hospital discharge data and 
written information from the subjects' general practitioners. The information was 
eventually coded by one physician, and the year of first diagnosis was recorded. 
Information on the vital status of participants was obtained till July 1990. One person 
had moved abroad and was lost to follow-up. The date on which he moved was used as 
his (censored) end-point date. Information on the causes of death was obtained from the 
Dutch Central Bureau of Statistics, after verification with hospital discharge data and 
information from the deceased's general practitioners. The causes of death were coded 
according to the 9th Revision of the International Classification of Diseases (ICD)21 and 
both the primary and secondary cause of death were considered. Death due to coronary 
heart disease was defined by ICD codes 410-414, death due to cardiovascular disease by 
codes 410-448, death due to all-cause cancer by codes 140-239, and death due to lung 
cancer by code 162. 
The main end-points investigated were the incidence of a first fatal or non-fatal 
coronary heart disease event among men without the disease at baseline (i.e. incidence of 
coronary heart disease), mortality from coronary heart disease and from all-causes. 
Statistical methods 
Statistical analyses were carried out using the SAS program (SAS Institute Inc., Cary, 
North Carolina, USA, 1989-1993, version 6.10). All tests were two sided and p-values 
smaller than five percent were considered statistically significant. Cox's proportional-
hazard (survival) analysis was carried out to investigate the associations of white blood 
cell count with end-points during five years of follow-up.22 The date on which an event 
occurred was used in the analyses. For coronary heart disease incidence July 1st of the 
year of diagnosis was used as the date of the event. Relative risks are presented according 
to a 109/L increase in white blood cell count. Interaction terms were evaluated at the 10 
percent level. Quintiles of white blood cell count were formed and adjusted relative risks 
for these quintiles were computed with the lowest category as the reference. 
Results 
The white blood cell count of the men at baseline ranged between 2.4 and 16.1 109/L. 
White blood cell count was not significantly associated with baseline age nor with most 
of the conventional risk factors for coronary heart disease (table 1). There was an inverse 
association with high density lipoprotein cholesterol and serum albumin levels and a 
positive association with hematocrit. White blood cell count was higher in the 58 men 
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with diabetes mellitus at baseline compared to men free of the disease (7.1, SD 1.8, 109/L 
versus 6.6, SD 1.8, 109/L). This difference was borderline significant. 
Table 1. Population characteristics and associations with white blood cell count in 884 men aged 64 
to 84 years (the Zutphen Elderly Study, 1985) 
Mean (standard deviation) Spearman correlation 
coefficient with white blood 
cell count (109/L) 
White blood cell count (lO'/L) 6.7 (1.8) 
Age (years) 71.5 (5.3) - 0.01 
Body mass index (kg/m2) 25.45 (3.20) 0.00 
Systolic blood pressure (mmHg) 151.0 (21.5) 0.03 
Diastolic blood pressure (mmHg) 85.4 (11.5) - 0.01 
Serum total cholesterol (mmol/L) 6.10(1.11) 0.01 
Serum high density lipoprotein 
cholesterol (mmol/L) 1.12 (0.29) - 0.08* 
Serum albumin (g/L) 44.1 (2.7) - 0.14t 
Hematocrit 0.45 (0.04) 0.12t 
Number (percentage) /7-value! 
Diabetes mellitus 58 (6.6) 0.07 
*: p < 0 . 0 5 
t: p< 0.001 
p . for Mann-Whitney (/-test of difference in mean white blood cell count between those with and those without 
diabetes mellitus 
White blood cell count was significantly higher in men who were cigarette smokers at 
baseline compared to former and never smokers (p < 0.0001) (table 2). There was no 
significant difference in white blood cell count between former smokers who quit more 
than 10 years ago and those who quit 10 years ago or less nor between the amount of 
cigarettes smoked among men who smoked in 1985 (table 2). 
White blood cell count was not associated with the prevalence of coronary heart 
disease at baseline (6.7, standard deviation (SD) 1.7, 109/L in 175 cases versus 6.6, SD 
1.8, 109/L in non cases). However, in 21 men who suffered a coronary heart disease event 
within half a year prior to the blood sampling white blood cell count tended to be higher 
than that of men without any evidence the disease at baseline (7.0, SD 1.4 109/L compared 
to 6.6, SD 1.8 109/L respectively, p-value = 0.10). 
White blood cell count was positively and independently associated with mortality from 
coronary heart disease during five years of follow-up (table 3), and the association 
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Table 2. Mean white blood cell count according to cigarette smoking habit in elderly men (the 
Zutphen Elderly Study, 1985) 
Cigarette smoking habit in 1985 N White blood cell count (lO'/L) 
Never smoker 162 6.4 (1.7)* 
Former smoker 454 6.3 (1.7) 
More than 10 years ago 268 6.2 (1.6) 
10 years ago or less 168 6.5 (1.9) 
Current smoker 267" 7.3 (1.8) 
1-9 cigarettes/day 63 7.2 (1.9) 
10-19 cigarettes/day 111 7.3 (1.7) 
S 20 cigarettes/day 92 7.5 (1.8) 
*: mean (standard deviation), overall Kruskal-Wallis test comparing never, former and current smokers: 
p < 0.0001 
tended to be exponential (figure 1). Additional adjustment for the presence of coronary 
heart disease at baseline did not affect the strength of the association (relative risk 1.32, 
95 percent confidence interval (% CI) 1.13 - 1.53). The association was of the same 
magnitude among 793 men with white blood cell count within the normal range of 4.5 to 
11 109/L (not shown). The association with the incidence of a first coronary heart disease 
event was also positive, though weaker than with mortality from the disease (adjusted 
relative risk 1.14, 95% CI 0.98 - 1.32). 
Table 3. Relative risks for mortality from coronary heart disease and all-causes associated with white 
blood cell count in elderly men (the Zutphen Elderly Study, 1985 - 1990) 
Coronary heart disease All-causes 
Percentage of deaths (n) 6.0 (53) 23.9 (211) 
Crude 1.27 (1.11 - 1.44)* 1.20(1.12- 1.28) 
Adjusted for age 1.30 (1.14 - 1.49) 1.24 (1.15 - 1.33) 
Adjusted for conventional risk factorst 1.32(1.15 - 1.51) 1.25 (1.17 - 1.35) 
Adjusted for additional risk factors! 1.27 (1.10 - 1.46) 1.21 (1.12- 1.30) 
*: relative risk (95 percent confidence interval) for lO'/L increase in white blood cell count 
t: age, body mass index, systolic blood pressure, total cholesterol, high density lipoprotein cholesterol, cigarette 
smoking 
p . conventional risk factors and albumin, hematocrit and diabetes mellitus at baseline 
White blood cell count was independently associated with all-cause mortality (table 3) in 
a graded fashion (figure 1). The association persisted even after adjustment for the 
presence of major chrome diseases at baseline such as cardiovascular diseases, cancer and 
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chronic obstructive pulmonary disease (relative risk 1.15, 95% CI 1.07 -1.24). Additional 
analyses revealed that white blood cell count was associated with increased risk of death 
from all cardiovascular diseases (risk factor and disease adjusted relative risk 1.21, 95% 
CI 1.09 - 1.34), cancer (adjusted relative risk 1.10, 95% CI 0.97 - 1.24) and all other 
causes (adjusted relative risk 1.15, 95% CI 0.98 - 1.35). 
The association of white blood cell count with coronary heart disease has often been 
ascribed to the effect of smoking on coronary heart disease. However, cigarette smoking 
status in 1985 was not significantly associated with mortality from coronary heart disease 
(p-trend = 0.64) nor all-causes (p-trend = 0.47) during five years of follow-up. Cigarette 
smoking was only significantly associated with lung cancer death (p-trend = 0.05). White 
blood cell count was positively associated with mortality from coronary heart disease 
regardless of the cigarette smoking status (table 4). The association tended to be stronger 
among the never smoking men, but was not significantly different from the other smoking 
categories. Regarding all-cause mortality, there was a significant association with white 
blood cell count among the non-smokers but not among the current smokers (p-interaction 
= 0.07). 
Coronary heart disease mortality 
RR (log scale) 
10 
0.1 
2 .4 -5 .1 5 . 2 - 6 . 0 6.1 -6 .9 7 . 0 - 7 . 9 > 8 . 0 
Quintiles of white blood cell count (10 9 /L) 
All-cause mortality 
RR (log scale) 
10 
0.1 
2 .4 -5 .1 5 . 2 - 6 . 0 6.1 - 6 . 9 7 . 0 - 7 . 9 > 8.0 
Quintiles of white blood cell count (10 9 /L) 
Figure 1. Relative risks and 95 percent confidence intervals for mortality from coronary heart disease 
and from all-causes according to quintiles of white blood cell count (The Zutphen Elderly Study, 1985 
- 1990) 
107 
Chapter 7 
Table 4. Relative risks for mortality from coronary heart disease and all causes associated with white 
blood cell count in elderly men according to smoking status at baseline (the Zutphen Elderly Study, 
1985) 
Smoking status in 1985 
Never (n = 162) Former (n = 454) Current (n=267) 
Coronary heart disease 
Percentage of deaths (n) 5.6 (9) 12 (25) 8.2 (22) 
Crude 1.47 (1.10- 1.96)* 1.28 (1.07 - 1.53) 1.21 (0.94 - 1.56) 
Adjusted for age 1.47 (1.10 - 1.95) 1.32 (1.09 - 1.59) 1.26 (0.97 - 1.63) 
Adjusted for conventional 
risk factorst 1.51 (1.10-2.08) 1.30 (1.07 - 1.59) 1.20 (0.90 - 1.59) 
Adjusted for additional 
risk factors^ 1.56 (1.13 - 2.16) 1.24 (1.00 - 1.54) 
All-causes 
1.27 (0.92- 1.74) 
Percentage of deaths (n) 24.5 (40) 23.4 (106) 24.3 (65) 
Crude 1.28 (1.10- 1.40) 1.29 (1.18 - 1.41) 1.05 (0.92- 1.20) 
Adjusted for age 1.28 (1.10- 1.49) 1.33 (1.21 - 1.46) 1.09 (0.95 - 1.25) 
Adjusted for conventional 
risk factorst 1.29 (1.10 - 1.51) 1.33 (1.20- 1.47) 1.05 (0.91 - 1.22) 
Adjusted for additional 
risk factorst 1.27 (1.09 - 1.49) 1.26 (1.13 - 1.40) 1.05 (0.91 - 1.22) 
*: relative risk (95 percent confidence interval) for 109/L increase in white blood cell count 
t: age, body mass index, systolic blood pressure, total cholesterol, high density lipoprotein cholesterol, cigarette 
smoking 
p . conventional risk factors and albumin, hematocrit and diabetes mellitus at baseline 
Discussion 
This is the first report on the association between white blood cell count and coronary 
heart disease in an elderly population. An increase of one standard deviation in white 
blood cell count was associated with a 65 percent increase in the risk of death from 
coronary heart disease. This effect is considerably higher than the 45 percent increased 
risk associated with one standard deviation increase in total cholesterol in the same cohort 
and during the same period.23 In studies in middle-aged people the effect of white blood 
cell count on coronary heart disease has been found to be similar2 to or even smaller6,8 
than that of total cholesterol levels. This suggests that, in advanced age, other factors than 
the conventional risk factors for coronary heart disease, such as white blood cells, become 
more important in predicting the disease. 
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Possible biologic mechanisms underlying the observed associations have been 
postulated. It is widely recognized that monocytes have a role in the pathogenesis of 
atherosclerosis.15 After monocytes are recruited at the site of endothelial injury, they 
adhere to the vessel wall, enter it and are eventually converted into foam cells. Since the 
monocyte count constitutes approximately two to ten percent of the total white blood cell 
count, it is probably not the only fraction of the total white blood cell count responsible 
for the observed association with coronary heart disease. Indeed, the most common 
granulocytes, the neutrophils, have also been implicated in the pathogenesis of 
atherosclerosis.10 In the presence of atherosclerosis, which can be viewed as an 
inflammatory disease,24 white blood cells may become activated. This leads to reduced 
deformability of especially the neutrophilic cells, to white blood cell aggregation and 
adherence to the endothelium, and to recruitment of white blood cells, all of which 
subsequently lead to capillary plugging and tissue ischemia. Activated neutrophils and 
monocytes may also release products which induce plaque rupture and subsequent 
thrombus formation which can also result in ischemia. 1 0 1 5 The main products released by 
the cells are oxidants, such as superoxide radicals and nitric oxide,25 and proteolytic 
enzymes10 which can all induce vascular injury. Pathological mechanisms have also been 
postulated for the association between white blood cell count and diseases other than 
coronary heart disease. Oxidation metabolites produced by activated white blood cells 
during inflammation may also be involved in the pathogenesis of cancer and lung 
disease.10 
Since white blood cell count is a general indicator of inflammation it may also be a 
marker of underlying athero-thrombotic disease. The observed association with coronary 
heart disease is therefore not necessarily causal. Which mechanisms underlie the 
association cannot be derived from this study. 
In our study, the association between white blood cell count and coronary heart disease 
incidence was less strong than for mortality. Through plaque rupture and thrombus 
formation, white blood cell count may be more strongly associated with more severe 
coronary heart disease leading to death.15 This may also explain the baseline results since 
there was no clear evidence that men with coronary heart disease at baseline had elevated 
white blood cell counts as compared to men free of the disease. This was especially 
observed in those who were first diagnosed with the disease more than half a year prior 
to the blood sampling. It is possible that the men with elevated white blood cell count 
have already died. The elevated white blood cell count in men who suffered a coronary 
heart disease event in the same year as the blood sampling may be the result of an active 
state of atherosclerosis, i.e. progression. 
White blood cell count also predicted all-cause mortality and this has been observed 
previously in middle-aged populations.8 2 6 An elevated white blood cell count may be a 
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marker for inflammation and is therefore also associated with increased risk of mortality. 
Although the association remained after adjustment for the clinical diagnosis of major 
chronic diseases, possible underlying (subclinical) disease may still have driven the 
observed association. Part of the association may be a consequence of the strong 
association between white blood cell count with mortality from coronary heart disease. 
The association between white blood cell count and coronary heart disease has often, 
at least in part, been attributed to smoking.2 ,3 ,7 In the present study, the positive association 
between white blood cell count and coronary heart disease was observed regardless of 
smoking status. White blood cell count predicted coronary heart disease and all-cause 
mortality in non-smokers, thus smoking status is does not explain the findings. 
Surprisingly, smoking status does not appear to be associated with coronary heart 
disease in the present study. Since the vast majority of the men in our study have smoked 
during their lifetime a larger population may be necessary to examine this association.27 
In addition, men who remain smokers in advanced age and survive its detrimental effects 
may be less susceptible to these effects than those who did not reach old age. The smokers 
in this study may form a select group of healthy men, regardless of their smoking habit, 
who are less susceptible to coronary heart disease. In a larger cohort study of older people, 
cigarette smoking has clearly been associated with increased mortality outcomes and 
cessation of smoking has been shown to improve survival in the elderly.27 Therefore 
caution is warranted in interpreting our findings regarding the risk of cigarette smoking. 
In conclusion, white blood cell count appears to predict future coronary heart disease 
and mortality independent of conventional risk factors. White blood cell count is probably 
not only an indicator of clinical or subclinical disease, but also a true risk factor for 
coronary heart disease. Whether a causal pathway is involved should be assessed in future 
experimental studies. Nevertheless, white blood cell count could be of important public 
health use since it is routinely measured by clinicians. Moreover, it seems of specific 
importance in older people since it appears to be more strongly associated to coronary 
heart disease than, for example, total cholesterol in this age group. 
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Chapter 8 
Serum albumin and the five-year risk of coronary heart 
disease and all-cause mortality in elderly men 
Abstract 
The associations of serum albumin with the incidence of coronary heart disease and 
mortality were investigated in men from the Zutphen Elderly Study followed for 5 years. 
In 1985, 820 men randomly selected from a population aged 64 to 84 years, had complete 
information on risk factors. Relative risks were adjusted for traditional risk factors (age, 
body mass index, diastolic blood pressure, total and high density lipoprotein cholesterol, 
smoking and alcohol consumption) and additionally for baseline health status indicators 
(white blood cell count, physician's health score, self-rated health and history of relevant 
diseases). Albumin was inversely associated with the incidence of coronary heart disease 
among men with elevated total cholesterol levels (> 6.5 mmol/L) only. The relative risk 
for one standard deviation increase (2.5 g/L) in albumin was 0.60 (95%-confidence 
interval: 0.38 - 0.96) and was not altered after additional adjustment for baseline health 
status. In all men, the relative risk for death due to coronary heart disease was 0.67 (0.49 -
0.92) and reduced to 0.84 (0.61 - 1.15) after adjustment for health status. Comparable 
health status adjusted relative risks were observed for mortality from cardiovascular 
diseases (0.83 (0.67 - 1.02)) and all causes (0.86 (0.73 - 0.99)). Independent of traditional 
risk factors, moderately low serum albumin is predictive of coronary heart disease and all-
cause mortality in elderly men. Only part of this could be explained by baseline health 
status. 
Submitted as: 
Weijenberg MP, Feskens EJM, Souverijn JHM, Kromhout D. Serum albumin, coronary 
heart disease risk and mortality in an elderly cohort. 
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Introduction 
Low serum albumin levels, even within the normal range of 35 g/L to 50 g/L, have been 
associated with all-cause mortality in several free-living older populations.1"3 Although 
plausible mechanisms for a causal association have been postulated,4"7 especially for 
coronary heart disease, very few studies present cause specific mortality data, or data on 
the incidence of coronary heart disease. To our knowledge, only the National Health and 
Nutrition Examination Survey Epidemiologic Follow-up Study provides data on these end-
points specifically in elderly people (65 to 74 years old). In this age group, no clear 
association between serum albumin and coronary heart disease incidence or mortality was 
observed.3 
Low albumin levels may be a marker of (mild) inflammation and (underlying) disease. 
Albumin is a negative acute phase protein8 and the serum level may be reduced due to a 
general increased vascular permeabihty during disease as a result of tissue damage.9 Some 
investigators suggest that the relation of low albumin with increased mortality reflects an 
association of other serum proteins with mortality10 ,11 or an association of activated 
macrophages with cardiovascular diseases.7 However, low serum albumin is conceivably 
more than just a marker. Through its specific binding capacity with free fatty acids it may 
inhibit platelet aggregation and thrombosis.6 Furthermore, albumin may act as an indirect 
and "sacrificial" anti-oxidant through its specific binding to metals and scavenging abilities 
of peroxyl radicals.4 ,12 
Hence, it is of interest to investigate whether the association between serum albumin 
and coronary heart disease and mortality persists after accounting for baseline health 
status. In addition to a history of disease and a physician's examination of an individual, 
other factors have proven to be indicative of baseline health status. Low self-rated health 
has been demonstrated to predict mortality independent of traditional risk factors and a 
history of chronic diseases.13 Increased white blood cell count has also been suggested as 
an indicator of inflammation and has been causally associated with coronary heart disease 
and other chronic diseases.14 In earlier reports among elderly people, 1 , 2 , 1 5 the association 
between serum albumin and mortality was not investigated independent of both traditional 
risk factors and acknowledged indicators of baseline health status. Therefore, we 
investigated the associations of serum albumin with the incidence of coronary heart 
disease and cause specific mortality in elderly men of a population-based cohort and 
accounted for traditional confounders as well as for baseline health status. 
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Methods 
Population 
The Zutphen Study, the Dutch contribution to the Seven Countries Study,16 is a 
longitudinal investigation of chronic disease risk factors initiated in 1960 among middle-
aged men. In 1985, 555 men from the randomly selected cohort from 1960 were still alive 
and were invited for new examinations. In addition, a random sample (two out of three) 
of all men of the same age living in Zutphen and not part of the 1960 cohort were invited 
to take part in the study. From then on, the study was continued as the Zutphen Elderly 
Study. Of the 1266 men approached 939 (74 percent) agreed to participate. Hundred-and-
nine men (9 percent) could not be examined because of serious illness or death, 62 men 
(5 percent) had moved and 156 men (12 percent) refused to participate or could not be 
reached. Complete information on risk factors was available for 820 men aged 64 to 84 
years. The study has been approved by the medical ethics committee of the University of 
Leiden, The Netherlands. Informed consent was obtained from all participants. 
Examinations 
The examinations took place between March and June 1985. Physical examinations were 
carried out by five trained physicians according to a standardized protocol and included 
anthropometric and blood pressure measurements, non-fasting venous blood sampling, and 
the assessment of the medical history. Height was measured to the nearest 0.1 cm and 
body weight was measured to the nearest 0.5 kg while the men were in underwear. Body 
mass index (weight (kg)/ height (m)2) was calculated. At the end of the physical 
examination, systolic and diastolic (fifth Korotkoff phase) blood pressures were measured 
in duplicate with a random zero sphygmomanometer at the right arm while subjects were 
in the supine position. The mean of the two blood pressure values was used in the 
analyses. 
Serum albumin levels were analyzed in an auto-analyzer (SMAC, Technicon, 
Tarytown, USA) in the Central Laboratory of Clinical Chemistry of the Academic Hospital 
in Leiden. Serum total and high density lipoprotein (HDL) cholesterol were determined 
enzymatically with the CHOD-PAP mono-testkit from Boehringer Mannheim.1 7 , 1 8 HDL 
was isolated after precipitation of apo B containing particles by dextran sulphate-Mg2+.19 
The lipid analyses were carried out in the standardized lipid laboratory of the Department 
of Human Nutrition, Agricultural University, Wageningen, The Netherlands. White blood 
cell count was determined using a Coulter Counter S880 in the Nieuwe Spitaal Hospital 
in Zutphen. 
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Information on smoking habits was assessed with a standardized questionnaire and is 
missing for one person. Life time occupation was used as an indicator of social economic 
status. It was obtained from a self-administered questionnaire, and divided into four 
categories: professionals, managers and teachers; small business owners; adniinistrative 
personnel; and manual workers. Information on alcohol consumption was assessed by 
trained dietitians with a cross-check dietary history,20 adapted to the Dutch situation.21 
Health status indicators and follow-up 
At the end of the physical examination, the physicians rated the general health of each 
participant on a five point scale ranging from excellent health to unhealthy. Participants 
were also asked to rate their own health on a self administered questionnaire and could 
choose between: healthy, rather healthy, moderately healthy or not healthy. The 
association with physicians' rating was moderate (Spearman correlation = 0.37). White 
blood cell count was also regarded as a health status indicator.22 
Information on the presence of diabetes mellitus, cancer and chronic obstructive 
pulmonary disease at baseline was obtained through a standardized medical questionnaire 
and was verified with hospital discharge data and written information from the subjects' 
general practitioners. 
Information on the presence of coronary heart disease was obtained during the physical 
examination in 1985 and a similar examination in 1990 using the Dutch translation of the 
Rose questionnaire.23 For men who did not participate in the 1990 examination, 
information on major chronic diseases was obtained from a questionnaire for 
nonparticipants. Coronary heart disease was considered to be present when either 
myocardial infarction or angina pectoris was diagnosed. The diagnoses were verified with 
hospital discharge data and written information from the subjects' general practitioners. 
For myocardial infarction the final diagnosis was based on whether two of the following 
three criteria were met: a specific medical history, i.e. severe chest pain lasting for more 
than 20 minutes and not disappearing in rest, characteristic electrocardiogram changes and 
specific enzyme elevations. The diagnosis of angina pectoris was based on information 
obtained from the Rose questionnaire.23 All information was eventually coded by one 
physician, and the year of first diagnosis was recorded. 
Information on the vital status of participants was obtained till July 1990. Information 
on the causes of death was obtained from the Dutch Central Bureau of Statistics, after 
verification with hospital discharge data and information from the deceased's general 
practitioners. The causes of death were coded according to the 9th Revision of the 
International Classification of Diseases (ICD)24 and both the primary and secondary cause 
of death were considered. Death due to coronary heart disease was defined by ICD codes 
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410-414, death due to cardiovascular disease by codes 390-459 and death due to all-cause 
cancer by codes 140-239. 
The main end-points investigated were the incidence of a first fatal or non-fatal 
coronary heart disease event (i.e. incidence of coronary heart disease), mortality from 
coronary heart disease, cardiovascular diseases, all-cause cancer, all other causes and all 
causes combined. 
Statistical methods 
Statistical analyses were carried out using the SAS program (SAS Institute Inc., Cary, 
North Carolina, USA, 1989-1993, version 6.10). All tests were two sided and p-values 
smaller than five percent were considered statistically significant. Analysis of variance and 
Kruskall-WalMs tests were carried out to examine differences in continuous variables 
between albumin tertiles. Chi-square test statistics were used to investigate associations 
between categorical variables. 
Cox's proportional-hazard (survival) analysis was carried out to investigate the 
associations of serum albumin with end-points during five years of follow-up. Relative 
risks were adjusted for traditional risk factors and additionally for baseline health status 
indicators. For coronary heart disease, cardiovascular diseases and all-cause mortality end-
points, the traditional confounders adjusted for were: age, body mass index, diastolic blood 
pressure, total and HDL cholesterol, cigarette smoking (never, former, current) and alcohol 
consumption (yes or no) at baseline. The same factors were adjusted for in the associations 
with mortality from cancer and all other causes with the exception of diastolic blood 
pressure and HDL cholesterol. Regarding the health status indicators, white blood cell 
count, physician's health score and self-rated health were always considered together with 
the history of specific diseases depending on the end-point investigated. Interaction terms 
were evaluated at the 10 percent level. 
Results 
The mean serum albumin level of men at baseline was 44.1 (SD 2.5) g/L. Three men had 
an albumin level lower than 35 g/L and thirty had a level lower than 40 g/L. Men with 
albumin levels in the lowest third of the distribution were significantly older, had lower 
body mass index, diastolic blood pressure and total cholesterol levels, higher white blood 
cell counts and were less often alcohol drinkers than men with higher levels of serum 
albumin (table 1). For diastolic blood pressure, total cholesterol and alcohol consumption 
the association was graded over the albumin tertiles. For other variables, the differences 
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were mainly observed between the lowest and the two higher albumin tertiles. Life time 
occupation was not associated with albumin levels (table 1). 
Table 1. Mean levels of baseline characteristics according to tertiles of serum albumin levels 
in elderly men (the Zutphen Elderly Study, 1985) 
Albumin tertiles 
Characteristics First 
(n = 311) 
Second 
(n = 274) 
Third 
(n = 235) 
Albumin range (g/L) 34.0 - 43.0 44.0 - 45.0 46.0 - 52.0 
Mean (standard deviation) 
Age (years) 72.5 (5.2) 70.9 (5.2) 70.4 (5.1)* 
Body mass index (kg/m2) 24.88 (3.17) 25.86 (3.26) 25.82 (2.86)* 
Systolic blood pressure (mmHg) 149.0 (20.8) 151.7 (21.4) 151.6 (21.6) 
Diastolic blood pressure (mmHg) 83.7 (12.0) 85.8 (10.3) 87.2 (11.5)t 
Total cholesterol (mmol/L) 5.88 (1.12) 6.13 (1.04) 6.38 (1.11)* 
HDL cholesterol (mmol/L) 1.11 (0.30) 1.14 (0.30) 1.12 (0.27) 
White blood cell count (109/L) 6.9 (1.9) 6.5 (1.7) 
Percentage 
6.4 (1.8)t 
Alcohol consumption (> 0 g/day) 67.5 73.7 78.7* 
Current cigarette smokers 32.9 29.9 26.4 
Former cigarette smokers 50.0 49.6 56.6 
Life-time occupation as 
professionals, managers or teachers 27.1 27.2 20.3 
*: p< 0.001 
f: ¿><0.01 
p . p < 0 . 0 5 
Serum albumin was associated with baseline health status indicators (table 2). Men with 
a history of major chronic diseases at baseline were more likely to have lower albumin 
levels. For men who where rated in excellent health by the physicians and those who rated 
themselves as healthy, serum albumin levels were less likely to be low (table 2). The 
differences between these health status indicators were generally most pronounced between 
the lowest albumin tertile and the two higher tertiles. 
Among 657 men free of coronary heart disease at baseline, 51 men became incident 
of a first fatal or non-fatal coronary heart disease event during the follow-up period. 
Serum albumin was not associated with the incidence of coronary heart disease (table 3). 
However, serum total cholesterol was an effect modifier in this association (p-interaction 
= 0.01), and an inverse association between serum albumin and the incidence of coronary 
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heart disease was evident in men with serum cholesterol levels of 6.5 mmol/L or higher 
(table 3). Additional adjustment for baseline health status did not alter the strength of the 
association. Albumin was not associated with coronary heart disease incidence among men 
with cholesterol levels lower than 6.5 mmol/L (table 3). 
Table 2. Baseline health status according to tertiles of serum albumin levels in elderly men (the 
Zutphen Elderly Study, 1985) 
Albumin tertiles 
Health status indicators First Second Third 
History of 
coronary heart disease 25.7 (80)* 16.4 (45) 16.2 (38)t 
cardiovascular disease 42.8 (133) 29.9 (82) 29.4 (69)f 
cancer 11.3 (35) 5.8 (16) 5.1 (12)$ 
chronic obstructive pulmonary disease 20.6 (64) 11.7 (32) 12.8 (30)t 
diabetes mellitus 7.1 (22) 6.6 (18) 4.7 (11) 
Health score given by physician 
in excellent health 21.4 (66) 35.3 (96) 32.1 (75)t 
Self rated health 
healthy 39.7 (120) 50.8 (134) 52.7 (118)t 
*: % (n) 
t: p < 0 . 0 1 
t: p < 0 . 0 5 
Table 3. Relative risks for five-year incidence of coronary heart disease according to one standard 
deviation (2.5 g/L) in serum albumin level in elderly men overall and by serum total cholesterol level 
(the Zutphen Elderly Study, 1985 - 1990) 
Number of Relative risk (95% confidence interval) 
incident 
cases Adjusted for 
traditional risk 
factorst 
Adjusted for traditional 
risk factors and health 
status$ 
Overall (n = 656)* 51 0.81 
(0.60 - 1.10) 
0.86 
(0.63 - 1.17) 
Serum total cholesterol 
< 6.5 mmol/L (n = 427)* 
30 1.04 
(0.69 - 1.57) 
1.13 
(0.74 - 1.71) 
Serum total cholesterol 
£ 6.5 mmol/L (n = 229)* 
21 0.60 
(0.38 - 0.96) 
0.60 
(0.35 - 1.02) 
*: Number of men free of coronary heart disease at baseline 
t: age, body mass index, diastolic blood pressure, total and HDL cholesterol, cigarette smoking and alcohol 
consumption 
t: white blood cell count, self-rated health, physician's health score and diabetes mellitus 
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For mortality from coronary heart disease, there was an inverse association with serum 
albumin independent of traditional coronary heart disease risk factors (table 4). The 
relationship was attenuated after additional adjustment for baseline health status indicators. 
For mortality from cardiovascular diseases, the relation with serum albumin was similar 
and of the same magnitude as that for mortality from coronary heart disease (table 4). 
Table 4. Relative risks for five-year mortality according to one standard deviation (2.5 g/L) increase 
in serum albumin level in elderly men (the Zutphen Elderly Study, 1985 - 1990) 
Causes of mortality Number of Relative risk (95% confidence interval) 
deaths Adjusted for 
traditional risk factors* 
Adjusted for traditional risk 
factors and health statust 
Coronary heart disease 46 0.67 0.84 
(0.49 - 0.92)$ (0.61 - 1.15) 
Cardiovascular diseases 96 0.69 0.83 
(0.56 - 0.86) (0.67 - 1.02) 
All-cause cancer 65 0.67 0.98 
(0.52 - 0.86) (0.76 - 1.27) 
All other causes 31 0.53 0.61 
(0.36 - 0.79) (0.40 - 0.91) 
All causes 189 0.67 0.86 
(0.56 - 0.76) (0.73 - 0.99) 
*: age, body mass index, diastolic blood pressure, total cholesterol, cigarette smoking for all end-points, and for HDL 
cholesterol and alcohol consumption for cardiovascular diseases and all-cause mortality end-points 
t: white blood cell count, self-rated health, physician's health score for all endpoints, and diabetes mellitus and a 
history of coronary heart disease or cardiovascular disease and/or cancer and/or chronic obstructive pulmonary 
disease depending on mortality outcome 
t: relative risk (95% confidence interval) 
For all other major causes of death the risk factor adjusted associations with serum 
albumin were also inverse (table 4). For cancer mortality the association disappeared after 
additional adjustment for health status indicators. For all other causes of death the 
association was only slightly reduced following adjustment for baseline health status. For 
all-cause mortality additional adjustment for baseline health status attenuated the relation 
with serum albumin (table 4). 
Discussion 
In this cohort of elderly men a low serum albumin level, within a normal range, was 
associated with the occurrence of a first coronary heart disease event in elderly men with 
elevated cholesterol levels. This association remained when traditional risk factors and 
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baseline health status were accounted for. A risk factor independent association with 
mortality from coronary heart disease, cardiovascular diseases and all-causes was observed 
which could partially be explained by baseline health status. 
Traditional risk factors 
The association of serum albumin with mortality has often, in part, been explained by its 
association with other factors associated with mortality 1 0 1 1 1 5 , 2 5" 2 7 or by underlying 
diseases.8 , 9 , 2 6 However, in many reports no adjustments were made for traditional risk 
factors for mortality such as body mass index,1"3 , 2 8 , 2 9 blood lipids, 1 , 2 , 3 0 blood pressure 
levels1 , 2 and smoking habits.2 In our study, we adjusted for acknowledged risk factors for 
cause-specific mortality, and the inverse association persisted for all end-points. The 
strength of the associations for cause-specific mortality end-points, for a 2.5 g/L increase 
in serum albumin, were of the same order of magnitude as those observed among middle-
aged men in the British Regional Heart Study.29 Hence, it appears that the predictive 
importance of serum albumin for cause-specific mortality does not decline with advancing 
age, as was observed in elderly men from the National Health and Nutrition Examination 
Survey Epidemiologic Follow-up Study.3 Within our cohort, there was even an indication 
that the observed associations were stronger among the older men (71 years or older) than 
among the younger ones (not shown). 
Some investigators ascribed the association of serum albumin with mortality to that of 
serum globulin with mortality.10 ,11 However, as these investigators have done, we estimated 
serum globulin from the difference between total serum protein and dbumin and no 
association with any of the end-points was observed (not shown). Therefore, it is probably 
albumin, rather than any of the other serum proteins, that is responsible for the observed 
associations. This was also reported in the British Regional Heart Study where globulin 
was directly measured in serum.31 
Baseline health status 
Since it is widely recognized that serum albumin is decreased as a result of infection, 
inflammation and disease, reported associations between serum albumin and mortality 
have been adjusted for clinical manifestations of baseline disease.1"3 ,29'30 In a cohort of men 
and women over the age of 71 years, Corti and colleagues additionally adjusted for 
physical disability, an indication of frailty and high mortality risk, and low albumin levels 
remained predictive of all-cause mortality. Both self-rated health and white blood cell 
count are well-recognized indicators of health status in the elderly.1 3 , 1 4 A physician's rating 
of the general health status of an individual may prove to be of value in addition to 
information on the presence of disease and an individual's self-rated health. This is 
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suggested by our findings since in the fully adjusted model of serum albumin with all-
cause mortality, baseline presence of cardiovascular diseases, cancer and chronic 
obstructive pulmonary disease, self-rated health, the physician's health score, and white 
blood cell count were all significant confounders. Therefore, by simultaneously adjusting 
for all these health status indicators, an attempt was made to account for baseline disease 
or inflammation as much as possible. 
After adjustment for baseline health status indicators the strength of the associations 
of serum albumin with mortality endpoints were of the same magnitude for mortality from 
coronary heart disease, cardiovascular diseases and all-causes. A low albumin level, even 
within the normal range, can be viewed as an indicator of inflammation and vascular 
injury,9 and possibly of progression of atherosclerosis. Concurrently, plausible mechanisms 
for the association between serum albumin and atherosclerosis as well as thrombosis have 
been proposed. Through its specific binding capacities, albumin is conceivably an indirect 
and "sacrificial" anti-oxidant,4'12 and an indirect inhibitor of platelet aggregation and 
thrombosis.6 Consequently, part of the inverse association between serum albumin and 
mortality from coronary heart disease and all cardiovascular diseases may be a result of 
underlying progression of atherosclerosis and thrombosis, as is observed after adjustment 
for prevalence of related disease at baseline. Another part may be causal. The latter is 
suggested by the finding that serum albumin was an equally strong predictor of a first 
coronary heart disease event ever in men with elevated serum total cholesterol levels after 
adjustment for traditional risk factor levels as well as after additional adjustment for 
indicators of baseline health. 
The effect modification by serum total cholesterol of the association of serum albumin 
with the incidence of coronary heart disease is somewhat surprising. Possibly a 
combination of a low serum dbumin level, even within the normal range, and an elevated 
total cholesterol level and thus an elevated low density lipoprotein cholesterol level, 
promotes the increase of circulating oxidized low density lipoprotein cholesterol. Low 
serum albumin may thereby indirectly induce the clinical manifestation of athero-
thrombotic disease. 
The association between serum albumin and mortality from cancer disappeared after 
adjustment for baseline health status. This suggests that low albumin levels may have been 
indicative of the presence of cancer at baseline as was observed in the BUPA study.26 Low 
serum albumin levels remained predictive of death due to causes other than cardiovascular 
diseases or cancer. However, we only adjusted for the prevalence of chronic obstructive 
pulmonary disease, since detailed information on other chronic diseases was not available. 
If the presence of these diseases could be accounted for, the strength of this association 
is expected to be reduced,26 as is the association with all-cause mortality. 
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In conclusion, low serum albumin, within the normal range, is associated with coronary 
heart disease and all-cause mortality in elderly men. This may partly be explained by 
baseline health status, but for coronary heart disease, biological mechanisms associated 
with progression of atherosclerosis or thrombosis, may also be involved. Since complete 
information on (underlying) diseases is usually lacking in large prospective studies in 
elderly populations, serum albumin, a routinely measured blood chemistry parameter, may 
be a useful risk indicator of overall mortality risk. 
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Chapter 9 
General discussion 
In this thesis prospective studies on the associations between biological risk factors and 
coronary heart disease occurrence in elderly people have been described. Many of the 
limitations and strengths of the specific investigations as well as the implications of the 
specific results have been discussed in the previous chapters. Following a brief 
recapitulation of the main findings, this chapter focuses on some methodological 
considerations including the validity of the findings and issues specific to epidemiologic 
research in older populations. The experience obtained from the studies is discussed in this 
context. Thereafter, some pathophysiologic and etiologic features of coronary heart disease 
in the elderly are addressed with respect to the findings. Finally, the overall public health 
implications of the studies are considered. 
Main findings 
The major results of the five year follow-up of men from the Zutphen Elderly Study are 
summarized in the table (based on chapters 4 and 6 through 8). The relative risks are 
presented for one standard deviation increase in a risk factor and are adjusted for all 
factors simultaneously, including age, body mass index, cigarette smoking habit and 
systolic blood pressure. Generally, associations of risk factors with the incidence of 
coronary heart disease were weaker than those with mortality from the disease. An 
increased serum total cholesterol concentration was predictive of short-term mortality from 
coronary heart disease (chapter 4). In the 17-year follow-up study, a similar association 
was observed among elderly women, but among elderly men the association was inverted 
t7-shaped (chapter 3). High density lipoprotein cholesterol tended to be inversely 
associated with the short-term incidence of coronary heart disease, but was not associated 
with mortality outcomes (chapter 4). Homocysteine was associated with mortality from 
coronary heart disease in the first 1.5 years of follow-up only, but an association with the 
incidence of the disease was lacking (chapter 6). An increased white blood cell count 
(chapter 7) and a reduced serum albumin concentration (chapter 8) were related to an 
increased risk of coronary heart disease mortality. Systolic blood pressure was an 
independent risk factor for long-term mortality from coronary heart disease in elderly 
women, but not in elderly men (chapter 3). In the five year follow-up study, systolic and 
diastolic blood pressure were also not linearly related to coronary heart disease, but the 
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associations tended to be [/-shaped (chapter 2). However, strong linear associations were 
observed between blood pressure levels and sudden cardiac death (chapter 2). 
Table 1. Associations of main risk factors* investigated in the five year follow-up of the Zutphen 
Elderly Study among men aged 64 to 84 years at baseline in 1985 
Risk factor Relative risks for 1 standard deviation increase in the risk factor 
(1 standard deviation) (95% confidence interval)! 
Incidence of CHD 
55 events 
701 at risk 
Mortality from CHD 
52 deaths 
872 at risk 
Mortality from all-causes 
209 deaths 
872 at risk 
Serum total cholesterol 1.25 1.53 1.14 
(1.10 mmol/L) (0.93 - 1.68) (1.16-2.02) (0.98 1.32) 
HDL cholesterol 0.77 1.12 0.97 
(0.29 mmol/L) (0.56 - 1.07) (0.86 - 1.47) (0.85 - 1.11) 
Serum homocysteine 0.90 0.99 1.00 
(8.2 nmol/ml) (0.67 - 1.22) (0.77 - 1.27) (0.89- 1.12) 
White blood cell count 1.25 1.55 1.41 
(1.8 109/L) (0.95 - 1.63) (1.20- 1.99) (1.23 - 1.61) 
Serum albumin 0.84 0.71 0.73 
(2.7 g/L) (0.63 - 1.12) (0.55 - 0.92) (0.64 - 0.83) 
*: except for blood pressure since associations were f/-shaped (see text) 
t: adjusted for all risk factors simultaneously including age, body mass index, cigarette smoking habit and systolic 
blood pressure 
Methodologic considerations 
There are several methodologic issues which should be considered in interpreting the 
results of different studies. The validity of prospective studies is briefly discussed 
succeeded by some issues specific to epidemiologic research in elderly people. 
Validity 
Validity deals with the question whether a study measures what it intends to measure. In 
general, the internal and external validity are considered.1 
Internal validity With regard to the internal validity, care needs to be taken in avoiding 
biases and confounding. Selection and recall biases are unlikely to have occurred in our 
studies since the exposures, risk factor levels, were ascertained before the occurrence of 
the disease of interest, e.g. coronary heart disease. Loss to follow-up was also not a major 
concern since there was only one such a case in both cohorts studied. In investigating the 
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associations between risk factors and end-points, all currently known potential confounders 
were carefully considered and adjusted for. A disputable confounder is the presence of 
coronary heart disease at baseline. Within the strict definition of the concept, the presence 
of the disease at baseline is not a confounder since it is probably an intermediate in the 
causal pathway between risk factor and end-point. Adjustment for the presence of the 
disease therefore generally attenuated the observed associations. 
External validity The external validity of the studies refers to their generahzabihty. 
Regarding the cohort from the general practice in Rotterdam (chapter 3), it must be noted 
that nearly all people in the Netherlands are registered in a general practice. In addition, 
all elderly individuals from this general practice were invited to participate in the study 
with the exception of 30 individuals whom the general practitioner had judged physically 
or mentally unable to participate. The general practice was located in a working-class area. 
Therefore, the cohort is not representative of the general Dutch elderly population of that 
time: it was generally healthier and from a specific socio-economic class. The cohort of 
the Zutphen Elderly Study consisted of two randomly selected population-based samples 
(see the methods sections of chapters 2, 4, 6-8). One was based on the middle-aged male 
population of Zutphen in 1960 who where followed up into old age and the other of the 
elderly male population of Zutphen in 1985. Women were originally excluded from the 
study because, at the initiation of the Zutphen Study in 1960 as part of the Seven 
Countries Study, coronary heart disease was viewed as a major health problem of middle-
aged men. In 1985, funding to include elderly women in the Zutphen Study was applied 
for but not obtained. Although the participation rates of both cohorts were quite high, 86 
percent for the Rotterdam cohort and 74 percent for the Zutphen cohort, the participants 
conceivably had more favorable risk factor levels and a lower risk of coronary heart 
disease than the rest of the Dutch population of the same age. Results from a non-response 
survey during the 1993 examination period of the Zutphen Elderly Study confirmed that 
participants had a lower prevalence of coronary heart disease than non-respondents.2 
However, the possible existing differences between the two cohorts and the general Dutch 
elderly population do not necessarily imply that the etiologic associations studied in this 
thesis are different from those in the general population. There is indeed no indication for 
such a difference with the exception of the gender difference with regard to the Zutphen 
Elderly Study. The results obtained from this study need verification in elderly women. 
Overall, the generalizability of the findings does not merely depend on whether the cohorts 
represent the general population from which they have been sampled or on the sample size 
of the cohorts. The internal validity, as discussed previously, may be more important.1 
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In conclusion, the findings described in this thesis are judged to be valid and generalizable 
with respect to the etiologic knowledge that they have provided on risk factors for 
coronary heart disease in elderly persons. 
Issues specific to epidemiologic research in the elderly 
Some considerations have to be made when interpreting findings from prospective 
epidemiologic studies in the elderly. Specific features of elderly populations are discussed 
with regard to methodology and findings, such as the high prevalence of disease, the high 
mortality rate, natural selection mechanisms, and age-related changes and individual 
variations in risk factor levels. Furthermore, special attention is given to the interpretation 
of the measure of association in epidemiologic studies in the elderly. Finally, some 
possible methodological explanations for the different findings for incidence and mortality 
from coronary heart disease are discussed. 
Comorbidity and comortaiity The frequency of comorbidity and comortality increases 
with advancing age in a population. Since the co-existence of diagnosed or underlying 
disease or death from causes other than coronary heart disease may modify the association 
between risk factors and coronary heart disease, this issue is of major concern. The 
prevalence of diseases at baseline was high in the two elderly cohorts described in this 
thesis. In the Zutphen Elderly Study for example, 61 percent (542/885) of all men had at 
least one of the major chronic diseases, i.e. diabetes mellitus, cardiovascular diseases, 
different types of cancer or chronic non-specific lung diseases. Although this point is 
widely recognized, there are no satisfying procedures on how to deal with it. 
The exclusion of all people with major chronic diseases at baseline does not offer a 
solution. The remaining group would be a distinct group not representative of a general 
elderly population. In addition, as was discussed in chapter 8, underlying, undiagnosed 
disease may be very common in elderly people. This is partly caused by an increased 
propensity to accumulate illnesses with advancing age. The high prevalence of 
undiagnosed disease may also be a result of the belief of some elderly people as well as 
clinicians that a certain degeneration in their health is a normal concomitant of aging. The 
presence of an actual illness may therefore be disregarded. In our studies, possible 
indicators of underlying disease, white blood cell count and serum dbumin, were 
investigated in combination with the conventional risk factors for coronary heart disease 
in order to account for possible underlying illness (chapters 7 and 8). The main 
conclusions regarding the conventional risk factors were not altered (table 1 on page 130). 
However, the results of our studies indicate that it is preferable to investigate 
interactions between indicators of (underlying) ill-health and risk factors of interest since 
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certain diseases can alter risk factor levels. In the Zutphen Elderly Study for example, an 
interaction was observed between total cholesterol and body mass index in the association 
with mortality from coronary heart disease (chapter 4). The association with total 
cholesterol was lacking among the lean men. As addressed in chapter 4, a possible 
explanation could be that men with low body mass index form a heterogenous group. Part 
of the group may include healthy men with normal total cholesterol levels and at a 
decreased risk of coronary heart disease mortality, and the other part may include 
unhealthy men with reduced total cholesterol levels and at an increased risk of coronary 
heart disease mortality. There was also an interaction between total cholesterol and serum 
albumin in the association with the incidence of the disease (chapter 8). The association 
with serum albumin was lacking in men with low total cholesterol levels. Additional 
analyses revealed a positive association between total cholesterol and the incidence of 
coronary heart disease in men with low serum albumin concentrations, while the 
association was lacking in men with high serum dbumin concentrations. The latter group 
may form a select group of healthy men, who remained free of coronary heart disease at 
middle-age, and in whom an elevated total cholesterol concentration is not associated with 
an elevated risk of coronary heart disease at this older age. These possible explanations 
for the observed interactions cannot be verified. However, they suggest pronounced 
heterogeneity of the cohort comphcating the interpretation of the results. 
Comortality is partly taken into account in Cox's proportional hazards analysis. This 
method has the advantage of being able to include individuals who are censored due to 
death from another cause than coronary heart disease in the analysis.3 All relative risks 
presented in this thesis are therefore estimated from Cox's proportional hazards models. 
However, one must keep in mind that the relative risks for cause-specific mortality 
endpoints invariably retain the assumption that there are no competing risks.1 The only 
endpoint that meets this assumption is all-cause mortality. The association between risk 
factors and all-cause mortality was always addressed in our studies. In prospective studies 
of morbidity and specific causes of death, like those described in this thesis, it is not 
possible to eliminate or to account for competing causes of death. In order to obtain a 
better notion of the importance of potential competing causes of death, associations of 
factors with other endpoints than coronary heart disease mortality were additionally 
investigated if the factors were suspected to be involved in the etiology of these other 
diseases (chapter 2, 6 and 8). 
Selective survival The progressive age related decline in the associations of some risk 
factors with coronary heart disease may have to do with selective survival. With advancing 
age, there could be a progressive elimination of susceptible individuals with elevated risk 
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factor levels from the population. The remaining individuals with elevated risk factor 
levels may be less susceptible to coronary heart disease and may have a similar risk for 
the disease than those with normal risk factor levels.4 This phenomenon possibly explains 
the inverted [/-shaped association between total cholesterol and mortality from coronary 
heart disease among men followed for 17 years (chapter 3). Among middle-aged men of 
the Zutphen Study followed for 25 years a selective loss of individuals with high 
cholesterol levels was observed.5 The inverted [/-shaped association was not observed 
between total cholesterol and coronary heart disease incidence or mortality in men from 
the Zutphen Elderly Study followed for five years (chapter 4). As discussed in chapter 4, 
differences in length of follow-up may explain this discrepancy. 
Changes in risk factor levels with age It is important to acknowledge that the level 
of a particular risk factor measured at old age may not represent the level of a life-time 
exposure when interpreting the results.6 As was discussed previously, elderly people have 
a high prevalence of (underlying) disease. Many chronic diseases are known to influence 
the levels of the conventional risk factors, e.g. to lower blood pressure and the total blood 
cholesterol concentration. Moreover, the frequency of medication use for coronary heart 
disease, hypertension and hypercholesterolemia increases with age and usually lowers the 
levels of conventional risk factors. Thus, people with initial elevated levels of these risk 
factors who are thereby at an increased risk of coronary heart disease, may eventually 
have lower levels of the risk factors while the ultimate event remains coronary heart 
disease. This possible misclassification of older people according to their risk factor level 
attenuates associations between the risk factors and coronary heart disease occurrence. It 
must be noted that the decline in risk factor levels may be a result of other factors than 
the presence of (underlying) disease. Indeed, in chapter 5, the total cholesterol 
concentration of elderly men was shown to decline with age regardless of selective 
survival, loss to follow-up and the health status at the time of the measurement. Although 
these age-related physiologic changes may occur independent of health status, they also 
have the potential to attenuate the total cholesterol-coronary heart disease association. 
Thus, regardless of the presence of (underlying) illness, it is desirable to know whether 
coronary heart disease risk factors change with age. Age-related changes in risk factors 
other than total and high density lipoprotein cholesterol were not addressed in this thesis 
since the measurement of these risk factors were not available for more than two 
examination rounds of the Zutphen Elderly Study. 
Although the level of a particular risk factor measured at old age may not represent the 
level of a life-time exposure, it is important to consider its etiologic association with 
coronary heart disease. The question arises whether a recent short-term exposure or a long-
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term exposure to a harmful level of a risk factor is associated with the occurrence of an 
event.4 As will be discussed in the next section, the etiology of coronary heart disease is 
complex, and both short and long term effects of risk factors appear to be of importance. 
This emphasizes the need for studies investigating age-related changes in risk factor levels. 
Within-person variation All biological variables have a tendency for individual 
variation. Depending on the variable, night and day, daily, weekly or monthly variations 
exist. A single measurement of a risk factor in individuals of a population will give an 
accurate mean for that population but the range will be larger than when multiple 
measurements are made. A single measurement of biological risk factors can thereby lead 
to a substantial underestimation of the true associations of the usual level of the risk 
factors with coronary heart disease.7 This phenomenon is known as regression dilution bias 
and is not specific to older populations. The amount of underestimation of an association 
can only be assessed if multiple measurements of biological risk factors from (a subsample 
of) individuals of the populations under study are available. This information was only 
available for total and high density lipoprotein cholesterol in the Zutphen Elderly Study 
(chapter 5) and for total cholesterol and blood pressure in the Rotterdam general practice 
cohort (chapter 3).8 Reliability coefficients can be computed from repeated measurements 
and this coefficient can be used to estimate the relative risks adjusted for regression 
dilution bias.8 For serum total cholesterol, for example, the relative risks for mortality 
from coronary heart disease in the 17-year follow-up study (table 4 of chapter 3) were 
underestimated by 40 and 15 percent for the second and third tertile respectively. In the 
Zutphen Elderly Study the relative risk for mortality from coronary heart disease was 
underestimated by 13 percent per 1 mmol/L increase in total cholesterol (table 3 of chapter 
4). 
Relative versus absolute risk The prevailing notion that the strength of the association 
between risk factors and coronary heart disease generally diminishes with age deserves 
careful attention. Relative risks for coronary heart disease may indeed be lower in the 
elderly than in middle-aged populations, but absolute risks tend to increase with advancing 
age. This is best illustrated in chapter 2 where interactions were observed between blood 
pressure and age in the associations with sudden cardiac death and all-cause mortality. The 
mortality rates in the reference blood pressure categories were much higher in the older 
men as compared to the younger men. The risk differences between blood pressure 
categories were also generally higher in the older versus the younger men, whereas the 
relative risks were similar or lower. Therefore, the evaluation of the age-related change 
of an association depends on the measure of effect. 
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Incidence versus mortality from coronary heart disease The relatively weak 
association of most risk factors with the first occurrence of a coronary heart disease event 
as compared to the associations with mortality from the disease in our studies may be due 
to methodological issues. Associations with incidence were estimated from a population 
initially free of coronary heart disease at baseline, whereas those with mortality were 
estimated from a population including people with a history of the disease. Hence, the 
source populations were different, making comparisons difficult. Excluding people with 
coronary heart disease at baseline for the mortality analyses would lead to an exceptionally 
healthy population. Moreover, most people who died of coronary heart disease already had 
manifestations of the disease. Out of 53 men who eventually died from coronary heart 
disease in the Zutphen Elderly Study, 34 already had a history of the disease at baseline 
and another 17 had a non-fatal event during the course of the follow-up period before 
eventually dying from the disease. Adjusting for a history of coronary heart disease at 
baseline would be an over-adjustment, because, as discussed previously, it is more likely 
to be an intermediate than a confounder in the associations studied. A lack of power is 
probably not a potential explanation for the differential strengths of the associations since 
the number of events for both coronary heart disease outcomes are similar (56 incident 
cases and 53 mortality cases).1 ,9 
Pathophysiology and etiology of coronary heart disease in elderly 
people 
Apart from methodological issues specific to epidemiologic studies in the elderly, the 
pathophysiology and etiology of coronary heart disease may be altered in this age group 
as compared to middle-aged people. These possible changes with advancing age may 
underlie some of the associations described in the previous chapters and they are briefly 
addressed in the ensuing paragraphs. 
Atherosclerosis and inflammation Coronary atherosclerosis is generally well advanced 
in the elderly. It is estimated that approximately half of the elderly population of the 
industrialized countries have more than 50 percent occlusion of one of the coronary 
arteries.10 The question rises as to what factors contribute to the manifestation of coronary 
heart disease in a population with such high prevalence of atherosclerosis. Risk factors 
associated with the onset of atherosclerosis per se may not be sufficient at advanced age 
to distinguish between those who will and those who will not develop a clinical event. 
Possibly the identification of factors specifically associated with the progression of the 
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disease may improve the prediction of clinical events in older populations. Since the 
introduction of the response to injury hypothesis by Ross and Glomset in 1976, 1 1 , 1 2 the 
progressive state of atherosclerosis is generally regarded to be an inflammatory disease 
state.13 Therefore, in addition to the conventional risk factors for coronary heart disease, 
factors associated with the inflammatory state of atherosclerosis may enhance the 
prediction of the occurrence of clinically evident coronary heart disease in elderly people. 
Indeed, as was observed in our studies, indicators of inflammation, such as an increased 
white blood cell count (chapter 7) and a reduced serum albumin (chapter 8), proved to 
predict coronary heart disease occurrence in addition to the conventional risk factors blood 
cholesterol, blood pressure and cigarette smoking. Since white blood cell count and serum 
albumin are routinely measured by clinicians, they are potentially useful and promising 
indicators for the identification of elderly people at increased risk of coronary heart 
disease. 
The role of thrombosis Currently, thrombosis is thought to be the most common 
precipitating cause of myocardial infarction.14 In concurrence with the high prevalence of 
atherosclerosis in the elderly, specific thrombogenic risk factors may become more 
significant in predicting coronary heart disease with advancing age. Some potentially 
thrombogenic risk factors were investigated in this thesis. One of them is homocysteine. 
Findings from in vitro studies suggest that homocysteine can induce thrombosis.15 As 
discussed in chapter 6, the thrombotic effect of homocysteine can probably explain only 
a part of our prospective findings, i.e. the positive associations between homocysteine and 
fatal coronary heart disease in the first 1.5 years of follow-up, and fatal cerebrovascular 
disease in men without hypertension. 
Activated white blood cells may also enhance the effects of thrombosis since they may 
have an important hemorheological function by increasing blood viscosity.16 In addition, 
as a result of the release of oxidative agents by activated white blood cells, especially the 
monocytes, vulnerable or unstable plaques may rupture which can lead to thrombus 
formation and acute occlusion of a coronary artery.14 These mechanisms may explain the 
observed association between white blood cell count and coronary heart disease described 
in chapter 7. 
Moreover, the conventional coronary heart disease risk factors, blood pressure and 
blood cholesterol, may also have a role in promoting thrombosis. As a result of sheer 
stress on the arterial wall, elevated blood pressure may play a key role in triggering an 
acute coronary heart disease event.14 Increased pressure on the arterial wall may cause the 
disruption of an athererosclerotic plaque resulting in thrombus formation and the occlusion 
of a coronary artery. This may be one of the mechanisms involved determining the strong 
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linear association between increased blood pressure levels and sudden cardiac death 
(chapter 2). The accumulation of cholesterol crystals increases the stiffness of 
atherosclerotic plaques which, in turn, partially determines its vulnerabiMty to rupture and 
induce thrombus formation and eventually an acute coronary heart disease event.14 This 
may explain part of the association between increased serum total cholesterol and 
mortality from coronary heart disease (chapter 4). 
Altered autonomic function Another mechanism which can lead to the manifestation 
of acute coronary heart disease, other than arterial occlusion, may be increased electrical 
instability of the heart.17 This may lead to archytrimia, especially ventricular fibrillation, 
and subsequently to sudden cardiac death. Since there is increased sympathetic stimulation 
with advancing age, and this may lead to electrical instability of the heart, 1 8 1 9 related 
factors may become increasingly important in predicting acute coronary heart disease in 
older people. As discussed in chapter 2, this could be one of the explanations for the 
observed association between elevated blood pressure and sudden cardiac death. 
Altered manifestation of coronary heart disease Our findings suggest that, in general, 
associations of risk factors with the incidence of coronary heart disease were weaker than 
those with mortality from the disease. As discussed previously, methodological issues may 
partly explain this difference. Possibly, the manifestation of coronary heart disease is 
altered with advancing age. Clinical coronary heart disease is more often atypical and 
asymptomatic in older as compared to younger persons.20 This is additionally reflected by 
the strikingly high prevalence of silent myocardial infarction in advanced age. 2 1 , 2 2 Results 
from a population-based study among people over 55 years of age in Rotterdam, the 
Netherlands, for example, revealed that for 57.5 percent of the people with an infarction 
pattern on the electrocardiogram the myocardial infarction had been silent.22 This may 
partly be the result of a reduced sensation of pain in some older people or to their 
conviction that certain symptoms are a normal concomitant of ageing. In these people, a 
clinical coronary heart disease event may not come to the attention of a general 
practitioner. In addition, other coronary disorders possibly become relatively more 
important in elderly people as compared to younger people and might compete with 
coronary heart disease, such as for example heart failure.23 These altered manifestations 
and occurrences of coronary heart disease in the elderly may partly explain the generally 
weak associations observed between risk factors and the incidence of the disease as 
described in this thesis. 
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Altered risk factor levels Apart from the possibly altered pathophysiology of coronary 
heart disease in elderly people, advanced atherosclerosis in the elderly may also have an 
impact on risk factor levels and thus on their association with disease occurrence. Reduced 
diastolic blood pressure associated with isolated systolic hypertension in the elderly is one 
of the most apparent examples of this phenomenon, and this is extensively discussed in 
chapters 2 and 3. 
In conclusion, the pathogenesis and manifestation of coronary heart disease can change 
with advancing age and may influence risk factor levels. These age specific features of 
coronary heart disease should be considered when conducting epidemiologic studies in the 
elderly and may underlie some of the associations described in this thesis. However, it is 
not possible to identify which mechanisms ultimately drive the observed associations. 
Further clinical and experimental research is needed to improve insights herein. 
Public health implications 
The reasons for conducting prospective studies like the ones described in this thesis are 
to obtain insight in the causation of coronary heart disease in elderly people and 
eventually to enhance the knowledge needed to improve the public's health. 
Overall, the associations between the conventional risk factors and coronary heart 
disease incidence tended to be reduced in our studies as compared to studies in middle-
aged people. As was discussed previously, this is probably true in terms of relative risks, 
but the absolute impact of these risk factors on disease occurrence in the elderly may be 
substantial. The associations with mortality from coronary heart disease as well as all-
cause mortality were generally comparable to those observed at middle-age suggesting that 
the absolute impact of the risk factors on mortality endpoints was larger than that 
commonly observed at a younger age. In addition, the total number of elderly people 
afflicted by the disease is considerable.24 This is expected to influence the prevalence of 
disability in the elderly and their quality of life and eventually associated health care costs. 
Therefore, unfavorable levels of risk factors in the elderly can have a considerable impact 
on public health. Major achievements herein can conceivably be obtained by aiming 
preventive strategies specifically at elderly people. 
Intervention of conventional risk factors The usual way to assess whether prevention 
is effective in reducing a public health problem is by conducting randomized controlled 
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trials for the reduction of risk factors. Regarding the conventional risk factors, several 
successful prevention trials have been conducted specifically in the elderly. 
Five randomized trials conducted in hypertensive patients over 60 years of age have 
provided convincing evidence for the protective effect of antihypertensive treatment on 
cardiovascular diseases.25"29 An overall difference of 15/6 mmHg in systolic/diastolic blood 
pressure levels was achieved between the treatment and the control groups. This was 
associated with a 19 percent reduction in coronary heart disease incidence and a 34 
percent reduction in stroke incidence in treatment versus control groups while non-vascular 
mortality did not differ between groups.30 These figures are comparable in size to those 
observed in younger patients. However, the absolute measures of effect are more than 
twice as large as those for middle-aged patients.30 These short-term effects of treatment 
(4.7 years) are comparable to the expected longer term effects of prolonged blood pressure 
differences deducted from prospective observational studies.7 Therefore, most of the effect 
of blood pressure lowering on coronary heart disease risk reduction can possibly be 
obtained in the first years of treatment. A recent nutrition intervention in older people with 
mild to moderate hypertension was successful in reducing blood pressure levels in a short 
time-period.31 Replacement of sodium salt by a low sodium, high potassium, high 
magnesium mineral salt has achieved significant reductions of 7.6/3.3 mmHg in 
systolic/diastolic blood pressure levels in just 24 weeks. Thus, non-pharmacological 
treatment of hypertension in the elderly appears to be promising with respect to coronary 
heart disease prevention. 
Recent secondary prevention trials for total cholesterol lowering including elderly 
persons 3 2 - 3 3 have shown clear benefits in lowering both cardiovascular morbidity and 
mortality and all-cause mortality. Moreover, a primary prevention trial in middle-aged men 
without signs of coronary heart disease proved that total and low density lipoprotein 
cholesterol can be lowered successfully with a statin (HMG-CoA reductase inhibitor).34 
Furthermore, the treatment was successful in reducing the risk of coronary heart disease 
and all-cause mortality without increasing non-coronary heart disease mortality. In general, 
the degree of benefit depends on the degree of total cholesterol lowering and not on the 
type of intervention. However, some cholesterol lowering drags, namely fibrates and 
hormones, have adverse effects on coronary heart disease (hormones only), non-coronary 
heart disease and total mortality independent of their cholesterol lowering effect.33 
Comprehensive lifestyle changes (i.e. a low-fat vegetarian diet, stopping smoking, stress 
management training, and moderate exercise) in middle-aged patients have shown similar 
reductions in total cholesterol concentrations as can be achieved by drag treatment.35 In 
addition, this intervention has achieved significant regression of atherosclerosis. 
A recent pilot study conducted specifically in elderly people suggested a similar 
cholesterol lowering effect of treatment by statins than has been observed in middle-aged 
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persons.3 Therefore, the beneficial effect of cholesterol lowering on coronary heart disease 
and mortality in the elderly is expected to be similar to observations in younger people. 
Moreover, both pharmacological and lifestyle interventions are suggested to be successful. 
In the Zutphen Study a secular decline in serum total cholesterol between 1990 and 1993 
was observed in elderly men which could not be explained by laboratory drifts (chapter 
5). As discussed in chapter 5, a nationwide "Fat Watch" campaign during the same period 
may explain part of the decline. The secular change may also be a result of changes over 
the years in the composition of certain foods. Thus the food industry may have an 
important role in population-based strategies of lipid management.37 A recent Finnish 
trial,38 for example, suggests that serum total and low density lipoprotein cholesterol can 
be reduced in subjects with mild hypercholesterolemia by substituting margarine 
containing sitostanol-ester, which inhibits cholesterol absorption, for part of the daily fat 
intake. Future primary and secondary prevention trials, conducted specifically in elderly 
people, are necessary to be certain that total cholesterol lowering in this age-group is 
beneficial in terms of coronary heart disease incidence, total mortality and quality of life. 
With respect to high density lipoprotein cholesterol, the Scandinavian Simvastatin 
Survival Study (4S) trial showed that treatment with simvastatin significantly increased 
high density lipoprotein cholesterol levels.32 A similar increase in high density lipoprotein 
cholesterol was observed in the pilot phase of the statin-trial conducted specifically in 
elderly persons.36 Whether the increase in high density lipoprotein cholesterol can also 
explain (part of) the reduced risk of the disease cannot be derived from the 4S trial3 2 or 
any other trial up to date. However, several prospective studies have provided evidence 
for an etiologic association between reduced high density lipoprotein cholesterol and 
coronary heart disease.39'40 Moreover, the study described and discussed in chapter 4, 
suggests that high density lipoprotein cholesterol is also inversely associated with coronary 
heart disease incidence, but not mortality, in elderly men. Concurrently, increasing this 
lipoprotein cholesterol level in elderly people with relatively low levels is expected to be 
associated with a reduced risk of the disease. Future clinical trials, specifically in elderly 
persons, are necessary to determine the beneficial effect of increasing high density 
lipoprotein cholesterol levels through treatment or hygienic measures for coronary heart 
disease incidence, total mortality and quality of life. 
Most intervention trials have been carried out specifically in middle-aged persons. Since 
elderly people tend to have more subclinical coronary heart disease than middle-aged 
persons, primary prevention of adverse risk factor levels is expected to have an even larger 
absolute effect on reducing the burden of the disease in this age group than in middle-age. 
Whether primary prevention trials are effective in reducing the risk of disease and 
mortality in the elderly remains to be established. 
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Intervention of other risk factors Regarding the other risk factors addressed in this 
thesis, homocysteine appears to be the most readily modifiable factor. Indeed, parenteral 
supplementation of vitamin B12, B6 and folate has been shown to rapidly reduce 
homocysteine levels in elderly persons.41 Moreover, there are suggestions that prevention 
of the progression of atherosclerosis in middle-aged people can be achieved through 
homocysteine-lowering treatment.42 Similar effects are to be expected in elderly people 
since their vitamin B status is generally poor4 3 and their serum homocysteine 
concentrations were elevated (chapter 6). Moreover, since homocysteine may also be 
involved in other chronic diseases than cardiovascular diseases, such as cancer and 
cognitive impairment (chapter 6), the treatment of elevated levels in elderly people may 
have beneficial effects for the general health and quality of life of the elderly population. 
However, the association between homocysteine and the occurrence of coronary heart 
disease, as well as these other conditions, is still not established in the elderly (chapter 6). 
Intervention studies are needed to investigate whether reduction in homocysteine reduces 
the risk of coronary heart disease and other chronic diseases in this age-group. 
Concerning white blood cell count and serum albumin, information on potential 
determinants is lacking with the exception of cigarette smoking for white blood cell count. 
Further studies are needed to investigate what lifestyle factors possibly determine these 
clinical variables. As discussed in the various chapters (chapter 7 and 8), white blood cell 
count and serum albumin may be useful indicators of progression of atherosclerosis and 
of general underlying disease and useful factors for identifying elderly persons at increased 
risk of coronary heart disease and other chronic diseases. In addition, they may be 
important for monitoring changes in the risk of these chronic conditions. 
In general, several factors should be considered with regard to primary prevention of 
coronary heart disease in the elderly. These include life expectancy, quality of life and the 
presence of other risk factors.6 In this respect, the multifactorial etiology of coronary heart 
disease should be taken into account.1 4 , 4 4 The evidence obtained in this thesis supports the 
notion that risk factors act independently in predicting coronary heart disease occurrence 
in the elderly. Moreover, the lifestyle associated with favorable coronary heart disease risk 
factor levels is also associated with a lower risk of other major chronic diseases such as 
other cardiovascular diseases, cancer, cognitive impairment and thus presumably a poor 
quality of life. Whether multifactorial lifestyle-intervention strategies aimed at elderly 
persons reduce all-cause mortality and improve quality of life and thereby the public's 
health needs to be addressed in future trials. 
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Conclusion 
In conclusion, the classical biological risk factors for coronary heart disease (i.e. blood 
pressure, total and high density lipoprotein cholesterol) are still important in predicting the 
disease in elderly people. The experience obtained from the studies described in this thesis 
has made clear that elderly people are a heterogenous group with respect to risk factor 
levels as well as coronary heart disease risk. It would therefore be desirable to have a 
measure of susceptibility for coronary heart disease to identify and eventually treat elderly 
people who are at increased risk of the disease. Our studies suggest that white blood cell 
count and serum albumin, routine clinical blood chemistry values, may be useful in this 
respect in addition to the classical risk factors. Future intervention studies should aim at 
assessing the effectiveness of a multifactorial approach of risk factor management on 
coronary heart disease and all-cause mortality as well as on quality of life in older men 
and women. 
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In industrialized countries like the Netherlands there will be a striking increase in the 
number of older people in the coming decades. This is expected to be accompanied by an 
increase in the absolute number of persons with coronary heart disease. Therefore, this 
disease is and will continue to be a major public health problem in the Netherlands 
especially in the elderly. Although advanced atherosclerosis may be present in 
approximately half of the elderly persons it is not considered to be an aging phenomenon 
per se. There is evidence that the progression of atherosclerosis can be stopped and 
regression can be induced. It is therefore imperative to obtain insight into possible risk 
factors for coronary heart disease in elderly persons. This age group has only recently 
become a focus of interest in epidemiologic research on the disease. In this thesis the 
associations between classical biological risk factors (i.e. total and high density lipoprotein 
blood cholesterol and blood pressure) and some new biological risk factors (i.e. serum 
homocysteine, white blood cell count and serum albumin) and the occurrence of coronary 
heart disease in elderly persons are described. 
Results are based on data from two Dutch cohorts. One is a cohort of 292 men and 
women, aged 64 to 87 years in 1971, from a general practice in Rotterdam, with a 
mortality follow-up of 17 years. The other is the Dutch cohort of the Seven Countries 
Study which consists of 939 men aged 64 to 84 years in 1985 from the town of Zutphen. 
The morbidity and mortality follow-up embraced five years. 
Systolic and diastolic blood pressure as well as isolated systolic hypertension were 
investigated in relation to coronary heart disease and sudden cardiac death in elderly men 
followed for five years (chapter 2). None of these blood pressure variables were 
significantly associated with the incidence of a first coronary heart disease event, and only 
diastolic blood pressure showed a [/-shaped association with mortality from coronary heart 
disease. Strong positive associations were observed with sudden cardiac death. The 
adjusted relative risk for men with definite isolated systolic hypertension was 9.20 (95 
percent confidence interval: 1.76-47.97). Elevated blood pressure levels and especially 
isolated systolic hypertension are thus important short-term predictors of sudden cardiac 
death in elderly men. Evidence from the literature suggests that this strong association may 
be a result of increased sympathetic activity with advancing age. Diastolic and systolic 
blood pressure showed a [/-shaped relation with coronary heart disease mortality which 
was not recorded as sudden. The literature suggests that this increased risk at the lower 
end of the blood pressure distributions may, in part, be explained by increased arterial 
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stiffness with advancing age. The highest risk for both sudden and non-sudden coronary 
heart disease mortality was observed in men on anti-hypertensive medication, who formed 
a distinct group with a clustering of cardiovascular risk factors. 
Systolic blood pressure was also an independent risk factor for mortality from coronary 
heart disease in elderly women followed for 17 years (chapter 3). The adjusted relative 
risk amounted to 4.1 (1.0-16.4) for women with a blood pressure of 175 mmHg or higher 
compared to women with a level lower than 155 mmHg. Although the difference between 
men and women was not significant, the association was less clear in men. A possible 
explanation for this difference between gender may be selective mortality in middle-aged 
men. 
In chapter 3, serum total cholesterol was also an independent risk factor for mortality from 
coronary heart disease in elderly women followed for 17 years whereas for men the 
association tended to be inverted [/-shaped (chapter 3). The adjusted relative risk 
amounted to 3.9 (1.1-13.7) in women with a total cholesterol level of 7.32 mmol/L or 
higher compared to those with a level lower than 6.34 mmol/L. Apart from possible 
selective mortality in middle-aged men as mentioned for blood pressure, these differences 
between gender could be explained by physiological changes in women as a consequence 
of menopause. 
The short-term predictive value of serum total as well as high density lipoprotein 
cholesterol for coronary heart disease incidence and mortality was also investigated in 
elderly men (chapter 4). Total cholesterol was not significantly associated with the 
incidence of coronary heart disease, but for mortaüty the relative risk corresponding to a 
1.00 mmol/liter increase was 1.40 (1.07-1.83). Additional analyses (chapter 8) revealed 
that total cholesterol only predicted coronary heart disease incidence in men with serum 
albumin levels below the median. These men may form a less healthy group more 
susceptible to the effect of total cholesterol on coronary heart disease incidence. High 
density lipoprotein cholesterol was not associated with mortality from coronary heart 
disease. The relative risk for the incidence of the disease, corresponding to a 0.26 
mmol/liter increase, was 0.80 (0.60-1.08). The ratio of high density lipoprotein to total 
cholesterol was independently associated with the incidence of coronary heart disease. 
These results show that in elderly men followed for a relatively short period of time, both 
total and high density lipoprotein cholesterol are important in predicting coronary heart 
disease. Total cholesterol seems to be a stronger risk factor for mortality from the disease, 
whereas high density lipoprotein cholesterol is more strongly associated with the incidence 
of a first coronary heart disease event. 
148 
Summary 
Longitudinal data on age-related changes in total and high density cholesterol levels in 
advanced age are scarce. Since such changes may have implications for the interpretation 
of their association with coronary heart disease, we investigated age-related changes in 
cholesterol levels in the Zutphen Study (chapter 5). The total and high density lipoprotein 
cholesterol concentration of men were determined in 1977/78 (n=571), 1985 (n=885), 1990 
(n=555) and 1993 (n=345). Linear regression analysis and random effects models were 
used to assess cross-sectional and longitudinal age and time related changes in cholesterol 
concentrations. In both cross-sectional and longitudinal analyses total cholesterol decreased 
by 0.04 mmol/L per year with age. The longitudinal change was observed in the entire 
population as well as in men who participated in all four examinations (n=135), and in a 
subgroup of men who were free of common chronic diseases, not on cholesterol lowering 
medication and/or prescribed diet and rated themselves as being 'healthy' (n=64). High 
density lipoprotein cholesterol did not change significantly with age on a cross-sectional 
nor on a longitudinal basis. These results suggest that caution is warranted in interpreting 
results of associations between serum total cholesterol measured at old age and different 
end-points since the measured level of exposure may not be representative of a life-time 
exposure. 
Since, with advancing age, associations of classical risk factors with coronary heart disease 
may be altered compared to those observed in middle-aged persons, there may be other 
risk factors of importance in the elderly. Some potentially new risk factors for the disease, 
i.e. serum homocysteine, white blood cell count and serum albumin, were investigated in 
the Zutphen Elderly Study. 
An elevated serum homocysteine level is thought to be atherogenic and thrombogenic, 
but a definite mechanism has not been described. Elevated non-fasting homocysteine 
concentrations were common in elderly Dutch men (chapter 6). Thirty-one percent of the 
men had homocysteine levels of 17 umol/1 or higher. After adjustment for established 
major risk factors, high homocysteine levels (upper tertile) at baseline were associated 
with an increased prevalence of coronary heart disease (odds ratio = 1.95 (1.24-3.05)) and 
of cerebrovascular disease (odds ratio = 4.16 (1.99-8.97)). High homocysteine levels were 
associated with an increased risk of dying from coronary heart disease in the first one-and-
a-half years of observation (adjusted relative risk 3.65 (0.76-17.42)). For cerebrovascular 
disease mortality the adjusted relative risk amounted to 17.23 (1.91-154.29) in men 
without hypertension. High homocysteine levels were not associated with an increased risk 
of first ever coronary heart disease or cerebrovascular disease. Finally, high homocysteine 
levels were associated with an increased risk of cognitive impairment at follow-up (odds 
ratio = 1.73 (1.03-2.92)), which was reduced after adjustment for age and occupation 
(odds ratio = 1.38 (0.79-2.40)). 
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White blood cell count, even within the normal range, was a strong predictor of both 
coronary heart disease incidence and mortality and all-cause mortality independent of the 
conventional risk factors for coronary heart disease (chapter 7). The adjusted relative risk 
for a Mf/L increase in white blood ceD count was 1.32 (1.15-1.51) for coronary heart 
disease mortality and 1.14 (0.98 - 1.32) for the first occurrence of the disease. These 
associations were observed regardless of cigarette smoking habit. Regarding all-cause 
mortality, the relative risk amounted to 1.25 (1.17-1.35). This association was strongest 
among never and former smokers. Apart from being a marker for underlying inflammation, 
an increased white blood cell count may also directly be involved in both atherogenesis 
and thrombosis which may explain its strong association with coronary heart disease. 
A reduced serum albumin is also a marker of (underlying) illness, but potential 
mechanisms for an association with coronary heart disease have also been described. Most 
elderly men had normal serum albumin levels, i.e. 35 g/L or higher. Albumin was 
inversely related with the incidence of coronary heart disease among men with elevated 
total cholesterol levels (> 6.5 mmol/L) only. The relative risk for one standard deviation 
increase (2.5 g/L) in albumin was 0.60 (0.38-0.96) and was not altered after additional 
adjustment for baseline health status. For all men, the relative risk for death due to 
coronary heart disease was 0.67 (0.49-0.92) and reduced to 0.84 (0.61-1.15) after 
adjustment for health status. Comparable relative risks, adjusted for health status, were 
observed for mortality from cardiovascular diseases (relative risk = 0.83 (0.67-1.02)) and 
all causes (relative risk = 0.86 (0.73-0.99)). Moderately low serum dbumin was predictive 
of coronary heart disease and all-cause mortality in elderly men independent of traditional 
confounders. Only part of this association could be explained by baseline health status. 
In the general discussion (chapter 9) some methodological issues including the validity of 
the findings and matters specific to epidemiologic research in older populations have been 
discussed. Several considerations have to be made when interpreting findings from 
prospective epidemiologic studies in the elderly. Specific features of elderly populations 
such as the high prevalence of disease, the high mortality rate, natural selection 
mechanisms, and age-related changes and individual variations in risk factor levels may 
have attenuated the observed associations. With advancing age, the etiology and 
pathophysiology of coronary heart disease may be altered as compared to middle-aged 
persons and this may underlie some of the observed associations. Finally, the overall 
public health implications of the studies are considered. Although associations with the 
incidence of coronary heart disease tended to be reduced in terms of relative risks, the 
absolute impact of these risk factors on disease occurrence in the elderly may be 
substantial. Therefore, unfavorable levels of risk factors in the elderly can have a 
considerable impact on public health. Major achievements herein can conceivably be 
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obtained by aiming preventive strategies specifically at elderly people. The evidence 
obtained in this thesis supports the notion that risk factors act simultaneously in predicting 
coronary heart disease occurrence in the elderly. Moreover, the lifestyle associated with 
favorable coronary heart disease risk factor levels is also associated with a lower risk of 
other major chronic diseases such as other cardiovascular diseases, cancer, chronic non-
specific lung disease and cognitive impairment. Presumably this will lead to an improved 
quality of life. 
In conclusion, the classical biological risk factors for coronary heart disease (i.e. blood 
pressure, total and high density lipoprotein cholesterol) are still important in predicting the 
disease in elderly people. The experience obtained from the studies described in this thesis 
has made clear that elderly people are a heterogenous group with respect to risk factor 
levels as well as coronary heart disease risk. It would therefore be desirable to have a 
measure of susceptibility for coronary heart disease to identify and eventually treat elderly 
people who are at increased risk of the disease. Our studies suggest that white blood cell 
count and serum albumin, routine clinical blood chemistry values, may be useful in this 
respect in addition to classical risk factors. Future intervention studies should aim at 
assessing the effectiveness of a multifactorial approach of risk factor management on 
coronary heart disease and all-cause mortality as well as on quality of life in older men 
and women. 
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Samenvatting 
Het aantal ouderen in de bevolking van geïndustrialiseerde landen zoals Nederland zal 
naar verwachting de komende decennia aanzienlijk stijgen. Dit zal waarsctójnlijk gepaard 
gaan met een toename in het totaal aantal personen met coronaire hartziekten. Deze 
aandoeningen zullen daarom een nog groter probleem worden voor de volksgezondheid 
in Nederland. Atherosclerose wordt niet als een normaal verouderingsproces gezien. Toch 
komt vernauwing van meer dan 50 procent van één van de coronairvaten voor bij meer 
dan de helft van de ouderen. Progressie van atherosclerose kan worden tegengegaan en 
regressie kan worden geïnduceerd. Het is daarom van groot belang inzicht te krijgen in 
mogelijke risicofactoren voor coronaire hartziekten bij ouderen. Pas recentelijk heeft 
epidemiologisch onderzoek naar deze aandoeningen zich gericht op deze leeftijdsgroep. 
In dit proefschrift zijn de verbanden beschreven tussen enerzijds de klassieke 
(serumtotaal- en hoge-dichtheidsUpoproteïne (HDL)-cholesterol en de bloeddruk) en enkele 
nieuwe (serumhomocysteine, het aantal witte bloedcellen en serumalbumine) biologische 
risicofactoren en anderzijds het optreden van coronaire hartziekten bij ouderen. De 
resultaten zijn gebaseerd op gegevens afkomstig uit twee bevolkingsonderzoeken. De 
eerste onderzoekspopulatie bestaat uit 292 mannen en vrouwen die in 1971 tussen de 64 
en 87 jaar oud waren, afkomstig uit een Rotterdamse huisartsenpraktijk. Na 17 jaar zijn 
de doodsoorzaken van de overleden deelnemers geregistreerd. De andere 
onderzoekspopulatie bestaat uit 939 mannen tussen de 64 en 84 jaar in 1985, woonachtig 
in Zutphen. Na vijf jaar is naast de mortaliteit ook het optreden van niet-fatale coronaire 
hartziekten geregistreerd. Dit onderzoek staat bekend als de Zutphen Ouderen Studie. 
De systolische en diastolische bloeddruk, alsmede geïsoleerde systolische hypertensie zijn 
onderzocht in relatie tot coronaire hartziekten en plotse hartdood bij oudere mannen uit 
de Zutphen Ouderen Studie (hoofdstuk 2). Er was geen verband tussen de bloeddruk-
variabelen en de incidentie van coronaire hartziekten en alleen de diastoüsche bloeddruk 
het een f/-vormig verband zien met sterfte aan deze aandoeningen. Er werden echter 
sterke positieve verbanden waargenomen tussen de bloeddruk-waarden en plotse hartdood. 
Het gecorrigeerde relatieve risico voor mannen met geïsoleerde systolische hypertensie 
bedroeg 9.20 (95 procent betrouwbaarheidsinterval: 1.76-47.97) ten opzichte van mannen 
zonder deze vorm van hypertensie. Een verhoogde bloeddruk en vooral geïsoleerde 
systolische hypertensie zijn daarom op relatief korte termijn belangrijke voorspellers voor 
plotse hartdood bij oudere mannen. Uit de literatuur blijkt dat een verhoogde sympatische 
activiteit met het ouder worden mogeüjk een verklaring is voor het sterke verband met 
153 
Samenvatting 
plotse hartdood. De diastolische en systolische bloeddruk toonden een £/-vormig verband 
met sterfte aan coronaire hartziekten indien deze niet tevens als plotse hartdood was 
gecodeerd. Mogelijk is het verhoogde risico op niet-plotse dood aan coronaire hartziekten 
bij oudere mannen met de laagste bloeddruk-waarden deels het gevolg van een toename 
in de stijfheid van de arteriën met het toenemen van de leeftijd. Mannen die anti-
hypertensiva gebruikten hadden het hoogste risico op zowel plotse als niet-plotse sterfte 
aan coronaire hartziekten en vormden een specifieke groep waarin een aantal 
cardiovasculaire risicofactoren frequent samen voorkwam. 
Bij oudere vrouwen was de systolische bloeddruk een onafhankelijke risicofactor voor 
de 17-jaars sterfte aan coronaire hartziekten (hoofdstuk 3). Het gecorrigeerde relatieve 
risico bedroeg 4.1 (1.0-16.4) voor vrouwen met een bloeddruk van 175 mmHg of hoger 
ten opzichte van vrouwen met een bloeddruk lager dan 155 mmHg. Dit lange-termijn 
verband verschilde niet significant tussen vrouwen en mannen, maar bij mannen was het 
verband minder duidelijk. Selectieve sterfte bij mannen met hypertensie op middelbare 
leeftijd zou dit verschil mogelijk kunnen verklaren. 
Serumtotaalcholesterol bleek eveneens een onafhankelijke risicofactor voor de 17-jaars 
sterfte aan coronaire hartziekten te zijn bij oudere vrouwen, terwijl bij mannen het lange-
termijn verband omgekeerd rZ-vormig leek te zijn (hoofdstuk 3). Het gecorrigeerde 
relatieve risico bedroeg 3.9 (1.1-13.7) bij vrouwen met een totaalcholesterolgehalte van 
7.32 mmol/L of hoger ten opzichte van vrouwen met een waarde lager dan 6.34 mmoI/L. 
Naast de mogelijkheid van selectieve sterfte bij mannen van middelbare leeftijd, zou het 
waargenomen verschil tussen mannen en vrouwen ook een gevolg kunnen zijn van 
fysiologische veranderingen bij vrouwen als gevolg van de menopause. 
Het korte termijn belang van serumtotaal- en HDL-cholesterol voor de incidentie en 
sterfte aan coronaire hartziekten is ook onderzocht bij oudere mannen (hoofdstuk 4). 
Totaalcholesterol was niet significant geassocieerd met de incidentie van de aandoeningen, 
maar voor sterfte werd wel een duidelijk verband gevonden; een toename in 
serumcholesterol van 1 mmol/L ging gepaard met een relatief risico van 1.40 (1.07-1.83). 
Uit additionele analyses (hoofdstuk 8) bleek dat totaalcholesterol wel gerelateerd was aan 
de incidentie bij mannen met een serumalbuminegehalte lager dan de mediaan. Mogelijk 
zijn deze mannen minder gezond en daarom meer gevoelig voor het effect van 
totaalcholesterol op de incidentie van coronaire hartziekten. HDL-cholesterol was niet 
geassocieerd met sterfte aan coronaire hartziekten. Voor de incidentie bedroeg het 
gecorrigeerde relatieve risico 0.80 (0.60-1.08) met een toename van 0.26 mmol/L in het 
HDL-cholesterol. De verhouding tussen HDL- en totaalcholesterol bleek onafhankelijk 
gerelateerd te zijn aan de incidentie van coronaire hartziekten. Deze resultaten tonen aan 
dat bij oudere mannen zowel het totaal- als het HDL-cholesterol op relatief korte termijn 
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nog steeds voorspellend zijn voor coronaire hartziekten. Het totaalcholesterol lijkt een 
sterkere voorspeller te zijn voor de sterfte aan deze aandoeningen terwijl HDL-cholesterol 
sterker gerelateerd is aan de incidentie. 
Longitudinale gegevens over leeftijdsveranderingen in totaal- en HDL-cholesterol met het 
ouder-worden zijn schaars. Dergelijke veranderingen zijn van belang voor de interpretatie 
van verbanden met coronaire hartziekten. Daarom zijn leeftijdsveranderingen in deze 
cholesterol-variabelen in de Zutphen Studie onderzocht (hoofdstuk 5). Voor deze analyse 
is gebruik gemaakt van het serumtotaal- en HDL-cholesterolgehalte van mannen die in 
1977/78 (n=571), 1985 (n=885), 1990 (n=555) en 1993 (n=345) onderzocht zijn. Lineaire 
regressie-analyse en 'random-effects models' zijn gebruikt om cross-sectionele en 
longimdinale veranderingen in cholesterolconcentraties met de leeftijd en de tijd te 
bestuderen. Uit zowel de cross-sectionele als de longitudinale analyses bleek het 
totaalcholesterolgehalte van het bloed met 0.04 mmol/L per jaar af te nemen. De 
longitudinale verandering werd in de totale onderzoeksgroep waargenomen, bij mannen 
die aan alle onderzoeken hebben deelgenomen (n=135), en tot slot in een subgroep van 
deze mannen zonder chronische ziekten, mannen die geen cholesterolverlagende 
medicijnen of dieet gebruikten en een goede ervaren gezondheid hadden (n=64). HDL-
cholesterol veranderde niet significant met de leeftijd zowel in de cross-sectionele als de 
longitudinale analyses. Deze resultaten suggereren dat het totaalcholesterolgehalte gemeten 
op oudere leeftijd niet representatief is voor een levenslange blootstelling aan een bepaald 
serumcholesterolgehalte. Bij de interpretatie van verbanden met verschillende eindpunten 
dient hiermee rekening te worden gehouden. 
Omdat verbanden tussen de klassieke risicofactoren en coronaire hartziekten mogelijk 
veranderen met de leeftijd, zijn andere factoren eventueel van belang bij ouderen. Nieuwe 
potentiële risicofactoren voor deze aandoeningen, zoals het serumhomocyste'ine, het aantal 
witte bloedcellen en het serumalbumine, zijn in de Zutphen Ouderen Studie onderzocht. 
Een verhoogd serumhomocysteihe is mogelijk zowel atherogeen als thrombogeen. Het 
onderliggende mechanisme is nog niet opgehelderd. Een verhoogde niet-nuchtere 
homocysteïne concentratie van het bloed komt bij ouderen veelvuldig voor (hoofdstuk 6). 
Één-en-dertig procent van de mannen had een homocysteïnegehalte van 17 umol/L of 
hoger. Na correctie voor mogelijke confounders bleek een hoog homocysteïnegehalte 
(bovenste tertiel) geassocieerd te zijn met een verhoogde prevalentie van coronaire 
hartziekten (odds ratio = 1.95 (1.24-3.05)) en cerebrovasculaire accidenten (odds ratio = 
4.16 (1.99-8.97)). Een hoog homocysteïnegehalte leek gerelateerd te zijn aan een verhoogd 
risico op sterfte voor coronaire hartziekten gedurende de eerste anderhalf jaar. Het 
relatieve risico bedroeg 3.65 (0.76-17.42). Voor sterfte aan cerebrovasculaire accidenten 
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bedroeg het relatieve risico 17.23 (1.91-154.29) bij mannen zonder hypertensie. Een hoog 
homocysteïnegehalte was niet geassocieerd met een verhoogd risico op de incidentie van 
coronaire hartziekten of cerebrovasculaire accidenten. Tenslotte waren hoge homocysteïne 
niveaus geassocieerd met een verhoogd risico op een verminderd cognitief functioneren 
(odds ratio = 1.73 (1.03-2.92)). Dit verband werd echter minder sterk na correctie voor 
leeftijd en beroep (odds ratio = 1.38 (0.79-2.40)). 
Het aantal witte bloedcellen, zelfs binnen de normaalwaarden, was een sterke 
onafhankelijke voorspeller voor zowel de incidentie als sterfte aan coronaire hartziekten 
alsmede voor totale sterfte (hoofdstuk 7). Het gecorrigeerde relatieve risico, geassocieerd 
met een 109/L toename in het aantal witte bloedcellen, bedroeg 1.32 (1.15-1.51) voor 
sterfte aan coronaire hartziekten en 1.14 (0.98-1.32) voor de incidentie van deze ziekten. 
Deze verbanden werden waargenomen ongeacht de rookgewoonte van mannen. Voor de 
totale sterfte bedroeg het relatieve risico 1.25 (1.17-1.35). Dit verband was het sterkst bij 
de niet-rokers. Het aantal witte bloedcellen is verhoogd als gevolg van ontstekingen. Er 
zijn echter aanwijzingen dat het tevens een rol speelt bij zowel atherogenese als 
thrombogenese. Dit zou een verklaring kunnen zijn voor het sterke verband met coronaire 
hartziekten. 
Een verlaagd serumdbumine is ook een indicator voor (onderliggende) ziekten, maar 
er zijn tevens biologische mechanismen beschreven voor een verband met coronaire 
hartziekten. De meeste mannen in de Zutphen Ouderen Studie hadden normale 
serumdbumine concentraties van 35 g/L of hoger (hoofdstuk 8). Albumine was invers 
gerelateerd aan de incidentie van coronaire hartziekten bij mannen met een verhoogd 
serurntotaalcholesterol (> 6.5 mmol/L). Het gecorrigeerde relatieve risico bedroeg 0.60 
(0.38-0.96) voor één standaard deviatie (2.5 g/L) toename in serumalbumine. Dit 
veranderde niet na extra correctie voor chronische ziekten, subjectieve gezondheid en het 
aantal witte bloedcellen aan het begin van het onderzoek. Voor de totale groep bedroeg 
het relatieve risico voor sterfte aan de ziekten 0.67 (0.49-0.92) en dit werd na correctie 
voor onderliggende ziekten 0.84 (0.61-1.15). Vergelijkbare relatieve risico's werden 
gevonden voor sterfte aan cardiovasculaire ziekten (0.83 (0.67-1.02)) en totale sterfte (0.86 
(0.73-0.99)). Een matig verlaagd seramalbumine was bij oudere mannen voorspellend voor 
coronaire hartziekten en totale sterfte onafhankelijk van traditionele confounders. Slechts 
een deel van dit verband kon door onderliggende ziekten worden verklaard. 
In de algemene discussie (hoofdstuk 9) is aandacht besteed aan enkele methodologische 
aspecten van de onderzoeken zoals de validiteit van de resultaten en aspecten die specifiek 
betrekking hebben op epidemiologisch onderzoek bij ouderen. Specifieke karakteristieken 
van oudere populaties zoals de hoge prevalentie van (onderliggende) ziekten, de hoge 
sterfte, natuurlijke selectie-mechanismen en leeftijdsveranderingen, kunnen de bestudeerde 
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verbanden hebben afgezwakt. Met het ouder worden verandert mogelijk ook de etiologie 
en pathofysiologie van coronaire hartziekten en dit kan de bevindingen eveneens deels 
verklaren. De algemene implicaties van de resultaten voor de volksgezondheid zijn 
besproken. Ondanks de soms zwakke relatieve risico's voor de incidentie van coronaire 
hartziekten in vergelijking tot mensen van middelbare leeftijd, is het absolute risico bij 
ouderen over het algemeen hoger dan op middelbare leeftijd. Een ongunstig risicoprofiel 
bij ouderen kan daarom grote gevolgen hebben voor de volksgezondheid in het algemeen. 
Verbeteringen hierin zouden kunnen worden behaald door preventieve maatregelen 
specifiek op ouderen te richten. De resultaten die beschreven zijn in dit proefschrift 
hebben verder aangetoond dat risicofactoren onafhankelijk voorspellend zijn voor 
coronaire hartziekten bij ouderen. Bovendien blijkt een gezonde levensstijl voor coronaire 
hartziekten ook het risico op andere chronische aandoeningen te verlagen zoals andere 
cardiovasculaire aandoeningen, kanker, CARA, en een verminderd cognitief functioneren. 
Dit zal vermoedelijk tevens bijdragen aan een verbeterde kwaliteit van leven. 
Concluderend kan gesteld worden dat de klassieke risicofactoren voor coronaire 
hartziekten (bloeddruk, totaal- en HDL-cholesterol) nog steeds belangrijk zijn voor het 
voorspellen van deze aandoeningen op oudere leeftijd. Ouderen vormen voor wat betreft 
hun risicoprofiel en hun risico op coronaire hartziekten een zeer heterogene groep. Het zou 
daarom wenselijk zijn om factoren te identificeren die een maat zijn voor de gevoeligheid 
van ouderen om de ziekten te krijgen. Uit de in dit proefschrift beschreven onderzoeken 
blijkt dat een aantal routinematig gemeten klinisch-chemische bloedparameters, zoals het 
aantal witte bloedcellen en het serumalbumine, in dit verband zeer bruikbaar is in 
combinatie met de klassieke risicofactoren. Toekomstig interventie-onderzoek zou gericht 
moeten zijn op de effecten van een multifactoriële benadering voor het normaliseren van 
het risicoprofiel op coronaire hartziekten, totale sterfte en kwaliteit van leven bij oudere 
mannen en vrouwen. 
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